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Preface 
  
       Like in the three previous editions, this E-book compiles a series of 
contributions in the multidisciplinary research arena of Pharmaceutical 
Sciences. The E-book has been organized in 12 chapters, whose main topics 
belong to the fields of pharmacology, physical chemistry, plant physiology, 
microbiology, physiology, preventive medicine and public health, food 
science, botany, clinical pharmacy and pharmacotherapy, organic 
chemistry, biochemistry and molecular biology, and parasitology. 
      Excessive sugar consumption is becoming increasingly recognized as a 
huge public health problem, inasmuch as it is associated to increased 
prevalence of a number of human diseases including obesity, dyslipidemia, 
insulin resistance, and cardiovascular disease. This might make necessary 
the promotion of policies to control the use of sugar, and particularly that of 
fructose, widely used as a sweetener in the food and beverage industry, but 
before, the putative toxic effects of fructose need to be clearly established. 
In Chapter 1, some recent studies performed in animal models and humans 
about the harmful effects associated with short-term or chronic high 
consumption of fructose are discussed. Protein misfolding and aggregation 
into amyloid structures are associated with many human diseases, 
prominently neurodegenerative diseases such as Alzheimer’s, Parkinson’s, 
and prion diseases. In Chapter 2, amyloid aggregation is presented as a 
generic property of proteins in both eukaryotic and prokaryotic cells, not 
only with pathologic but also with functional roles. Chapter 3 reviews the 
phenomenon of hybrid necrosis as a form of post-zygotic reproductive 
isolating barrier in plants, mainly focusing on those cases that are associated 
to the immune system, and reports on recent findings about immune-
triggered hybrid incompatibilities in the plant model Arabidopsis thaliana. 
Chapter 4 reports on structural studies performed in the Antarctic Gram-
negative bacterium Shewanella vesiculosa M7
T
 that have revealed that apart 
from conventional one-bilayer outer membrane vesicles (OMV), a hitherto 
unknown double-bilayer OMV that can incorporate DNA is also released. 
The implications of these DNA-entrapping structures in lateral gene 
transfer, and hence, in prokaryotic evolution and transfer of antibiotic 
resistance or virulence genes within bacteria are also discussed. Disruption 
of the intestinal epithelial barrier function contributes to diarrhoea and 
perpetuation of the inflammatory process associated with enteritis caused  
by Salmonella enterica, serotype Enteritidis. In Chapter 5, the mechanisms  
 responsible for the regulation of tight junctions, one of the adhesion 
systems that afford structural integrity to the epithelium, are discussed, as 
well as the importance of this knowledge in the design of novel approaches 
to minimize the spread of Salmonella in the food animal industry. Chapter 
6 reports on some epidemiological studies of measles virus outbreaks and 
discusses the importance of enhanced surveillance and adapting 
vaccination strategies, i.e. immunization schedules, to particular 
epidemiological scenarios as an efficient way for early detection and 
control of the disease. In Chapter 7, the so far little explored procedures for 
authentication of organic chicken products are discussed, highlighting the 
importance of the availability of fingerprinting approaches to 
unequivocally identify authentic products, the updating of authentication 
models and their implementation into regulations with the final aim of 
supporting administrative controls to direct inspections towards suspicious 
fraudulent samples. Chapter 8 describes a comprehensive ethnobotanical 
survey and discusses the contribution of such approaches to the knowledge 
of the traditional use of plants and the benefits derived from that 
knowledge, e.g. enabling the detection and prevention of interactions and 
other problems resulting from combined medicinal plants and synthetic 
drugs or the identification of new drugs. Chapter 9 reports on the moisture 
permeability tests that have to be performed for guaranteeing the stability 
of medicines contained in multicompartment compliance aid devices, 
thereby being of utmost importance in the pursuit of a high-quality 
professional service by pharmacists. Chapter 10 presents an overview of 
the synthetic strategies used to access each of the four key structural classes 
of Lycopodium alkaloid, namely phlegmarine, lycopodine, lycodine, and 
fawcettimine, which include an important number of biologically active 
compounds. Particular emphasis is given to methodologies that rapidly 
construct each nucleus utilizing tandem reactions. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) belongs to the class of the so-called 
moonlighting proteins, i.e. multifunctional proteins, in which the different 
functions, unrelated and independent, are associated with a single 
polypeptide chain. Chapter 11 summarizes the so far scarcely studied 
moonlighting functions of bacterial GAPDH, including its role in 
colonization, modulation of host immune responses, transcriptional 
regulation, DNA repair or quorum sensing signaling, among others. 
Chapter 12 reviews current treatments for cutaneous leshmaniasis, one of 
the two basic clinical forms of leishmaniasis, as well as new drugs, 
formulations and drug combinations under clinical testing. 
       As a final remark, the aforementioned contributions, through which 
this E-book tries to cover the broad scope and multidisciplinarity of 
pharmaceutical sciences, may be also of interest in the biological, 
chemical, and medical research fields. 
                                                                           
              Dr. Diego Muñoz-Torrero 
                                                                    Dr. Manuel Vázquez-Carrera 
                                                                                       Dr. Joan Estelrich   
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Abstract. Global changes in dietary habits in the last decades 
caused an increase of added sugar consumption all over the world, 
which has been linked to the increasing prevalence of obesity, 
dyslipidemia, insulin resistance and cardiovascular disease. Fructose 
is widely used as a sweetener in the food and beverage industry, 
either as an integrant of the sucrose molecule or as a component of 
high fructose corn syrups. The consumption of fructose in beverages 
is especially dangerous, as the process of energy compensation by 
reduction in the ingestion of other foods does not work equally well 
with liquid than solid foods. Besides, fructose is the carbohydrate 
with the highest ability to induce hypertriglyceridemia, due to a 
marked increase in lipogenesis compared with glucose. In this 
review we will discuss some of the most recent studies performed in 
animal models and in humans to investigate the effects of excessive 
fructose consumption. 
 
Correspondence/Reprint request: Dr. Núria Roglans, Department of Pharmacology and Therapeutic Chemistry, 
School of Pharmacy, University of Barcelona, Av. Joan XXIII 27-31, 08028 Barcelona. E-mail: roglans@ub.edu 
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Introduction 
   
 Fructose is a natural sugar contained in fruits and honey, and in this 
form it constitutes a component of a healthy, well-balanced diet. Fructose 
is also used to sweeten foods and beverages during processing or 
preparation, and then we refer to fructose as an “added sugar”. Usually, 
fructose is added to foodstuffs as sucrose (table sugar, a disaccharide 
composed of glucose and fructose) or as high fructose corn syrup (HFCS, a 
mixture of fructose and glucose at variable proportions, typically 55% 
fructose/45% glucose). Global changes in dietary habits in the last decades 
caused an increase of added sugar consumption all over the world, but 
especially in industrialized countries. As an example, US dietary data show 
that between 1977 and 1994 the average daily consumption of added 
sugars increased by 35% [1]. Although these data refer to all caloric 
sweeteners added to food or drinks, added sugars are considered a 
surrogate for fructose consumption [2]. The increase in the consumption of 
added sugars has been linked to several health disturbances, such as 
obesity, dyslipidemia, insulin resistance and cardiovascular disease [3-6]. 
Recognizing these deleterious effects to human health, several dietary 
guidelines from different countries provided recommendations to moderate 
the intake of added sugars, and possibly as a result of these policies, their 
consumption has decreased since 1999 [7]. However, sugar consumption is 
still excessive according to the American Heart Association latest 
recommendations, which fixed an upper limit of intake for added sugars of 
100-150 calories per day [8]. Consistent with this, research on the 
metabolic effects of the main added sugar, fructose, and the molecular 
mechanisms involved is warranted. In previous articles we revised 
scientific evidences, from both animal and human studies, linking fructose 
consumption to metabolic disturbances, up to 2011 [9,10]. In the present 
review, we will focus on articles published during 2012 and 2013, as well 
as on our own results, obtained using liquid fructose-supplemented rats 
and mice as experimental models. We will also review some of the most 
recent studies investigating the effects of high fructose consumption in 
humans. 
 
1. Studies in animal models  
 
 Fructose administration to laboratory animals (most commonly rodents) 
induces metabolic derangements in several tissues -namely liver, adipose 
tissue, heart and skeletal muscle- so these animals can be used as models to 
decipher the molecular mechanisms involved in these alterations. 
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1.1. Fructose effects in the liver 
 
1.1.1. Fructose, fatty liver and mechanisms involved 
  
 In an earlier study [11] we demonstrated that fructose administration to 
male rats (10% w/v in drinking water for 14 days) causes 
hypertriglycerideamia and hepatic steatosis due the conjunction of two 
metabolic alterations, an increase in liver lipogenesis and a decrease in 
hepatic fatty acid oxidation. The latter is a pathway that catalyzes the 
catabolism of fatty acids after they are activated to their acyl-CoA forms by 
the enzyme acyl CoA synthase (ACS). Recently, Dong et al [12] investigated 
the role of long chain ACS (ACSL) in hamsters fed a diet containing 60% of 
fructose for 28 days. Their results showed that the fructose diet specifically 
reduced ACSL through liver X receptor (LXR) and retinoid X receptor 
(RXR) signaling, opening the possibility that LXR agonists, by increasing 
hepatic ACSL expression, could reduce fructose-induced hepatic steatosis.  
 Creszenzo et al. also found an increase in hepatic de novo lipogenesis in 
male Sprague Dawley rats fed a fructose-rich diet (30% fructose in solid 
form) for 8 weeks [13]. The most interesting finding of this study was 
increased hepatic mitochondrial mass in fructose-fed rats. The authors 
hypothesize that this would increase the flux of substrates through pyruvate 
carboxylase and pyruvate dehydrogenase, generating substrates for 
gluconeogenesis. Increased hepatic gluconeogenesis is one of the classic 
features of insulin resistance, and in fact we observed a rise in the liver 
glucose output after a bolus administration of a direct gluconeogenic 
precursor, such as pyruvate, to 14-day fructose-supplemented rats [14]. 
However, we were surprised to notice a significant reduction in the 
expression of two key gluconeogenic enzymes, phosphoenol pyruvate 
carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pc), despite a clear 
impairment in insulin signaling in the livers of these rats. Creszenzo et al 
proposed that an increase in the expression of enzymes controlling the 
substrate flux from cytosolic pyruvate to glucose formation could explain 
enhanced hepatic gluconeogenesis [13]. In fact, we observed an increase in 
the hepatic expression of the enzymes malate dehydrogenase and malic 
enzyme in 14-day fructose-supplemented rats, which could explain the 
increased liver output of glucose in the pyruvate tolerance test, despite the 
reduced expression of both G6Pc and PEPCK [14]. 
 Several studies analyzed how fructokinase, the first enzyme in the 
hepatic metabolism of fructose, contributes to the deposition of fat in the 
liver. Ishimoto et al. [15] demonstrated that mice lacking both fructokinase 
isoforms (A and C) were protected from the fructose-induced features of 
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metabolic syndrome (including hepatic steatosis) observed in wild type 
mice. Moreover, these effects were exacerbated in mice lacking fructokinase 
A, suggesting that this isoform protects against fructokinase C-mediated 
metabolic syndrome.  
 Lanaspa et al [16] used fructokinase knockout mice to evaluate the 
effects of glucose supplementation (10% w/v in drinking water). Glucose 
feeding induced fatty liver in wild type but not in fructokinase-deficient 
animals, showing that this effect was almost entirely mediated by 
fructokinase. However, fructokinase does not metabolize glucose, therefore 
the protective effect was attributed to the fact that a significant proportion of 
the ingested glucose was converted into fructose in the liver. Metabolism of 
this endogenous fructose is blocked in fructokinase-deficient mice, 
protecting against fatty liver. More recently, the same research group studied 
whether fructokinase had also a role in fatty liver induction through a high 
fat-high sucrose diet (HFHSD) [17]. They observed that wild type mice fed a 
HFHSD developed more severe hepatic steatosis compared to mice fed a 
high fat diet. Moreover HFHSD-fed wild type mice showed hepatic 
inflammation and collagen deposition in the liver, while the development of 
steatosis from a high fat diet alone did not induce inflammation or fibrosis. 
Importantly, fructokinase knockout mice fed a HFHSD were completely 
protected from the development of hepatic inflammation and fibrosis despite 
similar energy intake compared to wild type mice.  
  
1.1.2 Fructose and hepatic insulin resistance 
 
 In animal models, fructose feeding (especially at high percentages in 
solid form) induces hepatic insulin resistance. We also observed insulin 
resistance in female, but not male rats, supplemented with 10% fructose in 
liquid form for 2 weeks [9]. Our preliminary results, after 8 weeks of 
supplementation in female rats, show hyperinsulinemia and a clear reduction 
in the expression of insulin receptor substrate (IRS)-2, a major transducer of 
insulin signaling in the liver (Figure 1). However, plasma glucose levels and 
ISI were not altered, suggesting that in these animals increased insulin 
suffices to control plasma glucose levels, masking the underlying insulin 
resistance (unpublished results). We also observed that mice fed a high fat 
(western) diet plus 15% liquid fructose (W+F) consumed an equivalent 
amount of calories compared to mice fed the western diet alone without 
fructose (W), but only the W+F group exhibited hyperinsulinemia and a 
reduction in the insulin sensitivity index (ISI) compared to mice fed normal 
chow [18]. This is in line with the reduced Akt phosphorylation seen only in 
the W+F group, and points out to a specific effect of fructose, only when it is 
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given in combination with a high fat diet, on hepatic insulin signaling in 
mice [18]. 
 We reported previously that carbohydrate response element binding 
protein (ChREBP) is the main responsible for the increase in hepatic 
lipogenesis following fructose supplementation in rats [11, 19-21]. Recently, 
Erion et al studied whether ChREBP is also related to fructose-induced insulin 
resistance [22]. To this end, they administered a ChREBP specific antisense 
oligonucleotide to male Sprague-Dawley rats fed a high-fructose diet             
(60% fructose in solid form). As expected, knockdown of ChREBP led to a 
decrease in the expression of genes controlled by this transcription factor 
(lipogenic genes such as ACC, FAS and SCD-1). ChREBP knockdown caused 
a tendency towards decreased de novo lipogenesis, but these changes did not 
correlate with a decrease in hepatic triglyceride, and therefore were not 
associated with improvements in hepatic insulin sensitivity. 
 
1.1.3 Endoplasmic reticulum stress, autophagy and inflammation 
 
 It has been suggested that endoplasmic reticulum (ER) stress may play a 
role in the development of hepatic insulin resistance under conditions of 
elevated de novo lipogenesis, as occurs with increased fructose consumption. 
ER stress is characterized by the activation of the unfolded protein response 
(UPR) signaling, that reduce temporarily the flow of proteins that reach the 
ER. The UPR is initiated by three transmembrane proteins: IRE1               
(inositol-requiring enzyme 1), PERK (protein kinase-like reticulum kinase) 
and ATF-6 (activating transcription factor-6). A recent study in mice fed a 
high fat diet (60% from saturated fat) or a high fructose diet (35% fructose in 
solid form), showed that both diets caused liver steatosis and hepatic insulin 
resistance, but only the high fructose diet increased de novo lipogenesis, and 
this effect was coupled with activation of the IRE1 and PERK patways [23]. 
The same research group demonstrated recently that treatment of the 
fructose-fed mice with fenofibrate, a PPARα agonist, eliminated               
fructose-induced hepatic steatosis and insulin resistance while causing an 
activation of the IRE1 and PERK branches of the UPR [24]. 
 We also studied the effects of fructose feeding (10% w/v in drinking 
water for 8 weeks) in female Sprague Dawley rats on ER stress pathways 
[25]. Neither PERK nor ATF-6 branches were affected by fructose, while 
there was a marked increase in IRE1 phosphorylation, indicative of 
activation. This is in accordance with our previous results in female rats 
supplemented with fructose for 2 weeks [9]. However, while in 2-weeks 
supplemented rats the increase in IRE1 phosphorylation correlated with an 
increase in the spliced form of X-box-binding protein (XBP)-1 mRNA and 
nuclear protein [9], this effect is not apparent after 8 weeks of treatment 
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(Figure 1), suggesting that ER stress is somehow compensated in these 
animals. It remains to be determined whether longer treatments with fructose 
maintain or rather exacerbate the ER stress response.  
 Due to the involvement of ER stress in the metabolic alterations caused 
by fructose feeding, Ren et al studied the effects of an ER stress inhibitor  
(4-phenylbutyric acid, PBA) on rats fed a high fructose diet [26]. The 
authors showed that treatment with PBA significantly reduced hepatic ER 
stress and improved liver steatosis induced by high-fructose feeding.  
 Insulin resistance has also been associated to a state of chronic low-
grade inflammation derived from the activation of the inflammasome [27]. 
The inflammasommes are large multimolecular complexes that upon 
activation by various stimuli result in the processing and maturation of the 
precursors of the inflammatory cytokines interleukin (IL)-1  and IL-18, via 
caspase-1. A significant increase in renal nucleotide-binding domain and 
leucine-rich repeat protein 3 (NLRP3) inflammasome has been recently 
shown in rats fed fructose [28] or high fructose corn syrup [29]. However, it 
is not known whether the NLRP3 inflammasome is also induced in tissues 
related to insulin resistance such as the liver, muscle or adipose tissue.  
 There are also evidences suggesting that autophagy, a pathway that 
allows the recycling of cellular constituents and facilitates cellular health 
under ER stress, may play an important role in obesity-induced insulin 
resistance [30], and recently it has been shown that activated mammalian 
target of rapamycin (mTOR) suppresses autophagy [31]. Recent results of 
our research group indicate that fructose markedly increases mTOR activity 
in the livers of 2- [14] and 8-week supplemented rats. Thus, it is plausible 
that chronic fructose administration would reduce autophagy via mTOR 
activation. Our preliminary unpublished results are in line with this 
hypothesis, as the ratio of active to inactive light chain 3 (LC3B), an 
indicator of autophagy, seems to be reduced in the livers of 8-week     
fructose-supplemented female rats (Figure 1). 
 It has been suggested that leptin, an adipokine mostly produced by white 
adipose cells, may also regulate autophagy [32]. A recent report showed that 
long-term (6 months) postnatal high fructose diet (60% in solid form) in 
Wistar rats did not affect plasma leptin levels, but decreased the mRNA 
expression of leptin receptors and autophagy-related genes in white adipose 
tissue, while increasing them in the liver [33]. Our results in rats supplemented 
with 10% liquid fructose for 8 weeks (non-published) show a significant              
1.8-fold increase in plasma leptin levels. However, when we express these 
results related to white adipose tissue weight, there is no difference between 
control and fructose-supplemented rats, suggesting that the increase of adipose 
tissue mass accounts for the observed hyperleptinemia.  
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a)
 
 
b)
 
 
Figure 1. Differential effects of fructose in the livers of female Sprague-Dawley rats 
supplemented with 10% liquid fructose for a) 2 weeks and b) 8 weeks.  
 
 On the other hand, in our recent studies in C57/BL6 mice, we observed a 
2.3-fold, 5.5-fold and 7-fold increase in plasma leptin levels after 3 months 
of feeding a 15% liquid fructose diet, a western diet and western diet plus 
15% liquid fructose, respectively (non-published results). In this case, the 
increase of adipose tissue mass cannot explain the observed increases; 
moreover, the mRNA leptin expression in adipose tissue was also increased 
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by the three diets, following the same pattern of stepwise increase as plasma 
leptin levels.  
 
1.1.4. Progression to non-alcoholic steatohepatitis 
 
 The increase of de novo lipogenesis and liver steatosis induced by 
fructose feeding have been related to non-alcoholic fatty liver disease 
(NAFLD), which is considered the hepatic manifestation of the metabolic 
syndrome. Accumulation of triglycerides in the liver leads to oxidative stress 
and expression of proinflammatory cytokines, which results in progression 
from NAFLD to non-alcoholic steatohepatitis (NASH), characterized by 
inflammation, hepatocellular injury and hepatic fibrosis. Zhang et al. [34] 
showed that male Wistar rats fed a high fructose diet (32% fructose) 
developed hepatic steatosis at 4 weeks, but features of NASH (inflammatory 
cell infiltration and focal necrosis) appeared only at 8 weeks of fructose 
feeding. As oxidative stress plays a critical role in the progression of 
NAFLD to further stages of severity, Zhang et al. examined the role of the 
transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), which 
mediates protection against oxidative stress and inflammation by increasing 
the hepatic expression of antioxidative enzymes. They showed that the 
amount of Nrf2 in rat hepatic nuclei was increased in rats fed the                     
high-fructose diet, a compensatory response which was not sufficient to 
overcome the imbalance state of oxidative stress associated to fructose 
feeding [34].  
 Inflammation also contributes to the progression of fructose-induced 
NAFLD into NASH. Zhang et al [34] showed higher plasma tumor necrosis 
factor alpha (TNFα) levels and increased nuclear factor kappa B (NF-κB) 
p65 in the nuclei of liver cells of high fructose fed male Wistar rats. Our own 
study in female Sprague Dawley rats fed fructose for the same length                 
(8 weeks) but to a lower proportion (10%) and supplemented in liquid 
instead of solid form, showed no clear signs of hepatic inflammation or 
necrosis [25]. On the contrary, in our study with C57/BL6 mice fed with a 
high fat diet, alone or combined with 15% liquid fructose, we observed a 
clear trend towards increase in several markers of hepatic inflammation, 
such as monocyte chemoattractant protein 1 (MCP-1), as well as in markers 
of hepatic fibrosis (collagen type 1 expression) [18]. 
 Tsuchiya et al. fed C57BL/6J mice a high-fat, high-fructose diet for 2 
to 16 weeks. As expected, they observed that the diet induced hepatic 
steatosis and insulin resistance, but the most interesting finding was that 2 
weeks before the onset of these alterations there was a significant increase in 
hepatic non-heme iron content, and a decrease in antioxidant capacity in this 
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organ [35]. The authors of this study suggest that the high-fat high-fructose 
diet, through causing hepatic iron overload, increases oxidative stress which 
later results in insulin resistance in the liver.   
   
1.2. Fructose effects on extrahepatic tissues 
 
1.2.1. Heart and cardiovascular system 
 
 In addition to effects on hepatic cells, fructose also causes disturbances 
in other tissues such as the heart and the vasculature. Thus, fructose feeding 
causes cardiac insulin resistance in ovariectomized female rats, shown by an 
impairment of Akt/endothelial nitric oxide synthase pathway [36]. The same 
research group reported that estradiol replacement in this animal model 
specifically suppresses these effects [37]. The results of this study suggest 
that the heart of female rats during the reproductive period is partially 
protected from the negative effects of excessive fructose intake. In fact, 
estrogen replacement has not always demonstrated a protective role against 
the detrimental cardiovascular effects of fructose. Thus, Koricanac et al. [38] 
found that estrogen enhanced the effects of fructose feeding in 
ovariectomized rats on the distribution and expression of CD36, the most 
important fatty acid transporter in cardiomyocytes. These effects would 
reinforce the negative effects of fructose by increasing cardiac fatty acid 
uptake and utilization, which is characteristic of cardiac insulin resistance 
[38].  
 The deleterious effects of an excess of fructose consumption on kidney, 
endothelium and heart have been associated with systemic hypertension 
through several mechanisms, among them the generation of uric acid [39].  
Hyperuricaemia increases oxidative stress and thus it may promote 
endothelial dysfunction. Uric acid may also raise systemic blood pressure by 
activating the renin-angiotensin system and by inhibiting nitric oxide 
synthase [40]. The role of uric acid has recently been demonstrated by           
Tapia et al [41]. They showed that blocking the enzyme uricase in rats 
enhances the alterations induced by fructose on systemic and glomerular 
blood pressure, as well as on other metabolic alterations (plasma glucose, 
hepatic triglyceride and oxidative stress).  
 Akar et al. examined the effects of a diet supplemented with 10-20% 
HFCS on vascular function in male Sprague-Dawley rats [42]. Consumption 
of 20% HFCS for 10 weeks increased blood pressure, impaired vascular 
relaxation to acetylcholine and increased the contractile response of aortas to 
phenylephrine and to angiotensin II. These effects were related to a 
decreased endothelial nitric oxide synthase (eNOS) and sirtuin 1 (SIRT1) 
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expression, together with an increased expression of NADPH oxidase, which 
caused an increase in superoxide production in the aorta of these animals. 
Resveratrol supplementation preserved vascular function and increased 
eNOS and SIRT1 expression in aortas [42]. We also performed some 
experiments in order to assess the effects of fructose on vascular reactivity, 
in collaboration with Dr. Rahimian’s group from the University of the 
Pacific (unpublished results). We observed reduced sensitivity to 
acetylcholine vasodilation in aortas exposed to high fructose concentrations 
(25 mM). Interestingly, the effect was more pronounced in aortas from male 
than from female rats. Gender differences in the response of rats to fructose 
have been already found in our previous in vivo studies [20]. Sexual 
dimorphism was also observed in mice deficient in the dual-specificity 
glucose and fructose transporter GLUT8. Thus, DeBosch et al. showed that 
female mice deficient in GLUT8 exhibited enhanced jejunal fructose uptake, 
which was related to exacerbated increases in blood pressure in response to 
high-fructose feeding compared to wild type mice [43]. On the contrary, 
male GLUT8-knockout mice exhibited lower systolic blood pressure both at 
baseline and after high-fructose feeding [44].  
 The renin-angiotensin system plays also an important role in fructose-
induced hypertension. Therefore, blocking angiotensin II receptors with 
losartan was shown to enhance renal cortical vascular responses to adrenergic 
stimuli, thus reducing fructose-induced hypertension in rats [45]. Similarly, the 
development of hypertension after 8 weeks of treatment with 60% dietary 
fructose was prevented by renin inhibition with aliskiren treatment [46].   
 Recently, it has been proposed that the immune system may also be 
related to cardiovascular alterations induced by fructose feeding. Thus, in a 
study performed by Leibowitz et al [47], male Sprague-Dawley rats fed a 
high-fructose diet (60% fructose) for 5 weeks induced a metabolic-like 
syndrome associated to vascular oxidative stress, inflammation and reduced 
IL-10 secretion from T regulatory lymphocytes (Treg). This suggests that 
despite the total number of Treg is not changed, their function is decreased 
leading to a reduction in the protective effect of these cells on the 
development of vascular injury. In this study, however, blood pressure was 
not altered, suggesting that the effect of Tregs is independent from blood 
pressure. The lack of effect of fructose feeding on blood pressure is 
attributed by the authors to a short fructose exposure. In fact, we found a 
slight increase in blood pressure in female rats after 8 weeks of 10% liquid 
fructose supplementation (unpublished results). 
 Insulin resistance and dyslipidemia have also been associated to a 
proatherogenic state, and therefore an excess of fructose consumption may 
promote atherosclerosis development. There are only few studies addressing 
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this problem, and the conclusions are not clear enough, as the animal model 
used to evaluate atherosclerosis development is a key factor. For example, 
feeding rats with a high fructose diet for 8 weeks facilitates the development 
of balloon injury-induced neointimal formation in carotid arteries [48]. 
However, the formation of atherosclerotic lesions is better assessed in mouse 
models such as the LDL receptor knock-out mouse (LDLR
-/-
), which 
develops atherosclerotic lesions similar to humans when challenged with 
high fat diets. We have studied the effect of fructose supplementation in 
drinking water (15% w/v), combined or not with a high fat diet, for 3 months 
in male LDLR
-/-
 mice. Our preliminary results indicate that supplementation 
with fructose induced atherosclerotic lesions in the aorta, which were much 
more extensive when fructose was combined with a high fat-diet. 
  
1.2.2. Fructose and adipose tissue 
 
 Fructose consumption has been linked to weight gain and obesity, but this 
is not always apparent in studies using rodents. For example, we have not 
detected any increase in weight gain in rats supplemented with liquid fructose 
for 14 days in our previous studies [19-21]. However, our more recent results 
in female rats receiving 10% liquid fructose for 8 weeks showed not only 
increased body weight, but also a significant increase in visceral adipose tissue 
mass (unpublished results). Alzamendi et al. also found an increase in adipose 
tissue mass in male Wistar rats treated with 10% liquid fructose for 3 weeks 
[49]. This effect was accompanied by a decrease in the number of cells per 
gram of adipose tissue, while cell diameter and volume were significantly 
increased by fructose. Similarly, Creszenzo et al. observed differences in 
adipocyte number and morphology in male rats fed 30% fructose in solid form 
for 8 weeks [50]. Thus, the number of intra-abdominal adipocytes was reduced 
due to an increase in their mean diameter, while the opposite (increased 
number but decreased adipocyte size) was found for the subcutaneous 
abdominal depot. Moreover, changes in size correlated with cell function and 
sensitivity to insulin action, therefore intra-abdominal fat tissue from            
fructose-fed rats displayed decreased phosphorylated Akt levels, suggesting 
reduced insulin signaling [50].  
 In vitro experiments in murine 3T3-L1 cells incubated in standard 
differentiation medium showed that addition of fructose increased 
adipogenesis and the expression of PPARγ, C/EBPα and the fructose 
transporter GLUT4 [51]. The authors were not able to tell whether fructose 
directly induced this transporter or the results were due to the earlier 
appearance of GLUT4 due to fructose-induced adipocyte differentiation. Our 
own preliminary results in adipose tissue of rats supplemented for 8 weeks 
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with 10% fructose shown an increase, although non-statistically significant, 
in the mRNA levels of GLUT4, and also of another transporter (GLUT5).    
 There are some evidences showing an increase in glucocorticoid levels 
in adipose tissue after high fructose feeding, probably due to the induction of 
the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) [52]. 
Velickovic et al. [53] studied the relationship between glucocorticoids and 
inflammatory mediators in rat adipose tissue and liver after 9 weeks on a diet 
containing a 10% fructose solution in drinking water. They observed that the 
level of corticosterone and of macrophage migration inhibitory factor (MIF) 
was significantly increased in the adipose tissue, but not in the liver of 
fructose-supplemented rats. The authors concluded that the glucocorticoid 
effects predominated over those of MIF, leading to attenuated NF-κB 
activation and unchanged TNFα expression. Similarly, our recent studies in 
the adipose tissue of rats supplemented with liquid fructose for 8 weeks 
showed no increase in inflammatory mediators, such as TNFα and monocyte 
chemotactic protein-1 (MCP-1). Interestingly, in adipose tissue samples of 
C57/BL6 mice fed a high fat diet, the addition of 15% liquid fructose 
produced a more marked increase in these inflammatory markers, specially 
MCP-1, as well as in markers of fibrosis (collagen type 1 expression), 
compared with animals fed only the high fat diet [18].  
  
1.2.3 Fructose and skeletal muscle  
  
 The importance of skeletal muscle in glucose homeostasis is highlighted 
by the fact that it is the major site of insulin-mediated glucose uptake in the 
postprandial state. Moreover, insulin resistance in skeletal muscle has been 
suggested to be one of the initial events in the establishment of type 2 
diabetes [54]. In a recent paper, Benetti et al. showed that feeding mice with 
15% HFCS for 30 weeks caused skeletal muscle insulin resistance (shown 
by the impaired phosphorylation of IRS-1, Akt, and GSK-3β) and 
inflammation (shown by enhanced expression of NF-κB, iNOS and ICAM-1), 
and these effects were attenuated by co-administration of a PPAR-δ agonist. 
The improvement in insulin resistance by the PPAR-δ agonist was attributed, 
at least in part, to an increase in the expression of GLUT-4 and GLUT-5 
transporters in skeletal muscle [55]. In male Wistar rats, 30% fructose 
feeding in solid form for 8 weeks did not cause any difference in the degree 
of Akt phosphorylation in skeletal muscle [56]. Neither did we find changes 
in phosphorylated Akt in female Sprague Dawley rats supplemented with 
10% liquid fructose for 8 weeks (non-published results). However, in both 
models there was a significant decrease when the phospho-Akt levels were 
normalised to plasma insulin, suggesting that insulin action was impaired in 
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skeletal muscle from fructose-fed rats. Interestingly, we observed a marked 
increase in the mRNA expression of GPR 119 in the skeletal muscle of our 
fructose-supplemented rats. GPR 199 is a G protein-coupled receptor which 
under activation impairs fatty acid and glucose oxidation by skeletal muscle, 
a condition that potentiates insulin resistance [57]. Thus, our preliminary 
results may be in accordance with fructose inducing insulin resistance in this 
tissue. 
 
2. Epidemiological and clinical studies 
 
 Since our last review published in 2012, there have been a number of 
epidemiological and clinical studies investigating the effects of high 
consumption of fructose or other sugar-sweetened beverages, in humans. 
One of these studies aimed to investigate the association between the 
consumption of sweetened beverages (juices and nectars, sugar-sweetened 
soft drinks and artificially sweetened soft drinks) and the incidence of type 2 
diabetes in a European cohort, the EPIC-InterAct study [58]. In this cohort, 
composed of men and women, only sugar-sweetened soft drink consumption 
was associated with an increase in the risk for type 2 diabetes after 
adjustment for body mass index. This suggests that obesity is not the only 
nor the main mediator of the association, and that other mechanisms of 
action might be involved, such as insulin resistance. In a similar study 
performed in a cohort composed only of women, similar results were 
obtained, although in this case not only for sugar sweetened beverages but 
also for artificial sweetened beverages [59]. However, none of these studies 
specifically assessed the effects of fructose consumption. Aeberli et al. [60] 
performed a randomized, cross-over trial in 9 healthy, normal-weight male 
volunteers (aged 21-25 years) who consumed four different sweetened 
beverages for 3 weeks each: medium fructose (MF) at 40 g/day, and high 
fructose (HF), high glucose (HG), and high sucrose (HS) each at 80 g/day. 
The results of the euglycemic-hyperinsulinemic clamps showed that the 
suppression of hepatic glucose production during insulin infusion was 
significantly lower after the HF intervention compared with HG, showing a 
decrease in hepatic insulin sensitivity after fructose consumption. In contrast, 
no significant differences among diets were seen in insulin-mediated glucose 
clearance, which is a parameter of whole-body (essentially muscle) insulin 
sensitivity. This suggests that impaired glucose tolerance by high fructose 
intake is explained by impaired suppression of hepatic glucose output rather 
than by muscle insulin resistance, at least with short-term high-fructose 
diets. However, the authors consider that it is possible that longer periods of 
fructose administration could also alter muscle insulin sensitivity, possibly 
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through a progressive deposition of ectopic fat in skeletal muscle. Another 
important finding was that all diets containing fructose (MF, HF, and HS), 
caused an elevation in total and LDL cholesterol, but not in triglyceride 
levels, compared with HG [60]. The lack of effect on plasma triglyceride 
may be attributed to the relatively low amount of fructose administered, 
compared to previous studies [61, 62]. 
 The above cited trials were performed in healthy individuals, but it has 
been claimed that the effects of fructose may be worse in subjects with 
obesity or other related metabolic diseases. Lewis et al. [63] performed a 
randomized controlled crossover study in overweight/obese subjects, who 
completed two 6 week dietary periods (separated by 4 week washout) 
consisting of two isocaloric diets that differed only in their sucrose content, 
the low-sucrose diet contributing 5% of total daily energy and the high-
sucrose diet 15% of total daily energy. There was no difference between 
both diets on insulin resistance measured by the hyperinsulinaemic-
euglycaemic glucose clamp, suggesting that there is no beneficial effect of a 
low-sucrose diet on peripheral glucose utilization. However, fasting plasma 
glucose, which is determined mainly by hepatic glucose production, was 
higher after the 15% sucrose diet compared to the 5% sucrose diet. 
Moreover, the results of the oral glucose tolerance test indicated higher 
insulin levels after the high sucrose diet at comparable levels of glycaemia 
[63]. These results would suggest that there is indeed some degree of hepatic 
insulin resistance after the higher sucrose diet. 
 In another study by Sevastianova et al. [64], overweight subjects were 
instructed to continue their normal diet and in addition to consume an extra 
1000 kcal/day with 98% of energy from carbohydrates (candy, pineapple 
juice, sugar-sweetened soft drinks, and/or carbohydrate-loading drink) for 3 
weeks, and thereafter they were placed on a hypocaloric diet for 6 months. 
During the carbohydrate overfeeding period, the study subjects gained a 2% 
of their body weight, which was correlated with a 27% increase in liver fat. 
The ratio of saturated to essential fatty acids in serum and VLDL 
triglycerides, taken as an index of de novo lipogenesis, was also significantly 
increased and correlated with liver fat content. All these changes are 
reversible by weight loss. The results suggest that an excess of simple sugar 
intake has a key role in the pathogenesis of NAFLD. 
 Children and youngsters constitute a population segment in which the 
prevalence of obesity is increasing, and this has coincided with a large 
increase in the consumption of sugar-sweetened beverages. Refreshing 
beverages enriched in fructose actually are the main source of dietary sugars 
in children. To explore the acute effects of fructose, Jin et al. performed a    
2-day crossover feeding study in children with or without NAFLD [65]. 
Molecular insights on fructose effects 15 
Participants were randomly assigned to two nonconsecutive 24-h periods 
receiving three macronutrient-balanced meals with 33% of total estimated 
daily calories provided as an isocaloric, sugar-sweetened beverage 
containing either glucose or fructose, during a 24-h period.  The results 
showed that fructose caused a more marked increase in plasma triglyceride 
levels than glucose did, both in children with NAFLD and in those without 
NAFLD, but the increases were greater in children with NAFLD.  
 DeRuyter et al. [66] conducted a double-blind, randomized intervention 
study in 641 normal-weight children, who were randomly assigned to receive 
1 can per day of a noncaloric, artificially sweetened beverage or a                    
sugar-containing beverage (with 26 g of sucrose, providing 104 kcal). Both 
beverages tasted and looked essentially the same and were not labeled, to 
eliminate the effects of psychological cues and socially desirable behavior. 
The results of the study showed that weight gain, waist-to-height ratio, and fat 
mass were significantly higher in the group that received the sugar-sweetened 
beverage. To gain insight into the mechanisms explaining this difference, the 
same group recently conducted another similar study in children, and 
concluded that sugar-sweetened and sugar-free beverages produced similar 
satiety [67]. Therefore when children are given sugar-free instead of               
sugar-containing drinks they do not feel a need to eat more to compensate for 
the missing calories, so they gain less weight and accumulate less body fat. 
 Some clinical studies are intervention studies aimed to evaluate the effects 
of reducing fructose consumption. For example, Ebbeling et al [68] randomly 
assigned 224 overweight and obese adolescents who regularly consumed 
sugar-sweetened beverages to experimental and control groups. The 
experimental group received a 1-year intervention consisting of home delivery 
of noncaloric beverages to decrease consumption of sugar-sweetened 
beverages, with a follow-up for an additional year. At 1 year, increases in body 
mass index were significantly smaller in the intervention group than the 
control group, but changes were not sustained at 2 years.  
 
3. Conclusion 
 
 Excessive sugar consumption is beginning to be recognized as a huge public 
health problem worldwide. Some voices have risen about the need to promote 
policies to control the use of fructose [69], but others consider that public health 
policies to limit fructose in diet are premature because there is a lack of crucial 
studies demonstrating the toxicity of fructose [70,71]. Our studies performed in 
animal models, rats and mice receiving liquid fructose for short periods of time 
(2 weeks to 3 months) demonstrate that fructose exerts specific effects not 
merely dependent on the caloric excess provided. In addition, our results suggest 
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that the metabolic alterations induced by fructose are a dynamic continuum, and 
some effects that were apparent at short exposure times were not present after 
longer treatments. Taking into account that excessive fructose consumption in 
humans is usually a chronic dietary habit, our next challenge is to study the 
effects of fructose in these animal models after long-term supplementation.   
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Abstract. Protein misfolding and aggregation into amyloid-like 
structures is related with an increasing number of both non-
neuropathic (either localized or systemic) and neurodegenerative 
human disorders. Decrypting the mechanisms and implications 
underlying amyloid assemblies has become a central issue in 
biology and medicine. Compelling evidence show that the 
formation of amyloid aggregates has a negative impact in cell 
physiology, entailing the cell dysfunction and finally apoptosis and 
cell death. The aim of the present review is to illustrate the 
currently status of the most common and/or debilitating 
conformational diseases, from Alzheimer to prion diseases.  
 
Introduction 
 
 Proteins and peptides are the main cellular components allowing 
organisms to execute the cellular functions required for life through complex and 
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usually transient networks of intermolecular interactions [1]. In this complex 
network the proteins display functions of (1) binding, wherein the specific 
recognition of other molecules is central to protein function and specific 
binding is governed by shape complementarity and polar interactions such as 
hydrogen bonding; (2) catalysis, essentially every chemical reaction in the 
living cell is catalyzed, and most of the catalysts are protein enzymes;  (3) 
switching, since proteins are flexible molecules and their conformation can 
change in response to microenvironment changes act controlling cellular 
processes. 
 In the cell, the final protein conformational equilibrium is the result of a 
delicate and multi-step balance regulated by diverse intrinsic and extrinsic 
factors. It is known that the unfolded polypeptide chain dramatically 
determines the conformational structure and folding pathways of the proteins 
[2]. Usually, when the polypeptide chain leave the ribosome a fast 
conformational process is produced (with nanoseconds or picoseconds rates) 
favoring that the smallest proteins fold spontaneously on a millisecond or 
even microsecond time scale that exclude the possibility of a random-search 
mechanism for protein folding [3]. Since alternative structures, as               
amyloid-like ones that in addition may represent the primordial ground state 
of protein folding and assembly reactions, can be a possible alternative (even 
probable in certain situations) to native and functional protein structure, 
protein aggregation has now become recognized as an important and generic 
aspect of protein energy landscapes [4]. Since the biophysical properties that 
promote folding also tend to favor intermolecular contacts, leading to the 
formation of β-sheet-enriched insoluble assemblies, protein folding into 
stable globular conformations is in competition with aggregation into       
non-functional and usually toxic structures as amyloid-like structures [5]. 
 It is known that the self-assemble potential into -sheet enriched 
amyloid-like structures of any protein is embedded in their primary structure 
[6,7]. However, although all polypeptide chains could theoretically 
aggregated in amyloid conformations, it has been stated that while the 
majority of the primary sequence is unable to self-associate per se, short 
sequences in the chain protein, usually named ―hot-spots‖ are the final 
responsible to trigger the protein aggregation in amyloid conformation [8]. 
Interestingly, although these short regions, able to form amyloid fibrils by 
themselves [9], are inherently present in the sequence of globular proteins, 
evolutionarily it effect have been minimized by the flanking with anti-
aggregation sequences named ―gatekeepers‖, being embedded in the protein 
core or protected for the quaternary structure. Nevertheless, when these 
amyloid-like regions are exposed to solvent (i.e. in situations of deregulations 
of the protein synthesis, environmental alterations), the intermolecular 
contacts leading the formation of β-sheet enriched aggregates could be 
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drastically favored [10]. Importantly, the presence of these hot-spot regions is 
usually observed in the proteins involved in conformational diseases. 
 In the recent years, protein misfolding and aggregation has become a 
widely active area of research, mainly because of the connection between the 
formation of insoluble protein deposits in human tissues and the development 
of dozens of human diseases. The conformational diseases, linked to protein 
aggregation into amyloid conformations, ranked from neurodegenerative 
affections such as Alzheimer (AD), Parkinson (PD), Huntington (HD), 
frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) or human 
transmissible sporadic encephalopathies (TSEs) commonly known as prion 
diseases, to non-neurodegenerative systemic and localized amyloidosis as light-
chain (AL) amyloidosis or type II diabetes, respectively [11] (see Tables 1a-c). 
 
Table 1a. Human diseases associated with formation of extracellular amyloid deposits 
or intracellular inclusions with amyloid-like characteristics: Neurodegenerative 
diseases 
 
     Disease Aggregating protein or peptide 
     Alzheimer’s disease Amyloid β peptide  
     Spongiform encephalopathies Prion protein or fragments thereof  
 
     Parkinson’s disease α-Synuclein  
     Dementia with Lewy bodies α-Synuclein  
     Frontotemporal dementia Tau 
     Amyotrophic lateral sclerosis Superoxide dismutase 1  
     Huntington’s disease Huntingtin with polyQ expansion  
     Spinocerebellar ataxias Ataxins with polyQ expansion  
     Spinocerebellar ataxia TATA box-binding protein with  
polyQ expansion  
     Spinal and bulbar muscular atrophy Androgen receptor with polyQ  
expansion 
     Hereditary dentatorubral-pallidoluysian atrophy Atrophin-1 with polyQ expansión 
     Familial British dementia ABri 
     Familial Danish dementia ADan 
Extracted from ref. [11]. 
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Table 1b. Human diseases associated with formation of extracellular amyloid 
deposits or intracellular inclusions with amyloid-like characteristics: 
Neurodegenerative diseases: Non-neuropathic systemic amyloidosis. 
 
     Disease Aggregating protein or peptide 
     AL amyloidosis Immunoglobulin light chains or  
fragments 
     AA amyloidosis Fragments of serum amyloid A protein 
     Familial Mediterranean fever Fragments of serum amyloid A protein 
     Senile systemic amyloidosis Wild-type transthyretin  
     Familial amyloidotic polyneuropathy Mutants of transthyretin  
     Hemodialysis-related amyloidosis β2-microglobulin  
     ApoAI amyloidosis N-terminal fragments of  
apolipoprotein  
     ApoAII amyloidosis AI N-terminal fragment of  
apolipoprotein  
     ApoAIV amyloidosis AII N-terminal fragment of  
apolipoprotein AIV  
     Finnish hereditary amyloidosis Fragments of gelsolin mutants  
     Lysozyme amyloidosis Mutants of lysozyme 
     Fibrinogen amyloidosis Variants of fibrinogen 
     Icelandic hereditary cerebral amyloid angiopathy α-chain Mutant of cystatin C 
Extracted from ref. [11]. 
 
 These protein deposits, constituted mainly by fibrillar structures known 
as amyloid aggregates, are thread-like protein aggregates with a cross-β 
structure, which is composed by β-strands stacked perpendicular to the fibril 
axis [11]. For years the structural characterization of these amyloid-like 
aggregates were limited due to the lag of crystalline forms and their low 
resolution by solution nuclear magnetic resonance (NMR). However, these 
aggregates often display enriched β-sheet structure detectable by X-ray 
diffraction, Fourier transform infrared spectroscopy (FTIR) and circular 
dichroism (CD). Like this, they are able to bind amyloid-tropic dyes as 
Thioflavin-T (fluorescence spectroscopy and optical microscopy) or Congo 
Red (UV/Vis spectroscopy and birefringence), present proteinase K digestion 
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resistance and fibrillar structures are detectable by transmission electronic 
microscopy (TEM) or atomic forces microscopy (AFM). Moreover they 
show seeding capacity reminiscent of amyloids, form homogeneous 
aggregates without cross-aggregation, and display aggregation propensities 
strongly affected by mutations. Importantly, since some of these tests can be 
non-conclusive, giving false positive and false negative, nowadays the 
confirmation of amyloid structures is usually based upon the positive in 
diverse of these amyloid tests [2].  
 
Table 1c. Human diseases associated with formation of extracellular amyloid deposits 
or intracellular inclusions with amyloid-like characteristics: Neurodegenerative 
diseases: Non-neuropathic localized amyloidosis 
 
     Disease Aggregating protein or peptide 
     Type II diabetes 
Amylin, also called islet  
amyloid polypeptide (IAPP) 
     Medullary carcinoma of the thyroid Calcitonin  
     Atrial amyloidosis Atrial natriuretic factor 
     Hereditary cerebral haemorrhage  
     with amyloidosis 
Mutants of amyloid β peptide  
     Pituitary prolactinoma Prolactin  
     Injection-localized amyloidosis Insulin  
     Aortic medial amyloidosis Medin  
     Hereditary lattice corneal dystrophy Mainly C-terminal fragments of                 
kerato-epithelin  
     Corneal amylodosis associated with trichiasis Lactoferrin 
     Cataract γ-Crystallins  
     Calcifying epithelial odontogenic tumors Unknown 
     Pulmonary alveolar proteinosis Lung surfactant protein C  
     Inclusion-body myositis Amyloid β peptide 
     Cutaneous lichen amyloidosis Keratins 
Extracted from ref. [11]. 
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 Due to the large number of conformational diseases, in this review we 
tempt to provide readers concise information about the most prevalent 
conformational diseases as well as the most debilitating ones. In this way we 
have chosen: Alzheimer’s disease (AD), Parkinson’s disease (PD), 
forntotemporal dementia (FTD), Huntington’s disease (HD) and amyotrophic 
lateral sclerosis (ALS) as the most prevalent neurodegenerative diseases. In 
addition, spongiform encephalopathies including Creutzfeldt-Jakob’s disease 
(CJD), the most prevalent human spongiform encephalopathy, has been 
added as the most debilitating and transmissible case (see Table 2). 
 
Table 2. Human diseases associated with formation of extracellular amyloid deposits 
or intracellular inclusions with amyloid-like characteristics. 
 
Disease Cases Cases per 100,000 population* 
 
Alzheimer’s disease  
 
4 000 000 
 
1 450 
 
Parkinson’s disease 
 
1 000 000 
 
   360 
 
Frontotemporal dementia 
      
     40 000 
 
    14 
 
Huntington’s disease  
      
     30 000 
 
    11 
Amyotrophic lateral sclerosis      20 000      7 
Progressive supranuclear palsy       15 000      5 
Spinocerebellar ataxias      12 000      4 
Pick’s disease        5 000      2 
Prion disease          400    <1 
Extracted from ref. [12]. * Data are based on a population of approximately 275 
millions in 2000. 
 
1. Alzheimer’s disease  
 
 Among all dementia types, Alzheimer’s disease (AD) represents ≈70% 
of these cases. By 2009, more than 35 million cases of AD were recorded 
worldwide, with an expectancy of doubling this number in 2050 [1,13]. Two 
distinctive features characterize the brain physiopathology of AD patients: (1) 
the apparition of extracellular amyloid plaques formed as a consequence of 
the accumulation in amyloid form of -amyloid peptide (A ) and (2) 
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neurofibrillary tangles mainly formed by hyperphosphorylated forms of 
neuronal tau protein associated in microtubules [1,14]. 
 While amyloid plaques are primarily composed of the A , a host of other 
compounds such as proteoglycans, inflammatory molecules, serum related 
molecules, metal ions, amyloidogenic related molecules, protease and 
clearance related elements, antioxidant defense protein, cholinesterases and 
up to 26 proteins enrich these amyloid deposits [15,16]. A , the main 
component of amyloid plaques, is a hydrophobic 39–43 amino acid peptide 
resulting from the proteolysis of the trans-membrane amyloid protein 
precursor (APP) by - or -, and -secretases [15]. Interestingly, this 
proteolysis can follow two different pathways with different cleavages: (1) 
non-amyloidogenic pathway in which the action of the - and -secretases 
undergo the formation of a soluble and non-amyloid peptide or (2) 
amyloidogenic pathway wherein the action of the -secretase in a first step 
entail the apparition of a A  peptide that can be quickly aggregated in 
amyloid conformation [15]. 
 Tau protein binds microtubules through some repeated domains (R1–R4) 
(encoded by exons 9–12) located at the C-terminus of the molecule, however 
in AD this role is ineffective to keep the cytoskeleton well organized in the 
axonal process [17]. The conformational changes and misfoldings in the 
normal structure of tau lead the formation of paired helical filament (PHF), 
the main component of the neurofibrillary tangles, as result of microtubule-
associated protein tau in a hyperphosphorylated state. It is know that the 
hyperphosphorylation of tau trigger its inability to bind to microtubules that 
are associated in PHFs [18]. Inasmuch as tau protein stabilize the neural 
axons, this binding incapacity undergoes the axon disruption, and finally the 
neuron disfunction and neural cytotoxicity.  
 The apparition of extracellular amyloid plaques and neurofibrillary 
tangles lead to nerve cell death and tissue loss throughout the brain. In the 
Alzheimer's brain the cortex shrivels up, initially damaging areas involved in 
thinking (primarily in the formation of new memories) and language mainly 
affecting the Broca’s and Wernicke’s areas in the hippocampus. Although the 
disease progression rate varies greatly the average survival is 8 years can 
reach up to 20 in some cases. In early stages, that may have begun 20 years 
before diagnosis, extracellular amyloid plaques and neurofibrillary tangles 
begin to form in brain areas involved in learning and memory, and thinking 
and planning. In mild to moderate stages, generally last from 2 - 10 years, the 
evolution of the disease entails a dramatic increment of the presence of 
plaques and tangles in the memory, thinking and language, entailing clear 
language and spatial difficulties. Finally, in the severe stages, usually last 
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from 1 - 5 years, senile plaques and tangles are massively scattered for all 
cortex region entailing dramatic increment of neuronal death with serious 
damage and consequences for the patient. In this stage the patient lose the 
abilities of communicate, recognize, love and self-care. 
 
2. Parkinson’s disease 
 
 Parkinson’s disease (PD), disease associated to motor symptoms such as 
bradykinesia, tremor, rigidity and impaired postural reflexes, as well as 
mental disorders like depression or psychosis, is the second most common 
neurodegenerative illness after AD [19]. The prevalence of PD, affecting 
approximately 7 million people worldwide, is estimated at 0.3% of the entire 
population and about 1% in people over 60 years of age [20,21]. The 
prevalence and incidence of PD increase exponentially with age, and are 
slightly higher in men than in women. Interestingly, although PD 
traditionally has been considered a non-genetic disorder, around 15% of 
individuals with PD have a first-degree relative who has the disease and at 
least 5% of Parkinson’s cases have forms of the disease that occur because of 
a mutation of one of several specific genes [22]. 
 PD is a progressive neurodegenerative disease, primarily affecting voluntary 
and controlled movement, consequence of death of dopamine-generating cells in 
the substantia nigra and loss of dopaminergic terminals in the basal ganglia and 
with motor impairments [23]. The abnormal accumulations of -synuclein in 
Lewy bodies suggest that this protein has a central role in a group of 
neurodegenerative diseases known as synucleinopathies [23]. -synuclein is a 
presynaptic neuronal protein of 140 amino acids encoded by a gene on 
chromosome 4 with a putative role in synaptic function and neural plasticity [24]. 
Although -synuclein is extensively expressed in the central nervous system, 
neuronal death and Lewy body formation in PD are mostly restricted to the 
substantia nigra [23]. As previously shown in AD, under certain conditions              
-synuclein can self-polymerize in amyloid-like conformations. Thus,                       
-synuclein soluble monomers nucleate becoming oligomers (protofibrils) that 
can be associated forming fibrils and finally resulting Lewy’s body inclusions. 
While the toxicity of Lewy’s bodies is nowadays unclear, it seems clearer the 
implication of protofibrils in the toxicity via formation of circular amyloid pores 
entailing ion deregulation, membrane disruption and finally apoptosis and cellular 
death [25]. 
 Despite the amyloid aggregation of -synuclein is initially localized in 
the substantia nigra in the mesencephalon, during the progression of the 
disease are increasing protein aggregates that appears in different areas of the 
brain. The increment of the amount of Lewy’s bodies in the brain entails 
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increment in the severity of the symptomatology and neuronal affectation. 
Interesting, this pathology appears to spread throughout the brain as the 
disease progresses. Recent works show that this spreading process could be 
caused by neuron-to-neuron spread of α-synuclein aggregates and that the 
anatomical pattern of progression of lesions between axonally connected 
areas results from the axonal transport of such aggregates [26]. 
 
3. Frontotemporal dementia 
 
 Frontotemporal dementia is a term grouping diverse uncommon disorders 
that primarily affect the frontal and temporal lobes of the brain. The 
degeneration of these FTD lobes is associated with alterations of the 
personality, behavior and language. As previously observed in AD, the loss 
of neuronal cells is associated to the misfolding of tau protein. For years this 
fact has led to diagnostic confusions entailing an infra-diagnosis of FD cases 
which were erroneously attributed to AD; however, nowadays more accurate 
evaluation methods allowing more clear differentiation between both disease 
have shown that the incidence and prevalence of FTD were clearly more 
elevated than the initial considered. 
 Although FTD tends to occur at a younger age than does AD, typically 
between the ages of 40 and 70, but incidence and prevalence is increased for 
the age and it is more frequent in men. The prevalence estimates in the age 
categories of 45–64 years old have ranged from 15 to 22 per 100,000 person 
each year and an estimated incidence from 2.7 to 4.1 per 100,000 person each 
year [27]. Age-specific prevalence rates is calculated for 1.2 per 100,000 in the 
40 to 49 age group; 3.6 per 100,000 in the 50 to 59 age group; 9.4 per 100,000 
in the 60 to 69 age group; and 3.8 in the 70 to 79 age group. Thus, the highest 
prevalence is found at ages 60 to 70, although patients older than 85 years have 
been reported. Interestingly, about 25% of patients have a hereditary form of 
FTD with autosomal dominant inheritance. Mutations in the tau gene are 
present in less than half of familial FTD cases. A mutation in the CHMP2B 
gene on chromosome 3 is probably even rarer. Therefore, it is very likely that 
more common disease-causing genes, one of them possibly located on 
chromosome 17q close to the tau gene, have still to be identified [27,28]. 
 
4. Hungtington’s disease 
  
 Polyglutamine (polyQ) Pathies are a particular class of conformational 
diseases linked to proteins associated to several different types of hereditary 
neurodegenerative disorders wherein a polyQ extension become thus a 
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molecular hallmark for fibril propensity, undergoing the protein 
polymerization in amyloid-like conformations. Now, nine different 
conformational diseases have been shown to be related to polyQ extensions: 
Huntington’s disease (HD), spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7, 
17, dentatorubral-pallidoluysian atrophy (DRPLA) and bulbar muscular 
atrophy (SBMA) [1]. 
 Hungtington’s disease (HD), also known as Hungtington’s chorea, is a 
rare, adult-onset, autosomal dominant linked to mutation in Huntingtin (HTT) 
gene, and progressive neurodegenerative disease. HTT was the first               
disease-associated gene to be molecularly mapped to a human chromosome. 
The mutation turns out that the HTT gene contains a region where the triplet 
nucleotide CAG is repeated several times. The number of CAG repeats 
present in the HTT gene determines whether an individual will have HD. 
Thus, while from 6 to 26, normal allele, and 27-35, intermediate allele (IA) 
also termed large normal allele, CAG repeats do not entail misfolding protein 
and aggregationan; 36-39 repeats, incomplete or reduced penetrance allele 
(RPA), will be at increased risk for HD; and 40 or more CAG repeats, full 
penetrance allele (FPA), will definitely manifest disease phenotypes 
undergoing amyloid-like aggregation [29]. Importantly, recent works show 
that the length of polyQ extension is directly related with the protein 
destabilization, and consequently the formation of amyloid aggregates [30]. 
This fact is in correlation with the previously shown; the number of repeats 
determines the probability an individual will have HD because an increased 
number of repeats triggers the amyloid conversion of the protein. 
 The worldwide prevalence of HD, similar for men and women, is 5-10 
cases per 100,000 persons. HD symptoms, which typically manifest between 
35 and 55 years of age, ranked from behavioral changes, psychiatric, 
movement, feeding, communication and sexual problems in a progressive 
manner. In early stage the usual symptoms are personality changes, mood 
swings and unusual behavior as consequence of the initial affectation of basal 
ganglia called the neostriatum, which is composed of the caudate nucleus and 
putamen, as well as the substantia nigra, layers 3, 5 and 6 of the cerebral 
cortex, the hippocampus, purkinje cells in the cerebellum, lateral tuberal 
nuclei of the hypothalamus and parts of the thalamus [31].   
 
5. Amyotrophic lateral sclerosis 
  
 Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease 
and motor neuron disease, encompasses a group of genetic neurodegenerative 
disorders characterized by progressive and lethal muscle weakness caused by 
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loss of both upper and lower motor neurons of central and peripheral motor 
neurons [32-34]. The hallmark of this disease is the selective death of motor 
neurons in the brain and spinal cord, leading to paralysis of voluntary muscles. 
The paralysis begins focally and disseminates in a pattern that suggests that 
degeneration is spreading among contiguous pools of motor neurons [35]. This 
progressive degeneration of the motor neurons in ALS eventually leads to their 
death. When the motor neurons die, the ability of the brain to initiate and 
control muscle movement is lost. With voluntary muscle action progressively 
affected, patients in the later stages of the disease may become totally 
paralyzed. Symptoms typically have a localized limb or bulbar onset and 
progress to other muscle groups of the body. The degeneration of motor 
neurons, that can no longer send impulses to the muscle fibers altering the 
muscle movement, also entail denervation of respiratory muscles leading 
dysarthria from early phases of the illness and finally respiratory complications 
that are the most common causes of death. In addition, the dysphagia is a 
characteristic symptom that appears in the disease evolution dramatically 
difficulty the deglutition and the alimentation of the patients. Thus, ALS is 
characterized by 3- to –5-yr median survival post-diagnosis [36]. 
 The incidence and prevalence of ALS are 1–2 and 4–6 per 100,000 each 
year, respectively [35]. Although most cases are classed as sporadic ALS 
(sALS), 10% of cases are inherited known as familial ALS (fALS). 
Interesting, ALS most commonly occurs in people between the ages of 40 
and 60, and is slightly more men than women [37]. Five Mendelian gene 
defects were initially reported to cause ALS. The protein products of these 
mutated genes are cytosolic Cu/Zn superoxide dismutase (SOD1), alsin, 
senataxin (SETX), synaptobrevin/ VAMP (vesicle-associated membrane 
protein)-associated protein B (VAPB) and dynactin [35]. However, fALS 
have been attributed to mutations in 12 different genes, the most common 
being SOD1, FUS and TARDBP—mutations in the other genes are rare [38]. 
The SOD1 misfolding and precipitation in amyloid-like aggregates is 
considered one of the main causes of ALS. SOD1 is a ubiquitous, 
predominantly cytosolic protein consisting of 153 amino acids that acts as a 
homodimer. Each subunit of SOD1 binds one zinc and one copper atom, and 
through cyclical reduction and oxidation (dismutation) of copper, SOD1 
converts superoxide radicals, a by-product of oxidative phosphorylation, to 
hydrogen peroxide and molecular oxygen. The exact mechanism by which 
SOD1 mutations lead to ALS pathology is unknown although several toxic 
properties of mutant SOD1 such as aberrant oxidative stress, protein 
instability, and mitochondrial damage have been proposed to be causative 
[35]. Interestingly, the presence of mutant SOD1 in non-neuronal cells 
contributes to pathogenesis and is needed for disease progression [39]. 
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6. Spongiform encephalopathy 
  
 Prion diseases, also termed transmissible spongiform encephalopathies 
(TSEs), compresses fatal, progressive and transmissible neurodegenerative 
diseases that affect humans and a wide variety of animals [40]. Although 
initially the TSEs were considered caused by a ―slow virus‖, in 1982 the 
Nobel Prize Stanley B. Prusiner showed that the responsible of this group of 
diseases was a protein that coined ―prion‖ from the ―protein-only‖ concept. 
In human prion diseases include Kuru, Creutzfeldt-Jakob disease (CJD), 
variant CJD (vCJD) –―after mad-crows disease–, Gerstmann-Sträussler-
Scheinker (GSS) disease and fatal familial insomnia (FFI) (see Table 3) [40]. 
 The prion disease is related to a 209 amino acids protein normally found 
anchored in the cell membrane by a C-terminal glycosylphosphatidyl inositol. 
The prion propagation is usually associated with post-transcriptional 
convertion of normal cellular prion protein (PrP
C
) –soluble, protease-sensible 
and native form– to amyloid-like aggregated isoform (PrPSc) –less soluble 
and proteinase-K resistant– [12,41]. In the prion infectivity, the PrPSc 
transfers its amyloid conformation from the spleen to the central nervous 
system (CNS) in a biphasic model with the first phase characterized by 
widespread colonization of lymphoreticular organs and the second one 
involving the CNS and also probably the peripheral nerves, acting in 
concomitance with vesicle-associated infectivity, and cell-free, free-floating 
oligomeric or protofibrils infectious particles [40,41]. 
 
Table 3. Human prion diseases. 
 
Disease Etiology 
Kuru  Infection 
Creutzfeldt-Jakob disease  
          Iayrogenic Infection 
          Sporadic  Unknown 
          Familial PRNP mutation 
          Variant  Presumed BSE infection 
Gerstmann-Sträussler-Scheinker 
disease 
PRNP mutation 
Fatal familial insomnia PRNP mutation 
                         Extracted from ref. [40]. 
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 The human prion diseases are classified as infectious, inherited or 
sporadic disorders, depending on the clinical, genetic, and neuropathological 
findings. The clinical evolution is characterized by widespread 
neurodegeneration; therefore, affected individuals exhibit clinical symptoms 
of both cognitive and motor dysfunction. After infection and/or conversion 
triggering the disease undergoes a fast and progressive dementia, myoclonus, 
visual or cerebellar impairment, pyramidal/extrapyramidal signs, and akinetic 
mutism [40]. 
 
8. Conclusion 
 
     In the cell, the biological function is determined for the native protein 
fold.  In this way, problems in the protein fold with the consequent 
apparition of misfolded species can disturb the essential cellular processes. 
The protein misfolding entailing the polypeptide aggregation into amyloid 
structures have been associated with an increasing number of human 
diseases as Alzheimer, Parkinson or prion diseases. Importantly, recent 
studies have shown that the amyloid aggregation process is not limited to 
disease-related proteins but appears to be a generic property of the proteins 
in both eukaryotic and prokaryotic cells. The possibility that the amyloid 
formation is a universal and omnipresent process shared for all life 
organisms entails important consequences in biology: (1) If the folding and 
aggregation compete in the cell, during the evolution the prevention of the 
protein aggregation have to be an essential selective mechanism of the 
regulation. (2) The fact that amyloid formation is an omnipresent process 
entails that the number of human genetic diseases associated to misfolding 
and aggregation could be much larger than previously thought. (3) 
Interestingly, as the paradigmatic case of the prion proteins that use the 
amyloid-like structure and the particular amyloidal properties to become 
self-perpetuating; in several cases, amyloid structures could have been 
selected during the evolution for functional purposes.  
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Abstract. A long-standing question in evolutionary biology is 
what defines a species. The biological species concept considers a 
species as a population of individuals that interbreeds freely and 
produces viable offspring. Therefore, reproductive isolation is the 
essence of species. Hybrid necrosis is one form of post-zygotic 
reproductive isolation. In this chapter, we summarize what is 
known to date about this phenomenon and highlight progress made 
in the understanding of these immune-triggered hybrid 
incompatibilities through our research in the plant model 
Arabidopsis thaliana.  
 
1. Introduction 
 
1.1. Reproductive isolation: The essence of speciation 
 
 According to the biological species concept (BSC) two populations are 
considered as separate species if they have departed from an interbreeding  
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situation [1]. Therefore, reproductive isolation (RI) leading to restriction and 
ultimately disruption of gene flow between populations [2] is, by definition, 
the essence of species. 
 Isolating barriers impeding gene flow can act before (pre-zygotic) or 
after (post-zygotic) fertilization. In plants, pre-zygotic RI barriers comprise 
pre-pollination and pollen recognition barriers. Pre-pollination barriers 
include factors such as ecological or geographical isolation, flower 
morphology and color with influence on pollinator-visitation, as well as 
(substantial) differences in flowering time. Pollen recognition barriers lead to 
the abortion and inhibition of pollen tube growth on stigma of other plant 
species. These processes and their implications in contributing to RI have 
been subject of recent reviews [2].  
 If post-zygotic RI barriers are at play, fertilization is possible but hybrid 
offspring may display a range of physiological and morphological defects. 
These defects range from embryo lethality, sterility or hybrid necrosis affecting 
growth and reproduction. Since some genetically characterized hybrid necrosis 
phenotypes have been associated to the immune system, the term „immune-
triggered hybrid incompatibilities‟ is being generalized, although there might 
be other cases where the immune system is not the cause of cell death. 
 The underlying genetic causes for post-zygotic RI barriers in plants can 
be polyploidy, large chromosome-rearrangements and lethal epistatic 
interactions between parental alleles among others [2,3].  A number of recent 
reviews summarize the major findings for the first two causes of post-zygotic 
RI barriers in plants [2,4,5]. In this chapter we will rather focus on the latter, 
which is the aim of our research: Epistatic interactions between parental 
alleles, which conform to the Dobzhansky-Muller (DM) model of HI and 
leading to an autoimmune-like response.  
 The DM model explains, in a relatively simple way, how incompatibilities 
between closely related species arise without either one having to go through a 
fitness valley (Fig. 1) [6,7]. It proposes that incompatible genes may arise in 
divergent lineages, which are neutral in a non-hybrid genetic background. 
However, it is agnostic about the reasons that drive divergence at incompatible 
loci. The major advance made by Dobzhansky and Muller was the conclusion 
that incompatibilities are due to the epistatic interaction between parental 
alleles [8]. This explains why, in the first place, incompatibilities can arise 
without going through an adaptive valley [8]. This would likely be the case, if 
incompatibility results from allelic divergence at a single locus (e.g. alleles „A‟ 
and „a‟ of one gene), because individuals with genotype „Aa‟ would suffer from 
reduced fitness. Despite the theory, single-locus incompatibilities, like 
heterozygous disadvantage, have been described elsewhere. However, evidence 
tells us that not all mutations supposedly lethal in the laboratories are 
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deleterious in nature and can be somehow tolerated for some generations. 
Anyhow, the focus of this chapter are DM incompatibilities owing to epistasis 
between two or more loci. 
 Typically, post-zygotic RI barriers are thought to contribute less to total 
RI than early-acting pre-zygotic RI barriers [2]. However, pre-zygotic RI 
such as geographical isolation or occupation of ecological niches (ecological 
speciation) might drive the evolution of post-zygotic RI, in particular those 
conforming to the DM-model of hybrid incompatibilities [2]. Furthermore, 
plant speciation, involving post-zygotic RI barriers often requires the 
accumulation of multiple independent DM-incompatibilities to achieve and 
maintain a sufficient cessation of gene-flow between separating species [2,5]. 
Studying speciation is possible in two different approaches: one is the 
“spyglass” – looking at individual species and identifying processes that 
might have lead to speciation [9]. The other is the “magnifying glass” – 
studying within-species incompatibilities between ecotypes or races that may 
be indicative of incipient speciation [9,10].  
 For evolutionary biologists and geneticists, studying DM 
incompatibilities within species offers the unique opportunity to examine 
possible incipient speciation and the underlying molecular mechanisms [9].  
 
 
 
Figure 1. The Dobzhansky–Muller (DM) model of genetic incompatibilities. (a) In 
the DM model, starting from an ancestral genotype (aabb) different incompatible 
alleles (A and B, depicted in green and red, respectively) arise in divergent 
populations which are neutral in their own non-hybrid genetic backgrounds (AAbb 
and aaBB). Hybridization brings together both incompatible alleles that have not met 
before together (AaBb) and triggers incompatibility. (b) In divergent populations 
genetic drift and/or selection may lead to an increase of incompatible alleles. This is 
illustrated by an increase of green (A) and red (B) area.  
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1.2. Hybrid Necrosis: immune-triggered HI 
 
 Frequently, plant breeders have observed a common phenomenon of 
post-zygotic RI, known as hybrid necrosis, which occurred in F1 and F2-
hybrids as well as in later back cross generations. Thus, the causal genes can 
be either dominant or recessive [11]. This phenomenon is accompanied by a 
set of recurring characteristics: growth inhibition, cell death and necrosis of 
leaf tissue. Therefore, it is commonly referred to as hybrid necrosis or hybrid 
weakness [12].  
 It occurs in crosses within and between plant species, monocots and 
dicots, inbreeding and outcrossing, annual and perennial as well as wild 
plants species and many crops [11]. Most hybrid necrosis cases known to 
date have been reported for crop plants. Perhaps the most well-known hybrid 
necrosis in a crop plant comes from wheat and involves the interaction 
between the two “necrosis alleles” Ne1 and Ne2 [12]. Modifiers in different 
genetic backgrounds were suggested as a reason for the range of severity  
[13].  
 Plant breeders have been particularly systematic in describing and 
analyzing the phenotypes of hybrid necrosis. However, as plant breeders are 
interested in hybrid vigor, hybrid necrosis was rather treated as an irritating 
problem when trying to introgress desirable traits into elite cultivars. In this 
regard, the wide-spread occurrence of Ne1 and Ne2 alleles in many wheat 
cultivars was recognized as a problem for wheat breeders [14]. Conversely, 
this is a fascinating case for evolutionary biologists. 
 Extensive (out-) crossing by plant breeders has been suggested as a 
potential reason for this “crop bias” in the occurrence of HI [11].  
Interestingly, a milder form of hybrid necrosis, leaf-tip necrosis, has been 
successfully used as a morphological marker that is associated to increased 
resistance to spot blotch disease in wheat e.g. [15], thus already pointing to 
an involvement of the plant immune-system components in hybrid necrosis. 
Many of these cases have been compiled recently [11] and the authors 
concluded that, at least in some cases, autoimmunity might be the underlying 
cause for hybrid necrosis.  
 Although it is astonishing that hybrid necrosis has so far never been 
reported for maize, mutational studies in this crop identified a vast collection 
of lesion mimic mutants (LMM), that exhibited programmed cell death 
(PCD) and necrosis, which in many cases is accompanied by increased or 
altered disease resistance [15] . Emerson [16] conducted perhaps one of the 
earliest studies in one of these maize mutants. He described a recessive 
mutation that causes blotched leaves, a necrosis that is reminiscent to the 
plants‟ response to infection, but lacked pathogen attack in this mutant. 
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Another LMM, Les1 has been studied by Hoisington et al. [15] . The Les1 
mutant-phenotype was found to depend on the genetic background and 
initiation of necrotic lesions could be suppressed by elevated („permissive‟) 
temperature, features which are now well known for many autoimmune 
mutants.  
 Similarly, a large number of autoimmune mutants exist in Arabidopsis 
thaliana, currently the most popular and best-studied model organism in plant 
sciences. These mutants display hallmarks of autoimmunity due to 
deregulated immune responses. These include development of spontaneous 
necrotic lesions, temperature- and humidity-dependent dwarfing and 
increased disease resistance owing to a constitutively active immune system 
in the absence of pathogen attack. Recent studies on hybrid necrosis in 
Arabidopsis thaliana reinforced the notion that autoimmunity underlies 
hybrid necrosis and may contribute to the establishment of post-zygotic RI 
barriers [17–19].  
 Thus, immune-triggered hybrid incompatibilities offer interesting 
possibilities for both evolutionary biologists aiming to elucidate the forces 
that drive incompatibilities between plant lineages, and plant breeders 
seeking to increase resistance of their cultivars without detriment to it. 
 
2. The plant immune system 
 
2.1. A very brief introduction to plant immunity 
 
 In nature, plants interact with a large amount of beneficial, non-
detrimental and detrimental microbes, known as the plant microbiota [20]. In 
this context it is intriguing how little susceptibility we observe in nature, at 
least with the naked eye. To detect and effectively defend themselves against 
pathogenic microbes, plants have evolved a two-layered innate immune 
system. Specific epitopes of conserved microbial features - so-called 
pathogen-associated molecular patterns (PAMPs) – are detected by pattern 
recognition receptors (PRRs). This comprises the first layer of plant innate 
immunity. For example the PAMPs flagellin and EF-tu are recognized by the 
PRRs FLAGELLIN SENSING 2 (FLS2) and EF-tu RECEPTOR (EFR), 
respectively, which belong to a class of trans-membrane receptor-like kinases 
(RLKs) [21].  
 Indeed, most PRRs and their interaction partners are RLKs, belonging to 
the leucine-rich repeat (LRR) class. Recognition of PAMPs triggers PAMP-
triggered immunity (PTI). This involves the induction of mitogen-activated 
protein kinase (MAPK) cascades, deposition of callose (an hemicellulose) at 
plasmodesmata to inhibit molecular flux between cells [21–24], generation of 
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reactive oxygen species (ROS) and gene expression changes to restrict 
growth of microbial pathogens [25]. To subvert PTI, adapted pathogens have 
evolved numerous effectors. These are deployed into plant cells to 
manipulate host targets in order to facilitate successful invasion of the host. 
To counteract these attacks, plants have evolved intracellular 
NUCLEOTIDE-BINDING LEUCINE-RICH REPEAT (NB-LRR) proteins. 
Based on their N-terminal motif they are classified into COILED-COIL 
(CC)- or TOLL INTERLEUKIN 1 RECEPTOR (TIR) – NB-LRRs. These R-
proteins act as molecular switches and sense pathogen effectors directly or 
indirectly through the effectors‟ action on a virulence target [26]. This layer 
of plant innate immunity is called effector-triggered immunity (ETI). Upon 
recognition, NB-LRRs undergo a conformational change and trigger a strong 
and effective reaction that leads to a hypersensitive response (HR) at the site 
of infection, which is often accompanied by cell death to deprive (hemi-) 
biotrophic pathogens of nutrients [27]. In this context it becomes clear that 
ETI-responses must be tightly regulated in order to prevent aberrant signaling 
with the associated effects. The strong negative effect on plant fitness can be 
seen in several Arabidopsis autoimmune-mutants, which display strong 
temperature- and humidity-dependent growth retardation and necrosis [28]. 
Autoimmunity in these mutants may result from gain-of function in NB-LRR 
genes or mutations in genes, which are thought to negatively regulate NB-
LRR gene expression [29].  
 
2.2. Predispositions for generating immune-triggered HIs 
 
 Several features predispose the plant immune system for generating 
hybrid incompatibilities.  
 Firstly, NB-LRR genes belong to the most variable class of plant genes 
and are highly polymorphic between Arabidopsis accessions [30]. As well,  
R-genes show a general tendency towards clustering. High quality whole-
genome sequencing of the Arabidopsis thaliana reference accession Col-0 
found 159 NB-LRR genes, including those family members that do not have 
both, NB and LRR domains. Of these genes, 113 were found in 38 clusters 
with a varying cluster size of two to nine NB-LRR genes, while 46 NB-LRR 
genes where designated as singletons [31]. Clustering offers the opportunity 
to generate variation in resistance and new recognition specificities by 
interallelic recombination and gene conversion, thereby rapidly creating 
divergent haplotypes [30,32–34]. The need to respond to rapidly evolving 
microbial pathogen populations that are spatially and temporally 
heterogenous might reflect a major force for the observed plant immune 
system diversification. Some (but not all) R-genes with different recognition 
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strengths and capacities to launch effective immune responses are maintained 
within plant populations by transient balancing selection [32]. A valid 
explanation for this might be the associated fitness-costs of increased disease 
resistance in the absence of pathogen pressure [32,35], although this is still a 
hypothesis.  
 Secondly, the guard-guardee model promotes indirect recognition of 
pathogen effectors [36,37]. In this model a guard – mostly an NB-LRR 
protein – monitors the status of the guardee – an effector target, which 
might be a central hub [26,38,39]– and induces ETI upon detection of 
effector manipulations on the guardee. Indirect recognition, rather then 
direct recognition might maximize recognition capacities and may be the 
main driver for R-gene diversification [28]. Perhaps the best-studied 
example of a guardee in Arabidopsis thaliana is RIN4 (RPM1-interacting 
protein 4). Pseudomonas syringae type III effectors phosphorylate 
(AvrRpm1 and AvrB) or cleave (AvrRpt2) RIN4. The NB-LRR receptors 
RPM1 (RESISTANCE TO PSEUDOMONAS SYRINGAE PV. 
MACULICOLA 1) and RPS2 (RESISTANCE TO PSUDOMONAS 
SYRINGAE 2) guard RIN4 against these effector modifications, 
respectively [40–42]. Indeed, rin4 null mutants are embryo lethal, due to 
constitutive RPM1 and RPS2-triggered immune responses [43]. rin4 rps2 
double knock-out mutants rescue the embryo-lethal phenotype but retain 
some constitutive activation of ETI-responses, dependent on RPM1. This 
was shown by increased expression of the marker gene PR1 and enhanced 
resistance to Pseudomonas syringae strain DC3000, which does not deliver 
AvrRpm1 effectors in rin4 rps2, but not rin4 rps2 rpm1 [43]. Perhaps not 
surprisingly, RIN4 underlies one of the interacting loci conditioning 
immune-triggered hybrid incompatibility in offspring derived from an 
interspecific cross between the domesticated Lactuca sativa and its wild 
relative Lactuca saligna [44].  
 As mentioned before, induction of MAPK signaling cascades upon 
PAMP recognition is a hallmark of PTI [24]. One MAPK cascade that 
functions in PTI is the MEKK1-MKK1/2-MPK4 cascade [45]. The type III 
effector HopA1 is known to inactivate MAPK signaling to successfully 
suppress this defense response [46]. In a recent study it was shown that 
autoimmunity in Arabidopsis mekk1, mkk1/2 fully and mpk4 largely depends 
on activation of the CC-NB-LRR receptor SUMM2 (suppressor of mkk1, 
mkk2, 2) [47]. Furthermore, the study showed direct interaction of HopA1 
and MPK4 in co-immunoprecipitation (Co-IP) experiments. However, the 
absence of a direct interaction of SUMM2 with MPK4 suggests that SUMM2 
indirectly guards the above MAPK cascade against effector perturbations by 
monitoring MPK4 activity, rather than directly [47]. 
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 Thirdly, ligand-induced heterooligomeric complexes of PRRs with other 
RLKs or signaling partners initiate MAPK cascades in PTI [21]. For 
example, FLS2 and EFR associate in complexes with their signaling partner 
BAK1 (BRI1-ASSOCIATED KINASE 1) upon recognition of flagellin and 
EF-Tu, respectively [48,49].  These complexes may also contain additional 
RLKs [21]. It is conceivable that PRRs, PRR-containing complexes and 
individual RLKs in these complexes are well-suited targets for pathogen 
effectors aiming to evade PTI. For example, BAK1-containing complexes are 
targeted by bacterial effectors, to suppress downstream signaling [50]. 
However, bak1 knock-out mutants do not display obvious autoimmunity. But 
a double knock-out of BAK1 and BKK1 (BAK1-LIKE1) shows severe 
dwarfing and constitutive activation of immune responses, indicating some 
functional redundancy between BAK1 and BKK1 [51]. Another receptor-like 
kinase, which interacts with BAK1 is BIR1 (BAK1-INTERACING 
RECEPTOR-LIKE KINASE 1) and temperature-dependent dwarfing and 
autoimmunity is observed in bir1 mutants [52]. In the latter case, the 
temperature-dependent phenotype can be partially rescued by loss-of function 
of the TIR-NB-LRR gene SNC1 (SUPRESSOR OF NPR1-CONSTITUTIVE 1) 
[52]. Interestingly, RLKs  - many of which have a function in plant immunity 
- are numerous and among the more variable proteins between accessions in 
the Arabidopsis genome with a capacity to form divergent clusters and 
chimeric genes [30,53].  
 It seems evident that under these circumstances guard-guardee pairs must 
evolve under the above molecular constraints in order to prevent aberrant 
signaling and constitutive activation of ETI. This might be due to recognition 
of a divergent guardee as modified-self, which can be altered protein 
function, folding or altered downstream response. Thus, genes encoding 
guard and guardee in divergent populations might provide excellent epistatic 
pairs for the evolution of immune-triggered hybrid incompatibilities.  
 
3. Immune-triggered hybrid incompatibilities 
 
 Despite the numerous examples of hybrid necrosis among various plant 
taxa and hints that plant immunity might be involved in some of these cases 
as early as 1926 [54], only recently have the causal genes in this epistatic 
interactions been identified [17–19,44,55]. The picture has emerged, that the 
model plant species Arabidopsis thaliana provides an excellent system for 
the study of genetic incompatibilities, such as immune-triggered hybrid 
incompatibilities, indicative of incipient speciation [10,56].  
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3.1. Immune-triggered HI between Landsberg erecta and 
Central Asian accessions 
 
 In a recent study by Alcázar et al. [18] we have examined a set of 
Arabidopsis thaliana recombinant inbred line (RIL) populations for growth at 
14 °C (referred to as low), a temperature that plants frequently encounter in 
nature, compared to 20 °C (standard laboratory conditions, referred to as 
moderate).   
 In two RIL populations derived from a cross of the North European (NE) 
accession Landsberg erecta (Ler) to the Central Asian (CA) accessions 
Kashmir (Kas-2) or Kondara (Kond), plants which displayed extreme 
dwarfism, delay in flowering time, reduced number of seeds and necrosis 
(referred to as incompatible lines) at 14 °C were identified (Fig. 2). 
 The same genotypes resembled their parents when grown at moderate 
temperature. Quantitative trait locus (QTL) analysis revealed epistatic 
interactions involving 3 loci in Ler x Kas-2 and 2 loci in Ler x Kond 
incompatible lines to be causative of the above genotype by environment 
(GxE) interaction. In both cases incompatibility segregates as a recessive trait 
and commonly shares homozygous Ler alleles on QTL 3 (chromosome 3) 
and homozygous Kas-2- or Kond-alleles on QTL 4 (chromosome 4). All F1 
plants derived from crosses of incompatible Ler x Kas-2 and incompatible 
Ler x Kond RILs displayed dwarfism. This, and the recessive nature of QTL4 
suggests that incompatibility in both RIL populations is controlled by the 
same loci. The study additionally identified another locus, QTL 5 on 
chromosome 5 in Ler x Kas-2 RILs, which is dominant for incompatible  
Kas-2 alleles and acts as a modulator for growth. Fine-mapping of QTL 3 to an 
 
 
 
Figure 2. Incompatible phenotype of the Ler x Kas-2 near-isogenic line (NIL) 
compared to its parental lines (Kas-2 and Ler). Plants were grown for 5 weeks at              
14-16 ºC. 
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interval of 71,4 kb was performed. This interval includes 2 RPP1-like genes 
of the TIR-NB-LRR class in the reference accession Colombia (Col). 
However, absence of dwarfism in F2 progenies of Col x Kas-2 crosses with 
Col alleles on QTL 3 and Kas-2 alleles on QTL4 and 5 suggested that 
polymorphisms between Ler and Col in this interval are the likely 
determinants for mediating incompatibility. Sequencing of a Ler bacterial 
artificial chromosome (BAC) spanning this interval revealed a cluster of 8 
RPP1-like genes in Ler, instead of 2 in Col. The other genes in this interval 
were mostly conserved between Ler and Col, thus indicating that interactions 
of one or more RPP1-like genes from Ler (RPP1-like
Ler
) with Kas-2 or Kond 
alleles on QTL 4 induce incompatibility. This RPP1-like locus was also 
identified to underlie DANGEROUS MIX 2 (DM2) of Uk-1 in F1 hybrid 
necrosis of two accessions from Umkirch, Germany, namely Uk-1/Uk-3 
hybrids [17]. However, the RPP1-like
Uk-1
 cluster is fully compatible with 
Kas-2 alleles on QTL 4 and QTL 5 and represents a different allele of this 
locus [18]. Regarding the fact that 38 gene clusters of the NB-LRR class exist 
in Arabidopsis thaliana [31] it is intriguing that the first two published cases 
of immune-triggered hybrid incompatibility in this species involve 
polymorphic alleles at this locus. Particular “trigger-happiness” could be a 
potential reason for this. Indeed, this polymorphic RPP1-like cluster locus 
might underlie additional other epistases leading to immune-triggered hybrid 
incompatibilities. We observed variation in the degree of incompatibility in 
Ler x Kas-2 incompatible lines. A Near Isogenic Line (NIL) with an 
introgression spanning the RPP1-like
Ler
 cluster in a Kas-2 genetic 
background was developed. These plants are severely stunted in growth and 
show strong leaf lesions, exacerbating the effects observed in incompatible 
RILs. This, and the observed variation among incompatible RILs points to 
additional modifiers in Kas-2 genetic background [18]. The involvement the 
RPP1-like
Ler
 TIR-NB-LRR gene cluster underlying the effects of QTL 3 in 
this epistatic interaction and the strong temperature-modulation of the above 
phenotypes resemble phenotypes seen in Arabidopsis autoimmune-mutants, 
displaying aberrant ETI signaling involving TIR-NB-LRR genes. 
Investigation of cell death by trypan blue (TB) staining of incompatible Ler x 
Kas-2 RILs, the NIL and both parental accessions at low and moderate 
temperature revealed a correlation between induction of cell death and 
temperature dependent dwarfing. However, parental Kas-2 lines displayed 
some necrotic spots at 14 °C which was not seen in Ler, thus pointing to 
different thresholds for the activation of cell death programs at low 
temperature in both parents. QTL analysis for cell death at 14 °C revealed 
four main effect QTL in Ler x Kas-2 RILs of which 2 co-located with the 
previously identified growth-related QTL 3 and 4. We concluded that growth 
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is suppressed at the expense of cell death program initiation. Growth 
retardation might be associated with the metabolic cost of constitutive 
immune responses [35,57].  
 As a consequence, transcript levels of defense marker genes were analyzed 
by real time-PCR in a set of Ler x Kas-2 RILs grown at low and moderate 
temperature. Enhanced expression of marker genes for the plant defense 
hormone salicylic acid (SA; EDS1 and PR1) and for oxidative stress (GST-1) 
broadly correlated with cell death induction in incompatible lines at low 
temperature. Moreover, measuring free and total SA, it was established that the 
degree of incompatibility in these lines depended on the accumulation of SA. 
This was most evident in the highly incompatible NIL that accumulated 2 to           
3-fold more free SA than Kas-2 at low and moderate temperature. Indeed,                
SA-pathway activation drives hybrid incompatibility in these lines, as dwarfism 
and cell death at low temperature were fully suppressed by the dominant 
transgene NahG, which converts SA to catechol, and by mutations in genes 
involved in SA-biosynthesis (SID2) and regulation (EDS1) [18]. 
 In addition to this, and in line with the above observations, incompatible 
plants displayed increased resistance towards the virulent pathogen 
Hyaloperonospora arabidopsidis (Hpa), which is able to infect both parental 
accessions  (Ler and Kas-2) even at moderate temperatures. Incompatible 
dwarf plants readily developed pathogen-induced cell death upon infection, 
suggesting a lowered threshold for defense activation. Thus, the positive trait 
of enhanced resistance in incompatible hybrids at moderate temperature may 
become detrimental in the absence of pathogen attack and at low temperature 
[18]. Because even the highly incompatible NIL was ultimately able to 
flower and set viable seeds even at low temperature, the authors conclude that 
the characterized immune-triggered hybrid incompatibilities have incomplete 
penetrance and additional DM incompatibilities may be required to achieve 
complete hybrid breakdown [18]. 
 
3.2. A natural variant of a receptor-like kinase underlies QTL 4 
 
 In a follow-up study, the causal gene underlying the effects of QTL 4 
was identified as the Receptor-Like Kinase (RLK) STRUBBELIG 
RECEPTOR FAMILY 3 (SRF3), which was not predicted to be involved in 
plant immunity [19]. Sequencing of incompatible SRF3
Kas-2
 and SRF3
Kond
 
genes revealed different alleles at this locus inducing similar responses by 
incompatible interactions with the RPP1-like
Ler
 cluster. Further analysis by 
genotyping 603 accessions covering the natural growth range of Arabidopsis 
thaliana found the presence of these two incompatible allelic forms only in 
Central Asian accessions, but not in European accessions (Fig. 3). 
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Figure 3. Distribution of SRF3 alleles in Eurasia. The origin of accessions carrying 
Ler-like alleles (blue), Kas-2 alleles (green) and Kond alleles (red) is indicated. Kas-2 
and Kond alleles are only found in Central Asia. 
 
 33 Central Asian and 30 North and South European accessions were 
selected and crossed to Ler. Consistently, segregation of dwarfism in F2 
populations at low temperature was observed only in crosses derived from 
Ler with Central Asian accessions. Importantly, the identified incompatible 
alleles fall into distinctive genotypic clades within Central Asian 
accessions, as suggested by STRUCTURE analysis based on genotyping 
with 139 genome-wide SNP markers [58]. Transiently expressed in 
Nicotiana benthamiana SRF3 localizes to the plasma membrane. In 
addition to this, SRF3 is differentially phosphorylated in response to flg 22 
[59]. Flg22 is a conserved epitope of the bacterial MAMP flagellin, which 
is sensed by FLS2 [19]. This prompted the authors to investigate the 
involvement of different SRF3 allelic forms in plant immunity. Strikingly, 
incompatibility in the highly incompatible NIL (Kas-2 genetic background 
with RPP1-like
Ler
 introgression) could be suppressed by transformation 
with compatible and dominant SRF3
Ler
 (referred to as cNIL). Immune 
responses dependent on compatible (Ler) and incompatible (Kas-2, Kond) 
SRF3 alleles in compatible and incompatible genetic interactions with the 
RPP1-like
Ler
 cluster were further examined. As already mentioned, 
initiation of MAPK cascades upon pathogen recognition is an early event of 
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PTI signaling. Activation of MAPKs by treatment with flg22 was analyzed 
in these lines based on activities of MPK3, MPK4 and MPK6 and 
concluded that MPK4 activity (suppressor of immune signaling) and MPK6 
activity kinetics (activator of immune signaling) correlated with the extent 
of immune activation in isogenic backgrounds. In addition, plants with 
different allelic combinations were infected with the oomycete Hpa and the 
virulent bacterial strain Pseudomonas syringae pv. tomato DC3000 (Pst 
DC3000) and avirulent Pst DC3000 hrcC. The hrcC mutant mainly induces 
PTI responses, because it fails to deliver effectors into host cells. Infection 
phenotypes (measured as bacterial growth) displayed enhanced 
susceptibility towards Pst DC3000 as well as Pst DC3000 hrcC compared 
to the parental accessions when Kas-2 backgrounds were transformed with 
SRF3
Ler
 alleles [19]. This suggests that Central Asian alleles of SRF3 
contribute positively to basal resistance, and the opposite holds true for Ler 
SRF3 alleles. Since srf3 mutant lines in Col were neither more susceptible 
to Hpa isolates Noco2 and Cala2 nor towards Pst DC3000 or its mutant 
version hrcC [19], the effect of enhanced early immune responses observed 
for Central Asian alleles is background dependent or it requires specific 
point mutations rather than loss-of-function alleles. The study of different 
genetic backgrounds is the basis for the genetics of natural variation that 
allows the identification of weak alleles that do not show any phenotype in 
common laboratory accessions. Different crosses between Col, Kas-2 and 
Ler are underway to identify this complex background dependence. In line 
with activation of ETI responses in incompatible lines, the NIL showed 
enhanced resistance towards Pst DC3000 which deploys effectors into host 
cells compared to its parents. As mentioned in the introduction, new alleles 
such as those involved in DM incompatibilities can arise and may increase 
in frequency owing to genetic drift or natural selection in isolated or 
divergent populations. By applying an appropriate statistical test (Fay and 
Wu´s H) across the genomic region of SRF3 we looked for molecular 
signatures of selection. An excess of derived alleles as indicated by high 
negative values for Fay and Wu´s H, suggested a recent selective sweep in 
Central Asian populations. Thus, HI between Ler and Central Asian 
accessions likely evolved as a by-product of natural selection for 
incompatible SRF3 alleles in Central Asian populations to the biotic 
environment [19]. A current hypothesis for incompatible hybrids displaying 
autoimmunity is that polymorphisms in SRF3
Kas-2
 mimic effector 
modifications that are sensed by one or more RPP1-like receptors from Ler 
(Fig. 4). Thus, RPP1-like receptors and the LRR-RLK SRF3 would 
normally be in a guard-guardee relationship (Fig. 4). 
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Figure 4. Simplified model of different SRF3 allelic forms and RPP1-likeLer receptors 
in plant immunity and immune-triggered HI. a) In Central Asian populations 
“incompatible” SRF3 forms may contribute to early PTI responses. This may confer a 
relative advantage under high pathogen pressure (indicated by weight of the arrows). 
b) In the original Ler population pathogens may have evolved effectors to subvert PTI 
responses mediated by SRF3. In turn, RPP1-likeLer immune receptors arose to guard 
SRF3 against these perturbations and trigger effective local immune responses (ETI). 
c) Both incompatible alleles evolved independently. In a hybrid context incompatible 
SRF3 forms mimic effector modifications sensed by RPP1-likeLer TIR-NB-LRRs. 
This leads to autoimmunity at the expense of growth. d) Dominance of compatible 
SRF3Ler may be achieved, because a normal guard-guardee relationship is established 
and suppresses autoimmunity, thus promoting growth. 
 
4. Concluding remarks and future perspectives 
 
 Hybrid necrosis has been long observed and characterized by plant 
breeders and evolutionary biologists alike. Studying hybrid necrosis between 
different accessions of the model plant species Arabidopsis thaliana has 
contributed significantly to the understanding of the molecular bases of this 
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phenomenon [17–19] offering the opportunity to examine possible incipient 
speciation processes [9]. With the cloning of the first causal genes previous 
notions could be validated that, indeed in many cases autoimmunity underlies 
this form of DM incompatibility. As presented in the introduction, the DM 
model is agnostic with regard to the reason of allele divergence. Our studies 
[18,19] have identified immune-triggered hybrid incompatibility between a 
North European accession and numerous Central Asian accessions. The 
observed effects are caused by the negative epistatic interaction between a 
highly polymorphic cluster of TIR-NB-LRR genes (RPP1-like
Ler
) and 
incompatible alleles of the receptor-like kinase SRF3 in Central Asian 
accessions. We have established that incompatible SRF3 alleles in Central 
Asian populations have undergone a recent selective sweep and enhance early 
immune responses, potentially conferring selective advantage for these alleles 
in Central Asian populations. Thus, our studies provide an important example 
where DM incompatibilities displaying autoimmunity may arise as a              
by-product of adaptation to the biotic environment that is strongly modulated 
by temperature.  
 However, our studies also offer interesting future perspectives.  
 R-gene clusters are highly polymorphic and show signatures of transient 
balancing selection in local populations rather than world-wide selective 
sweeps [32]. Since the RPP1-like
Ler
 haplotype of this cluster is only found in 
Ler, it would be interesting to see its detailed geographical distribution on a 
large screen of accessions. Furthermore, incompatible hybrids offer the 
unique opportunity to identify additional modifiers of the described epistasis.  
With regard to SRF3, several interesting perspectives exist. Why are Central 
Asian alleles of this RLK incompatible? SRF3 was not identified in a plant 
immune context before our publication [19]. We know that RLKs often 
function in heterooligomeric complexes. Also SRF3 is dephosphorylated 
upon flg22 treatment. This immediately poses the questions, which are the 
molecular interaction partners of this RLK, and how flg22 signaling 
interferes with SRF3 phosphorylation.  
 
Acknowledgements 
 
 M.v.R. acknowledges a research fellowship of the International Max 
Planck Research School (IMPRS), Germany. R.A. acknowledges support 
from the Ramón y Cajal Programme of the Ministry of Science and 
Innovation (Spain). Research in R.A. laboratory at the University of 
Barcelona is supported by the BFU2013-41337-P grant of the Programa 
Estatal de Fomento de la Investigación Científica y Técnica de Excelencia 
(Ministerio de Economía y Competitividad, Spain), the Marie Curie Career 
Marcel von Reth & Rubén Alcázar  52 
Integration Grant (DISEASENVIRON) of the European Union, and the Grup 
de Recerca Consolidat GRC1060 of the Generalitat de Catalunya.  
 
References 
 
1. Mayr, E.: Systematics and the Origin of Species. Columbia University Press, 
New York; 1942. 
2. Rieseberg, L.H., Willis, J.H. 2007, Science, 317, 910. 
3. Mallet, J. 2007, Nature, 446, 279. 
4. Orr, H. A. 1995, Genetics, 139, 1805. 
5. Orr, H. A., Turelli, M. 2001, Evolution, 55, 1085. 
6. Muller, H. J., 1942, Biol. Symp., 6, 71. 
7. Dobzhansky, T.: Genetics and the Origin of Species. Columbia University Press, 
New York; 1937. 
8. Orr, H. A. 1996, Genetics, 144, 1331. 
9. Via, S. 2009, Proc. Natl. Acad. Sci. U.S.A., 106, 9939. 
10. Bomblies, K., Weigel, D. 2010, Philos. Trans. R. Soc. B Biol. Sci., 365, 1815. 
11. Bomblies, K., Weigel, D. 2007, Nature Rev. Genet., 8, 382. 
12. Hermsen, J. G. T. Hybrid necrosis in wheat. In: Proefschrift Landbouwhoge 
school Wageningen, 1962, pp.129. 
13. Hermsen, J. G. T. 1963, Genetica, 33, 245. 
14. Hermsen, J. G. T. 1963, Euphytica, 12, 1. 
15. Hoisington, D. A., Neuffer, M. G., Walbot, V. 1982, Dev. Biol., 93, 381. 
16. Emerson, R. A. 1926, Cornell Mem., 70, 3. 
17. Bomblies, K., Lempe, J., Epple, P., Warthmann, N., Lanz, C., Dangl, J. L., 
Weigel, D. 2007, PLoS Biol, 5, e236. 
18. Alcázar, R., García, A. V., Parker, J. E., Reymond, M. 2009, Proc. Natl. Acad. 
Sci. U.S.A., 106, 334. 
19. Alcázar, R., García, A. V., Kronholm, I., de Meaux, J., Koornneef, M., Parker, J. 
E., Reymond, M. 2010, Nature Genet., 42, 1135. 
20. Bulgarelli, D., Schlaeppi, K., Spaepen, S., van Themaat, E. V. L., Schulze-Lefert, 
P. 2013, Annu. Rev. Plant Biol., 64, 807. 
21. Zipfel, C. 2008, Curr. Opin. Immunol., 20, 10. 
22. Zipfel, C., Robatzek, S. 2010, Plant Physiol., 154, 551. 
23. Faulkner, C., Petutschnig, E., Benitez-Alfonso, Y., Beck, M., Robatzek, S., 
Lipka, V., Maule, A. J. 2013, Proc. Natl. Acad. Sci. U.S.A., 110, 9166. 
24. Asai, T., Tena, G., Plotnikova, J., Willmann, M. R., Chiu, W.-L., Gomez-Gomez 
L., Boller, T., Ausubel, F. M., Sheen, J. 2002, Nature, 415, 977. 
25. Nürnberger, T., Brunner, F., Kemmerling, B., Piater, L. 2004, Immunol. Rev., 
198, 249. 
26. Jones, J. D. G., Dangl, J. L. 2006, Nature, 444, 323. 
27. Mehdy, M. C. 1994, Plant Physiol., 105, 467. 
28. Alcázar, R., Parker, J. E. 2011, Trends Plant Sci., 16, 666. 
29. Hua, J. 2013 Curr. Opin. Plant Biol., 16, 406. 
Immune-triggered HI: A by-product of adaptation to the biotic environment  53 
30. Clark, R. M., Schweikert, G., Toomajian, C., Ossowski, S., Zeller, G., Shinn, P., 
Warthmann, N., Hu, T. T., Fu, G., Hinds, D. A., Chen, H., Frazer, K. A., Huson, 
D. H., Schölkopf, B., Nordborg, M., Rätsch, G., Ecker, J. R., Weigel, D. 2007, 
Science, 317, 338. 
31. Guo, Y.-L., Fitz, J., Schneeberger, K., Ossowski, S., Cao, J., Weigel, D. 2011, 
Plant Physiol., 157, 757. 
32. Bakker, E. G., Toomajian, C., Kreitman, M., Bergelson, J. 2006, Plant Cell, 18, 
1803. 
33. Noel, L., Moores, T. L., van Der Biezen, E. A., Parniske, M., Daniels, M. J., 
Parker, J. E., Jones, J. D. 1999, Plant Cell, 11, 2099. 
34. Michelmore, R. W., Meyers, B. C. 1998, Genome Res., 8, 1113. 
35. Tian, D., Traw, M. B., Chen, J. Q., Kreitman, M., Bergelson, J. 1998, Nature, 
423, 74. 
36. Dangl, J. L., Jones, J. D. G. 2001, Nature, 411, 826. 
37. Van Der Biezen, E. A., Jones, J. D. G. 1998, Trends Biochem. Sci., 23, 454. 
38. Mukhtar, M. S., Carvunis, A.-R., Dreze, M., Epple, P., Steinbrenner, J., Moore, 
J., Tasan, M., Galli, M., Hao, T., Nishimura, M. T., Pevzner, S. J., Donovan, S. 
E., Ghamsari, L., Santhanam, B., Romero, V., Poulin, M. M., Gebreab, F., 
Gutierrez, B. J., Tam, S., Monachello, D., Boxem, M., Harbort, C. J., McDonald, 
N., Gai, L., Chen, H., He, Y., European Union Effectoromics Consortium, 
Vandenhaute, J., Roth, F. P., Hill, D. E., Ecker, J. R., Vidal, M., Beynon, J., 
Braun, P., Dangl, J.L. 2011, Science, 333, 596. 
39. Chisholm, S. T., Coaker, G., Day, B., Staskawicz, B. J. 2006, Cell, 124, 803. 
40. Mackey, D., Belkhadir, Y., Alonso, J. M., Ecker, J. R., Dangl, J. L. 2003, Cell, 
112, 379. 
41. Mackey, D., Holt III, B. F., Wiig, A., Dangl, J. L. 2002, Cell, 108, 743. 
42. Axtell, M. J., Staskawicz, B. J. 2003, Cell, 112, 369. 
43. Belkhadir, Y., Nimchuk, Z., Hubert, D. A., Mackey, D., Dangl, J. L. 2004, Plant 
Cell, 16, 2822. 
44. Jeuken, M. J. W., Zhang, N. W., McHale, L. K., Pelgrom, K., Boer, E. den, 
Lindhout, P., Michelmore, R. W., Visser, R. G. F., Niks, R. E. 2009, Plant Cell, 
21, 3368. 
45. Gao, M., Liu, J., Bi, D., Zhang, Z., Cheng, F., Chen, S., Zhang, Y. 2008, Cell 
Res., 18, 1190. 
46. Zhang, J., Shao, F., Li, Y., Cui, H., Chen, L., Li, H., Zou, Y., Long, C., Lan, L., 
Chai, J., Chen, S., Tang, X., Zhou, J. M. 2007, Cell Host Microbe, 1, 175. 
47. Zhang, Z., Wu, Y., Gao, M., Zhang, J., Kong, Q., Liu, Y., Ba, H., Zhou, J., 
Zhang, Y. 2012, Cell Host Microbe, 11, 253. 
48. Chinchilla, D., Zipfel, C., Robatzek, S., Kemmerling, B., Nürnberger, T., Jones, 
J. D. G., Felix, G., Boller, T. 2007, Nature, 448, 497. 
49. Roux, M., Schwessinger, B., Albrecht, C., Chinchilla, D., Jones, A., Holton, N., 
Malinovsky, F. G., Tör, M., Vries, S. de, Zipfel, C. 2011, Plant Cell, 23, 2440. 
50. Shan, L., He, P., Li, J., Heese, A., Peck, S. C., Nürnberger, T., Martin, G. B., 
Sheen, J. 2008, Cell Host Microbe, 4, 17. 
Marcel von Reth & Rubén Alcázar  54 
51. He, K., Gou, X., Yuan, T., Lin, H., Asami, T., Yoshida, S., Russell, S. D., Li, J. 
2007, Curr. Biol., 17, 1109. 
52. Wang, Z., Meng, P., Zhang, X., Ren, D., Yang, S. 2011, Plant J., 67, 1081. 
53. Bomblies, K. 2009, Botany, 87, 1013. 
54. Burkholder, W. H., Muller, A. S. 1926, Phytopathology, 16, 631. 
55. Yamamoto, E., Takashi, T., Morinaka, Y., Lin, S., Wu, J., Matsumoto, T., 
Kitano, H., Matsuoka, M., Ashikari, M. 2010, Mol. Genet. Genomics, 283, 305. 
56. Alcázar, R., Pecinka, A., Aarts, M. G. M., Fransz, P. F., Koornneef, M. 2012, 
Curr. Opin. Plant Biol., 15, 205. 
57. Hulten, M. van, Pelser, M., Loon, L. C. van, Pieterse, C. M. J., Ton, J. 2006, 
Proc. Natl. Acad. Sci. U.S.A., 103, 5602. 
58. Platt, A., Horton, M., Huang, Y. S., Li, Y., Anastasio, A. E., Mulyati, N. W., 
Ågren, J., Bossdorf, O., Byers, D., Donohue, K., Dunning, M., Holub, E. B., 
Hudson, A., Le Corre, V., Loudet, O., Roux, F., Warthmann, N., Weigel, D., 
Rivero, L., Scholl, R., Nordborg, M., Bergelson, J., Borevitz, J. O. 2010, PLoS 
Genet., 6, e1000843. 
59. Benschop, J. J., Mohammed, S., O‟Flaherty, M., Heck, A. J. R., Slijper, M., 
Menke, F. L. H. 2007, Mol. Cell. Proteomics, 6, 1198. 
 
 
 
 Research Signpost 
 37/661 (2), Fort P.O. 
 Trivandrum-695 023  
 Kerala, India 
 
 
Recent Advances in Pharmaceutical Sciences IV, 2014: 55-72 ISBN: 978-81-308-0554-2  
Editors: Diego Muñoz-Torrero, Manuel Vázquez-Carrera and Joan Estelrich 
 
4. Outer membrane vesicles from                
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Abstract. Many Gram-negative, cold-adapted bacteria from the 
Antarctic environment produce large amounts of extracellular 
matter with potential biotechnological applications. Transmission 
electron microscopy (TEM) analysis after high-pressure freezing 
and freeze substitution (HPF-FS) showed that this extracellular 
matter is structurally complex, appearing around cells as a netlike 
mesh, and composed of an exopolymeric substance (EPS) 
containing large numbers of outer membrane vesicles (OMVs). 
Isolation, purification and protein profiling via 1D SDS-PAGE 
confirmed the outer membrane origin of these Antarctic bacteria 
OMVs.  In an initial attempt to elucidate the role of OMVs in cold-
adapted strains of Gram-negative bacteria, a proteomic analysis 
demonstrated that they were highly enriched in outer membrane 
proteins and periplasmic proteins associated with nutrient 
processing and transport, suggesting that the OMVs may be 
involved in nutrient sensing and bacterial survival. OMVs from 
Gram-negative bacteria are known to play a role in lateral DNA 
transfer, but the presence of DNA in these vesicles has remained 
difficult to explain. A structural study of Shewanella vesiculosa  
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 M7T using TEM and Cryo-TEM revealed that this Antarctic Gram-negative 
bacterium naturally releases conventional one-bilayer OMVs, together with a more 
complex type of OMV, previously undescribed, which on formation drags along inner 
membrane and cytoplasmic content and can therefore also entrap DNA. 
 
Introduction 
  
 Some of the world’s most primitive ecosystems are found in Antarctica, 
where environmental conditions are so extreme that, in terms of average 
values, it constitutes the world’s coldest, driest, and windiest continent.  
Among the few organisms that can survive in such a harsh environment are 
numerous types of bacteria that have developed various strategies for cold 
adaptation. Many polar cold-adapted Gram-negative bacteria produce 
extracellular polymeric substances (EPSs) that enhance their growth and 
survival in natural systems [1,2]. EPSs have been found to modify the 
physicochemical environment of bacterial cells, participate in cell adhesion to 
surfaces and retention of water, favor the sequestration and concentration of 
nutrients, retain and protect extracellular enzymes against cold denaturation 
and also act as cryoprotectants [2].  Although studies of bacterial EPSs have 
singled out exopolysaccharides as their major chemical constituent, it has 
become clear that they are also composed of other molecules such as 
proteins, lipids, and nucleic acids. An important finding is the abundant 
presence of particulate structures such as outer membrane vesicles (OMVs) 
within the extracellular matter that bacteria secrete to the environment, which 
may be the source, in part, of the aforementioned compounds [3-6].   
 OMVs are produced by a wide variety of Gram-negative bacteria during 
the course of normal metabolism and cell growth. These spherical bilayered 
lipid vesicles, ranging in size from 25 to 250 nm, are produced when small 
portions of the bacterial outer membrane (OM) bulge away from the cell and 
are released (Fig.1). Consequently, they are primarily composed of 
lipopolysaccharides (LPS), periplasmic proteins, outer membrane proteins 
and phospholipids [7]. 
 Described more than a decade ago, OMVs are currently seen as a new 
form of secretion [7]. Studies that were initially conducted on pathogenic 
bacteria and the delivery of toxins are now mainly focused on the mechanism 
of vesicle formation and their pathophysiological roles [5]. Although 
observed for many years, the process by which Gram-negative bacteria 
produce OMVs is still unknown [7,8]. Comparative studies of the protein 
profiles of OMVs and outer membranes (OMs) show high similarity, 
although OMVs are enriched with some proteins while others are entirely 
absent, suggesting that the vesicles are not randomly extruded from the outer  
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Figure 1. Process of formation of an outer membrane vesicle (OMV). In the first 
micrograph we can observe a portion of the cell envelope from the Gram-negative 
bacterium Shewanella vesiculosa M7T. In the second one the outer membrane starts to 
protrude at different points of the cell. Finally the third micrograph shows a released 
OMV. 
 
cell membrane, nor are they a product of cell lysis. In addition, extra bands 
can be detected in many OMVs corresponding to soluble periplasmic 
proteins. In brief, it has been established that the biogenesis of OMVs must  
be a well-regulated biological mechanism that leads to heterogeneous 
packaging of proteins and lipids, and varies according to certain 
physiological situations and the bacterial species [8]. 
 Once secreted, OMVs can spread away from the cell and accomplish 
several biological functions in the surrounding environment and in other 
cells: they are involved in pathogenesis, interspecies communication, nutrient 
acquisition, innate bacterial defenses and horizontal gene transfer [9]. Since 
Carla Pérez-Cruz & Elena Mercadé  58 
OMV release seems to be a conserved mechanism across Gram-negative 
bacteria and represents a high energy cost, it must play an essential role in 
cell survival. The biogenesis and biological roles of OMV are described in 
several up-to-date reviews, so we will not be revisiting these issues here 
[7,9]. The presence of OMVs in non-pathogenic bacteria is less studied and 
although multiple functions can be envisaged, such as cell-to-cell signaling, 
biofilm formation and bacterial survival, their role remains unclear and 
deserves further study. 
 The Antarctic environment is a rich source of new microorganisms with 
unknown properties, which have aroused growing interest throughout the 
scientific community in recent years. Our research group has isolated several 
cold-adapted microorganisms from water and marine sediments collected in 
the Antarctica area of the South Shetland Islands, which have been 
characterized as new species in distinct taxonomic groups [10-14]. A 
predominant feature of these bacterial colonies is their mucoid appearance, 
owing to the accumulation of large amounts of extracellular matter. Our 
study clearly shows the structural complexity of the extracellular matter of 
these Antarctic bacteria [5].  
 
1. Structural analysis of the extracellular matter secreted by 
cold-adapted antarctic bacteria 
 
 As mentioned above, one of the major adaptations to cold by Antarctic 
bacteria is the production of abundant extracellular matter, which in recent 
years has received considerable attention for its potential biotechnological 
applications. Exopolymeric substances, which are an integral part of the 
extracellular matter of many polar bacteria, have been chemically 
characterized, but the structural characterization of extracellular matter has 
been limited, partly by the difficulty of preserving these highly hydrated 
structures.   
  TEM analysis of ultrathin sections has been extensively used in the 
characterization of bacterial cell and envelope structures. The proper 
preparation of biological samples for electron microscopy is crucial for 
maintaining the original structure and avoiding the presence of artifacts. For 
many years the highly hydrated bacterial exopolymers escaped detection by 
electron microscopy using conventional techniques due to their low affinity 
for heavy metal stains, as well as their marked propensity to collapse and be 
removed during the dehydration preparatory steps at room temperature 
[4,15]. Our knowledge of extracellular matter was improved by the 
introduction of high-pressure freezing-fixation (HPF) and freeze-substitution 
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(FS) techniques. In HPF, biological samples are processed at a very low 
temperature, the principle objective being the ultrarapid solidification of 
water into an amorphous glassy state to prevent ice crystal formation. Then, 
FS allows water to be substituted with chemical fixatives and dehydrating 
agents at low temperatures (-80°C) to minimize secondary ice crystal growth 
[16]. The resulting biological specimens are embedded in plastic resins and 
are therefore amenable to standard thin-sectioning techniques at room 
temperature [15,16]. The use of these methods in bacterial studies has greatly 
improved ultrastructural preservation of extracellular matter. 
 The psychrotolerant strain Pseudoalteromonas antarctica NF3
T
 is a 
Gram-negative bacterium isolated from muddy soil samples of Antarctica 
that secretes large amounts of a mucoid exopolymer with a high protein 
content [3]. We examined the structure of P. antarctica NF3
T
 and the 
extracellular matter it secretes by conventional methods and compared this 
with information obtained by TEM after HPF-FS, and Epon resin embedding. 
When P. antarctica NF3
T
 was observed by standard chemical fixation, 
dehydration, and embedding techniques, cytoplasmic content was not 
uniformly distributed; holes and completely voided cells were frequent, and 
although P. antarctica colonies are extremely mucoid, no capsular or 
exopolymeric material was observed around the cells (Fig. 2A). However, 
examination of P. antarctica after HPF-FS revealed other, previously 
undetectable, structural features. Immediately striking was the absence of ice-
crystal damage to the cell structure, particularly when one considers              
that no cryoprotectants were used, indirectly pointing to the cryoprotectant                      
 
 
 
Figure 2. TEM of ultrathin sections from P. antarctica NF3T prepared by 
conventional embedding methods (A) and prepared by high-pressure freezing and 
freeze substitution (B). Bars, 100 nm. 
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Figure 3. TEM micrographs of ultrathin sections from five cold-adapted Antarctic 
bacteria prepared by HPF-FS. The left images show a general view of cells as well as 
large amounts of membrane vesicles (arrow heads). The right images show magnified 
views of cells surrounded by a halo of fibers of perpendicular orientation (arrows with 
double arrowhead). The right images also show the same bilayered structure around 
the vesicles and the bacterial outer membrane. Asterisks mark protrusions in the outer 
membrane. The perpendicular fibers can also be observed around vesicles and the 
outer membrane of cells (arrows with one arrowhead). Bars in the left images are 200 
nm; bars in the right images are 100 nm. (From Microb. Ecol. 2010. 59:476-486). 
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role of the extracellular matter of P. antarctica. Cells appeared turgid with  
homogeneously distributed cytoplasmic content and well-differentiated 
envelope profiles, and their surfaces were completely covered with a 
distinctive halo of fine fibers standing perpendicular to the cell wall. This fine  
fibrous fringe corresponded to the presence of a capsular material within the 
extracellular matter secreted by P. antarctica NF3
T
. In addition to the closely 
adherent halo, a polymeric material composed of a netlike mesh of more 
randomly arranged fibers extended far beyond the cells (Fig. 2B). A 
noteworthy feature observed in ultrathin sections of P. antarctica cells by 
HPF-FS was the large quantity of OMVs immersed in this netlike mesh. 
 In view of these results, we also analyzed the structure of other                   
cold-adapted Antarctic bacteria by TEM after HPF-FS [5]. Five strains 
(Shewanella livingstonensis NF22
T
, Shewanella vesiculosa M7
T
, 
Pseudoalteromonas sp. M4.2, Psychrobacter fozii NF23
T
, and Marinobacter 
guineae M3B
T
) were selected for their mucoid colony morphology, which is 
associated with the production of abundant exopolymeric substances. A 
complex composition was again found in all analyzed extracellular matter, 
with the presence of ordered fibrous material external to the outer membrane 
and large amounts of cell-derived membrane vesicles, which have not been 
previously described for members of the genera Psychrobacter and 
Marinobacter (Fig. 3).  
 The Antarctic bacterial OMVs showed the typical characteristics 
described for these structures. They appeared as spherical bilayered lipid 
vesicles extruded from regions of the bacterial OM with diameters ranging 
from 20 to 200 nm. TEM analysis also indicated that the OMVs were covered 
with the same capsular polymeric fibers as those found around cells. In our 
strains, this could facilitate the formation of a netlike mesh, which would 
allow OMVs to be retained near cells and also to adhere to surfaces or to 
other cells.  
 
2. Proteomic study of OMVs from cold-adapted Antarctic 
bacteria 
  
 In an initial attempt to elucidate the role of OMVs of Antarctic bacteria 
and their relation with cold adaptation, a proteomic analysis of the main 
proteins of OMVs produced by different Antarctic strains was performed. 
Although the full proteome analysis of Gram-negative bacteria OMVs has 
proved a useful approach to characterizing individual proteins and their 
functions, most of these studies have focused on pathogenic bacteria and little 
is known about the roles of OMVs in the Antarctic environment [3]. 
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 As mentioned above, OMVs are secreted during the normal growth of 
bacteria. Additionally, we observed that OMVs from cold-adapted bacteria 
are not found in isolation but within a surrounding netlike mesh. It should be 
emphasized that other components such as fimbriae and flagella may be 
present in this environment, so the choice of methods for obtaining and 
purifying the OMVs is crucial when studying their composition and functions 
if errors in interpretation are to be avoided [8]. 
 The first step in obtaining purified OMVs is to separate bacterial cells 
from culture broths by low-speed centrifugation (6,000-10,000x g; 10 min). 
Clarified supernatants have to be filtered through small pore size filters  
(0.22-0.45 µm) to remove any remaining cell. OMVs are then usually isolated 
from cell-free supernatants by high-speed centrifugation (≥40,000x g, 1h). At 
this point, there are other components in the culture medium that co-sediment 
with the OMVs, such as flagella, products from cell debris and soluble 
extracellular macromolecules. To characterize a pure population, OMVs must 
be separated from other supernatant material. Typically, this is accomplished 
by velocity or equilibrium density gradient centrifugation, which separates 
molecules on the basis of their buoyant density. Thus, the different 
components of the first pelleted OMVs are resuspended in a small volume of 
buffer and loaded at the bottom of an equilibrium density gradient such as 
45%-20%  iodixanol (100,000x g, 14 h). The different components distribute 
along the gradient and concentrate where their density matches with the 
surrounding solution. The OMVs usually float higher than the soluble 
proteins or flagella [7,8]. After the centrifugation, bands can sometimes be 
separated simply by observation with the naked eye. Otherwise, small 
portions of the gradient have to be removed and the presence and purity of 
the OMVs is verified by SDS-PAGE electrophoresis and TEM observation 
after negative staining.  
 Since OMVs are derived from Gram-negative bacterial OM, they are 
composed mainly of LPS, OM proteins and phospholipids. However, 
OMVs are not simply fragments of the OM released to the external 
medium; they also contain periplasmic proteins and in some cases are 
enriched with specific proteins while others are excluded, suggesting that 
they function as a distinct secretory pathway [7]. As in other bacteria, SDS-
PAGE analysis of OMV proteins from Antarctic strains showed different 
banding profiles from those of OM, suggesting some kind of protein sorting 
during vesicle formation (Fig. 4) [8]. 
 A proteomic analysis of purified OMVs from three Antarctic bacteria, 
Pseudoalteromonas antarctica NF3
T
, Shewanella livingstonensis NF22
T
 and 
S. vesiculosa M7
T
, was performed to characterize the main proteins present in 
these vesicles [3,5,6].  Beforehand, isolated OMVs were further purified on 
OMV from cold-adapted antarctic bacteria  63 
 
 
Figure 4. Negative-staining micrographs from membrane vesicles isolated from five 
Antarctic bacteria cultures, and Coomassie blue-stained SDS-PAGE (12%) protein 
profiles of outer membrane fractions (OM) and membrane vesicles (MV) from each 
strain. The molecular mass marker (MW) is expressed in kilodaltons. Asterisks 
indicate polypeptides that were overexpressed in membrane vesicle preparations. 
Arrows indicate flagella. Bar 200 nm. (From Microb. Ecol. 2010. 59:476-486). 
 
an Optiprep® density gradient to remove contaminants including flagella. 
Proteins from purified OMVs were separated using 12.5% 1D SDS-PAGE.  
Protein bands were excised from the gel and digested with trypsin. Peptides 
were separated by liquid chromatography and subsequently analyzed on a 
nano-ESIQTOF mass spectrometer. Data were submitted for database 
searching in MASCOT server, and were searched against the NCBI non 
redundant protein sequence database. 
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 The identification of OMV proteins from Antarctic strains, a challenging 
task since no peptide mass data were available for these new bacteria, was 
carried out by cross-species peptide mass finger printing. The proteomic 
analysis revealed the presence of OM and periplasmic proteins qualitatively 
similar to other OMVs characterized in Gram-negative species. Sequences of 
vesicle proteins matched those of multi-function proteins such as proteolytic 
enzymes, transport receptor and binding proteins, secretion proteins, 
polysaccharide biosynthesis proteins, enzymes involved in bacterial cell wall 
degradation, putative porins, proteins that participate in electron transport, 
adhesins and proteins involved in protein folding (Fig. 5).  
 The most abundant proteins detected were putative TonB-dependent 
receptors. This family of OM beta-barrel proteins is mainly involved in the 
uptake of molecules that are too large to diffuse through the porins, chiefly 
iron siderophores and vitamin B12 [5]. The overexpression of these proteins 
is thought to be a survival mechanism in nutrient-limiting conditions, since 
they could play a role in sensing nutrients and importing them into the cell. 
Nutrient limitation could also explain the presence of abundant proteins 
putatively identified as bifunctional UDP-sugar hydrolase/ 5′-nucleotidase 
periplasmic precursors, phosphate-binding periplasmic protein precursors, 
and phosphate-selective porins O and P. Phosphorous is an essential 
component of macromolecules and bacteria need an optimal supply of 
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Figure 5. Functional classification of the proteins identified in the proteomic analyses 
of three Antarctic bacteria OMV. Results are expressed as percentage of the total 
protein identified. 
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phosphorous from the environment. These precursors and porins may play 
roles in nucleotide salvage and in phosphorous metabolism [3]. 
 Proteomic analysis also revealed the presence of putative proteolytic 
degradative enzymes in OMVs. Their presence could contribute to the 
degradation of high molecular weight compounds present in the organic 
matter common to marine environments, which are largely unavailable for 
direct uptake by marine bacteria for catabolic and biosynthetic purposes [17]. 
Additionally, it has been suggested that the presence of these hydrolytic 
enzymes within OMVs confers a predatory activity, allowing the bacteria to 
kill other micro-organisms and use the lysis products to grow [9]. 
 In the psychrotolerant bacterium, S. livingstonensis NF22
T
, the growth 
temperature seemed to influence the amount and morphology of OMVs [5]. 
Quantification and TEM observation revealed that at low temperatures (4ºC), 
OMVs were more abundant, smaller (mean value 26.6 nm in diameter) and 
more regular in size than at higher temperatures (18 ºC) (mean value 40.2 nm 
in diameter). The overexpressed proteins in OMVs detected at low 
temperatures (mostly homologues of TonB-dependent receptors, porins, and 
phosphate-binding periplasmic protein precursors), are essentially related 
with membrane transport. Cold induction of these proteins may counteract 
the low diffusion rate of solutes at low temperatures.  At this stage, however, 
it is difficult to infer a function for cold-adapted bacterial OMVs mainly 
because Antarctic growing conditions cannot be reproduced in the laboratory 
and this implies that some of the identified proteins and their concentrations 
may differ from those in natural environments. 
 
3. New type of outer membrane vesicles: Implications in 
DNA content 
 
 Numerous studies, particularly on pathogenic bacteria, have shown that 
OMVs can contain DNA and, in some cases, transfer it to other bacteria 
[7,9,18-21]. The mechanism is a plausible one, since vesicles can protect 
DNA from degradation outside the cell and also favor DNA transmission 
between bacteria by association with cell envelopes [20]. Despite the great 
interest generated by the presence of DNA in bacterial OMVs, the 
mechanisms by which DNA is internalized in these vesicles are still not clear 
[21], particularly since all the vesiculation mechanisms proposed to date rule 
out the presence of any cytoplasmic membrane and therefore of any 
cytoplasmic components [7].  
 Among various models proposed to explain DNA packaging in OMVs 
[19,21], one involves the release of extracellular DNA after bacterial lysis is 
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internalized in the vesicles by a mechanism similar to that used in bacterial 
transformation. Another model involves the incorporation of DNA into 
OMVs before their release, assuming that the DNA somehow passes from the 
cytoplasm through the plasma membrane to be encapsulated within an OMV 
once in the periplasm. Nevertheless, neither of these models have been 
sufficiently backed up by experimental evidence [21].  A third model was 
proposed by Kadurugamuwa and Beveridge [19] to explain the presence of 
some cytoplasmic constituents in natural and gentamicin-induced OMVs of 
Pseudomonas aeruginosa. They suggested that the peptidoglycan layer can 
be weakened by autolysins and that transient and localized breaches in the 
peptidoglycan can lead to the formation of what they called complicated 
OMVs, which contain both inner and outer membranes as well as 
cytoplasmic components such as DNA. However, TEM images were 
inconclusive, and the existence of a new type of double-layered membrane 
vesicle was not demonstrated. 
 Shewanella vesiculosa M7
T
 is an Antarctic psychrotolerant Gram-
negative bacterium isolated by our research group from marine sediments 
collected on Deception Island (South Shetland Islands) [13]. This strain 
produces a huge amount of natural OMVs from solid or liquid cultures 
without any inducing factors such as the addition of membrane-perturbing 
agents. Initial structural analysis of the strain gave us an insight into a 
possible mechanism that would explain the presence of DNA inside OMVs of 
a Gram-negative bacterium.  
 In TEM observations of S. vesiculosa M7
T
 sections obtained after HPF-
FS, we repeatedly noted the presence of two different types of OMVs 
secreted from this strain. The first were conventional OMVs, surrounded by a 
bilayer membrane and with diameters ranging between 25 and 200 nm (Fig. 
6A and B). These vesicles were derived from the OM of S. vesiculosa M7
T
 
cells, as can be clearly observed in Fig.6A, with their membranes showing 
the same bilayer structure, width, and staining profile as the cell OM. The 
OMVs were also surrounded by the same fringe of fine fibers as the cells and 
contained material of low electron density similar to that in the cell 
periplasmic space. Unexpectedly, however, in some S. vesiculosa M7
T
 cells 
we noted the formation of membrane vesicles in which the plasma membrane 
(PM) was extruded as well as the OM. During this vesiculation process, we 
observed that cytoplasmic content (CC) also became entrapped within the 
vesicle (Fig. 6C to 6F). OMVs formed in this way had diameters of between 
100 and 250 nm and two bilayer membrane structures, i.e., the external 
membrane derived from the cell OM and an inner membrane corresponding 
to the cell PM, as Fig. 6C to 6F clearly depict. Inside this inner membrane, 
we observed an electron-dense material similar to that seen in the cell  
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Figure 6. TEM micrographs of ultrathin sections from S. vesiculosa M7T  prepared by 
HPF-FS. (A and B) A view of OMVs extruded from cells. Only one bilayer is 
observed around the vesicles, with the same structure as the outer membrane (OM) of 
the cell (arrows). (C) OMVs being released from cells and dragging the plasma 
membrane (PM) and a portion of the cytoplasmic content (CC) in addition to the OM. 
(D) The same type of vesicle is depicted in panel C but once it is outside the cell. (E 
and F) More views of OMVs that on release have incorporated CC surrounded by the 
PM. Bars, 100 nm (A, C, E) and 200 nm (B, D, F). (From Appl. Environ. Microbiol. 
2013.79(6):1874-81). 
 
cytoplasm. Although much less common than the conventional OMVs, these 
singular double-layered vesicles were apparent in many of the sections 
analyzed. 
 The presence of these double-bilayer OMVs was confirmed by cryo-
TEM of thin frozen films of isolated OMVs. For this purpose, total OMVs 
from S. vesiculosa M7
T
 were isolated from liquid cultures. Vesicles were 
collected from exponentially growing cultures to avoid the presence of lysed 
cells. Single-bilayer OMVs (Fig.7, white arrow) predominated in all observed  
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Figure 7. Isolated OMVs from S. vesiculosa M7T observed by cryo-TEM. Two types 
of OMVs can be seen: most vesicles have a single membrane (white arrow), but 
occasionally vesicles with two membranes are observed (black arrow). Bar, 100 nm. 
(From Appl. Environ. Microbiol. 2013.79(6):1874-81). 
 
fields, but double-bilayer OMVs were also present (black arrow), always 
with a round shape, unlike those in TEM sections. After counting 9,000 
vesicles visualized by cryo-TEM of thin frozen foils, we found that 0.1% of 
the total vesicles corresponded to new double-bilayer OMVs. 
 OMVs obtained from liquid cultures of S. vesiculosa M7
T
 were also used 
to quantify their DNA content before and after DNase treatment, using the 
PicoGreen assay. The DNA content of OMVs was 2.1 ± 0.4 ng DNA/μg 
OMV protein before DNase treatment and 1.8 ± 0.24 ng DNA/μg OMV 
protein afterwards. This result confirmed that most DNA was inside the 
vesicles and not surface-associated, since approximately 85% remained after 
DNase treatment.  
 To further characterize OMVs from S. vesiculosa M7
T
 and verify that 
DNA was within the vesicles rather than surface-associated in a DNase-
resistant manner, we performed immunogold labeling with an antibody 
specific for double-stranded DNA. Isolated OMVs from exponentially 
growing cultures were first treated with DNase before cryoimmobilization 
and HPF-FS to eliminate DNA present outside the vesicles, and then the 
immunogold technique to label DNA was applied to Lowicryl HM20 thin 
sections of S. vesiculosa M7
T
 OMVs. Subsequent TEM observations showed 
the presence of both types of vesicles: (i) conventional or single-bilayer 
OMVs, which were rarely marked with gold and contained non-electron-
dense material (Fig. 8A) and (ii) OMVs with two bilayer membranes (Fig. 8B).  
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Figure 8. DNA immunolabeling on Lowicryl HM20 thin sections of isolated OMVs 
from S. vesiculosa M7T. (A) TEM micrograph showing single-bilayer OMVs 
immunolabeled with a monoclonal IgM specific against dsDNA and a secondary goat 
anti-mouse antibody coupled to 12-nm colloidal gold. No gold mark or electron-dense 
material is observed inside these vesicles. (B) TEM micrograph showing double-bilayer 
OMVs immunolabeled like the vesicles in panel A. The outer layer corresponds to the 
outer membrane (OM) of the cell and the inner layer to the plasma membrane (PM) of 
the cell. Vesicles are filled with an electron-dense material, and a gold mark is visualized 
inside the inner layer. (C) TEM micrograph of OMVs labeled only with the secondary 
antibody. Single- and double-bilayer OMVs are visualized without any gold marking. 
(D) TEM micrograph of OMVs labeled with a primary IgM monoclonal antibody to 
Plasmodium falciparum with no affinity to DNA and a secondary antibody coupled to 
12-nm colloidal gold. No gold mark is observed. (E) TEM micrograph of OMVs from 
grids preincubated with 1 mg/ml DNase I and then immunolabeled with IgM dsDNA 
and a secondary antibody coupled to gold. No gold mark is observed. Bars, 200 nm. 
(From Appl. Environ. Microbiol. 2013.79(6):1874-81). 
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The latter showed an external bilayer membrane that corresponded to the cell 
OM and an inner membrane also with a bilayer structure that corresponded to 
the cell PM, as depicted in Fig. 6. These double-bilayer vesicles were filled 
with an electron-dense material, and most of them exhibited a highly visible 
gold mark (Fig. 8B). As expected, the gold marker was not seen outside the 
vesicles due to previous DNase treatment before HPF (Fig. 8A and B). To 
check that gold immunolabeling was specific, we performed several control 
experiments (see Fig. 8C, D and E). 
 Several proteomic studies have described the presence of cytoplasmic 
and PM proteins inside Gram-negative bacterial OMVs, although all the 
vesiculation mechanisms proposed so far rule out the presence of such 
components [7,9]. To identify protein components of S. vesiculosa                   
M7
T
-derived OMVs we used a proteomic approach with 1-D SDS-PAGE and 
nano-LC-MS/MS analysis and their subcellular localization was analyzed 
using the PSORTb v3.0.2 program [22].  Along with the proteins mentioned 
in the previous section, the proteomic study also identified the presence of 
cytoplasmic membrane proteins within S. vesiculosa M7
T
-derived OMVs, 
such as cytochrome c oxidase and nucleoside transporters (CM) (6.5%), and 
cytoplasmic proteins such as FoF1 ATP synthase and Na+-quinone reductase 
(C) (4.3%). 
 This previously undescribed type of OMVs naturally produced by S. 
vesiculosa M7
T
, containing not only the cell OM but also PM and CC, with 
the consequent ability to entrap DNA, were named outer-inner membrane 
 
 
 
Figure 9. (A) Model proposed for the formation of new O-IMVs in Gram-negative 
bacteria and packaging of DNA. Plasma membrane and cytoplasmic content are 
included in the vesicle leaving the cell, thus allowing DNA to be incorporated. (B) 
TEM micrograph of an S. vesiculosa M7T cell supporting the model in panel A. (C) 
TEM micrograph showing an isolated double-bilayer vesicle from this strain after 
immunolabeling with a dsDNA antibody. OM, outer membrane; PM, plasma 
membrane; OMV, outer membrane vesicle; HPF-FS, high-pressure freezing and 
freeze-substitution. Bars, 200 nm. (From Appl. Environ. Microbiol. 2013.79(6):           
1874-81). 
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vesicles (O-IMV). This important finding corroborates a model proposed by 
Beveridge's group to explain how CC and DNA can be incorporated into 
OMVs before they are released from the cell [19].  
 
4. Conclusions 
 
 A common feature of most cold-adapted Antarctic bacteria is the abundant 
production of complex extracellular matter, which probably performs more 
than one function. The net-like mesh surrounding the cells composed of 
polymers and protein-charged OMVs most likely can modify the 
physicochemical properties around the cells, creating a micro-environment that 
may promote bacterial survival in a harsh environment. For instance, capsular 
polymers may have a cryoprotectant role and help in cell adhesion, and the 
polymeric fibers around vesicles could preserve the net-like mesh structure. On 
the other hand, the huge amount of OMVs entrapped in this mesh could be a 
source of different proteins with diverse functions, such as nutrient sensing, 
transport, and polysaccharide biosynthesis, as well as adhesins and degradative 
enzymes, which may help to concentrate nutrients around the cells. 
 We have demonstrated the existence of a previously unobserved type of 
double-bilayer OMV in the Gram-negative bacterium Shewanella vesiculosa 
M7
T
 that can incorporate DNA. The presence of DNA inside bacterial OMVs 
and the possibility that these structures constitute a new mechanism of lateral 
gene transfer have important implications in several areas, including 
prokaryotic evolution and in particular the transfer of antibiotic resistance 
genes or virulence genes within bacteria. For this reason, these new OMVs 
deserve further study, and future work will be directed to demonstrating their 
existence in pathogenic bacteria for which DNA transfer through OMVs has 
been already reported. 
 
Acknowledgements 
 
 This study was supported by the Government of Spain (CICYT project 
CTQ 2010-21183-C02-01/PPQ) and by the Autonomous Government of 
Catalonia (grants 2009SGR1212). Carla Pérez-Cruz is the recipient of 
fellowship FFAR2012.3 from the University of Barcelona. 
 
References 
 
1. Krembs , C., Eickenb, H., Jungea, K.,  Deminga, J.W. 2002, Deep-Sea Research 
I,  49, 2163. 
2. Mancuso, C., Garon S.,  Bowman J. P., Nichols P. D., Gibson J. A. E., 
Guézennec J. 2005, Microb. Ecol., 49, 578. 
Carla Pérez-Cruz & Elena Mercadé  72 
3. Nevot, M., Deroncelé, V., Messner, P., Guinea, J., Mercadé, E. 2006, Environ. 
Microbiol., 8, 1523. 
4. Nevot, M., Deroncele, V., López-Iglesias, C., Bozal, N., Guinea J., Mercadé, E. 
2006, Microb. Ecol., 51, 501. 
5. Frías, A., Manresa, A., de Oliveira, E., López-Iglesias, C., Mercadé, E. 2010, 
Microb. Ecol., 59:476 (erratum in Microb. Ecol. 2010, vol. 60, issue2, page 476). 
6. Pérez-Cruz, C., Carrión, O., Delgado, L., Martinez, G., López-Iglesias, C., 
Mercadé, E. 2013, Appl. Environ. Microbiol., 79, 1874. 
7. Kulp, A., Kuehn, M., 2010, Annu. Rev. Microbiol., 64, 163. 
8. Lee, E. Y., Choi, D. S., Kwang-Pyo, K., Yong, S. G. 2008,  Mass. Spectrom. 
Rev., 27, 535. 
9. Mashburn, L. M., Whiteley, M., 2005, Nature 437, 422. 
10. Montes, M. J., Mercadé, E., Bozal, N., Guinea, J. 2004, Int.  J. Syst. Evol. 
Microbiol., 54, 1521. 
11. Bozal, N., Montes, M. J., Mercade, E. 2007, Int.  J. Syst. Evol. Microbiol., 57, 
2609. 
12. Montes M. J., Bozal, N., Mercade, E. 2008, Int. J. Syst. Evol. Microbiol., 58, 
1346.  
13. Bozal. N., Montes, M. J., Miñana-Galbis, D., Manresa, A., Mercade, E. 2009, Int 
J. Syst. Evol. Microbiol., 59,336. 
14. Carrión, O., Miñana-Galbis, D., Montes, M. J., Mercade, E. 2011, Int J. Syst. 
Evol. Microbiol., 61, 2401. 
15. Graham, L. L., Harris, R., Villiger, W., Beveridge, T. J.   1991, J. Bacteriol., 173, 
1623. 
16. Beveridge, T. J. 1999, J. Bacteriol., 181, 4725. 
17. Chróst, R.J. 1991. Microbial enzymes in aquatic environments (Eds). 
Brock/Springer Series in Contemporary Bioscience, 29. 
18. Dorward, D.W., Garon, F. G. 1990, Appl. Environ. Microbiol., 56, 1960.  
19. Kadurugamuwa, J. L., Beveridge T. J. 1995, J. Bacteriol. 177, 3998. 
20. Yaron, S., Kolling, G. L., Beveridge T. J. 2000, Appl. Environ. Microbiol., 66, 
4414. 
21. Renelli, M., Matias, V., Lo, R. Y., Beveridge T. J. 2004, Microbiol., 150, 2161. 
22. PSORTb V3.0. Yu N. Y., Wagner M. R., Laird, G., Mellis, G., Rey, S., Lo, R., 
Dao, P., Sahinalp, S. C, Ester, M., Foster, L.J., Brinkman, F. S. L. 2010, 
Bioinformatics, 26, 1608.  
 
 
 
 
 
 
 
 Research Signpost 
 37/661 (2), Fort P.O. 
 Trivandrum-695 023  
 Kerala, India 
 
 
Recent Advances in Pharmaceutical Sciences IV, 2014: 73-84 ISBN: 978-81-308-0554-2  
Editors: Diego Muñoz-Torrero, Manuel Vázquez-Carrera and Joan Estelrich 
 
5. Loss of intestinal epithelial barrier 
function in Salmonella Enteritidis infection      
 
Raquel Martín-Venegas, M. Teresa Brufau and Ruth Ferrer 
Departament de Fisiologia, Facultat de Farmàcia, Universitat de Barcelona                                                 
E-08028-Barcelona, Spain 
 
Abstract. Intestinal infection with Salmonella enterica serotype 
Enteritidis, a food-borne infection spread to humans especially 
through contaminated eggs and egg-products as well as 
undercooked contaminated fresh meat, is the most common cause 
of intestinal inflammation in the European Union. Enteritis caused 
by Salmonella Enteritidis is characterized by fever, diarrhoea and 
abdominal pain. The disruption of the intestinal epithelial barrier 
function contributes to diarrhoea and is responsible for the 
perpetuation of the inflammatory process. In this sense, oxidative 
stress and the proinflammatory cytokines TNF-α, IFN-γ and IL-1β 
are described to induce the disorganization of the tight junctions 
(TJ), the most apical epithelial intercellular junctions and 
responsible for the paracellular permeability. The interest of this 
chapter relies not only in the investigation dealing with the 
mechanisms of TJ regulation but also in the contribution to the 
development of new tools for the prevention of epithelial barrier 
disruption in enteritis caused by Salmonella Enteritidis.  
 
Introduction 
   
      Salmonella are gram-negative bacteria consisting of non-spore forming bacilli 
and are a member of the family Enterobacteriaceae. The genus Salmonella 
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includes two species, Salmonella enterica and Salmonella bongori. The 
nomenclature of Salmonella is quite complex and is based on both serotype 
and subspecies names [1]. For the subspecies enterica of Salmonella 
enterica, more than 2500 serotypes have been described [2]. Thus, 
Salmonella enterica subspecies enterica serotype Enteritidis is shortened to 
Salmonella serotype Enteritidis or Salmonella Enteritidis. Salmonella 
Enteritidis is one of the leading causes of food-borne salmonellosis in 
humans all over the world [3]. The remaining cases of salmonellosis are 
caused by Salmonella enterica serotype Typhimurium, associated with the 
consumption of contaminated pig and beef meat, and other more minor 
serotypes. Poultry is considered the single largest reservoir of Salmonella 
Enteritidis and the consumption of chicken meat and egg products is the 
major source of human infection [4-7]. Salmonella causes asymptomatic 
intestinal infections in adult birds but acute outbreaks exhibiting clinical 
disease along with high levels of mortality occur in chicks younger than 2 
weeks old [8]. Birds that are asymptomatic carriers may facilitate the spread 
of disease infections among flock, thus constituting the major source of 
infection [9,10]. Salmonellosis is characterized by fever, diarrhea and 
abdominal cramps, but if the bacterium invades the bloodstream it can also 
cause life-threatening infections. 
 A necessary step in the successful colonization and ultimate production 
of disease is the ability of bacterial pathogens to adhere to host surfaces, 
which is an important determinant of virulence. Generally, binding to 
intestinal host cells is essential for the bacteria to resist the fluid flow of the 
luminal contents and the peristalsis of intestinal contraction. Once bound to 
the epithelial surface, bacteria may colonize and establish a permanent 
residence in the gut. The host cell is often an active participant in the 
adhesion process and does not function simply as an inert surface for 
attachment. Indeed, a wide range of mammalian cell surface constituents, 
including glycoproteins and glycolipids, can serve as receptors for bacterial 
attachment [11]. Salmonella Enteritidis possesses mannose-specific lectins in 
type-1 fimbriae that adhere to glycoproteins of the intestinal epithelium [12] 
and allow passage, mainly but not exclusively, through M cells (microfold 
cells) [13] (Fig. 1). This invasive mechanism is governed by the type III 
secretion system 1 (T3SS-1), which facilitates epithelial uptake and invasion 
[14]. The genes that encode the T3SS-1 machinery are associated with 
Salmonella pathogenicity island 1 (SPI-1) [15]. Pathogenicity islands (PI) are 
genetic elements that carry genes encoding virulence factors, such as 
adhesion, invasion, and toxin genes [16,17]. In fact, one of the major                     
clinical features of salmonellosis is diarrhea, which is caused by SPI-1 T3SS  
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Figure 1. Salmonella Enteritidis entry into intestinal epithelial cells, mainly via M 
cells. After crossing the M cell, the bacteria are engulfed by macrophages and induce 
their apoptotic death. This process allows the bacteria to invade adjacent epithelial 
cells and to elicit an inflammatory response. 
 
translocated proteins [18]. A number of additional proteins are translocated 
via the SPI-1 T3SS including SipA, SipC, and SopB (SigD), which interact 
with the actin cytoskeleton causing cytoskeletal rearrangements leading to 
membrane ruffling [19,20]. Membrane ruffling is characterized by a 
rearrangement of the cell membrane and cytosol such that the Salmonella is 
surrounded by the host cell and internalized within a membrane containing 
vacuole that serves as a protective niche from lysosomal degradation [21,22].  
 
1. Intestinal epithelial barrier function  
 
 The gastrointestinal epithelium is a selective barrier that allows the 
absorption of nutrients, electrolytes and water, but restricts the passage of 
larger potentially injurious compounds such as allergens, toxins and 
pathogens. Thus, this barrier prevents inflammation, mucosal injury, bacterial 
translocation and systemic infection. The epithelial cells create this selective 
permeability, constituting the so called epithelial barrier function, by two 
pathways: the transcellular and the paracellular pathway. The transcellular 
pathway is involved in the transport of nutrients, including sugars, amino 
acids, peptides, fatty acids, minerals and vitamins. As the cell membrane is 
impermeable, this process is predominantly mediated by specific transporters 
and channels (Fig. 2) located on the apical and basolateral membranes. The 
paracellular pathway is associated with diffusion though the intercellular 
space between adjacent epithelial cells. Therefore, the ability of the intestinal  
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Figure 2. Schematic representation of simple diffusion and mediated transport 
mechanisms. 
 
epithelium to establish the equilibrium between nutrient absorption and the 
prevention of harmful element entry constitutes the key backbone of 
intestinal barrier function. In addition, other elements also contribute to 
mucosal protection, such as the luminal mucus layer, antibacterial products 
and microbiota which not only protects against pathogens but also forms a 
sophisticated intestinal homeostatic colonization system, as well as 
intraepithelial lymphocytes and subepithelial immune cells with innate and 
adaptive immune systems [23].  
 The structural integrity of the epithelium is maintained by three distinct 
adhesion systems: tight junctions (TJ), adherent junctions, and desmosomes. 
The adherent junctions, along with desmosomes, provide strong adhesive bonds 
between the epithelial cells and also aid intercellular communication, but does 
not determine paracellular permeability (PP) [24]. TJ, the most apical 
component, are the rate-limiting step for PP and constitute the interface (fence) 
between apical and basolateral membrane domains [25]. TJ are formed by 
transmembrane proteins associated with cytosolic proteins and the cytoskeletal 
perijunctional actomyosin ring (Fig. 3). Five transmembrane proteins of the TJ 
have been identified until now: occludin, the claudin family, tricellulin, crumbs, 
and junctional adhesion molecules (JAM). These proteins are associated with a 
wide spectrum of cytosolic proteins, of which zonula occludens (ZO)-1, ZO-2, 
ZO-3, AF6, and cingulin are described as forming the nexus with cytoskeletal 
proteins [26]. Although the structure and in some cases the role of these 
proteins have been well described, the manner they work together to determine 
selective PP is not already completely well-defined [27].  
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Figure 3. Molecular structure of the tight junction (TJ) of intestinal epithelial cells. 
The TJ complex consists of transmembrane and intracellular scaffold proteins. The 
extracellular loops of the transmembrane proteins (occludin, claudins, JAMs, and 
tricellulin) create a selective barrier in the paracellular pathway. The intracellular 
domains of the transmembrane proteins interact with the intracellular scaffold proteins 
such as zonula occludens (ZO) proteins and cingulin, which in turn anchor the 
transmembrane proteins to the actin cytoskeleton.  
 
2. Disruption of the intestinal epithelial barrier function  
 
 The modification of TJ structure and therefore PP is dynamically 
regulated by various extracellular stimuli and is closely associated with 
health and susceptibility to disease [28]. In this sense, evidence from basic 
science and clinical studies indicate that the intestinal TJ barrier has a critical 
role in the pathogenesis of intestinal diseases such as inflammatory bowel 
disease, celiac disease and irritable bowel syndrome [28]. TJ barrier 
disruption and increased PP, followed by permeation of luminal 
proinflammatory molecules, can induce activation of the mucosal immune 
system, resulting in sustained inflammation and tissue damage. Thus, pro-
inflammatory cytokines, antigens, and pathogens contribute to barrier 
impairment [29]. In contrast, food factors and nutrients also participate in 
intestinal TJ regulation, and some of these could be developed as preventive 
and therapeutic tools for defective barrier-associated diseases [30]. 
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 Tumour Necrosis Factor-α (TNF-α), mainly produced by activated 
macrophages and T lymphocytes, has been described to be one of the main 
cytokines involved in the disruption of epithelial barrier function in intestinal 
inflammatory processes [31]. TNF-α regulates barrier function indirectly by 
the generation of oxidative stress and directly via an increase in myosin light 
chain kinase (MLCK) expression and activity [32,33] and TJ remodelling 
[34]. In this regard, MLCK activation triggers different cellular contractile 
events including a) occludin endocytosis to the cytosol leading to the 
disorganization of the TJ, and the b) contraction of the perijunctional 
actomyosin which generates mechanical tension at the TJ and induces its 
opening [35]. In fact, all these effects of TNF-  on TJ structure and 
permeability are prevented by genetic or pharmacological MLCK inhibition, 
as is diarrhea [32]. This highlights the close link between changes in TJ, 
epithelial barrier disruption and water loss. 
 The production of reactive oxygen and nitrogen species (ROS and RNS) 
has gained relevance in recent years in the context of the regulation of TJ 
permeability. In Caco-2 cells, H2O2 has been reported to induce the 
dissociation of the complex formed by occludin and ZO-1 and the separation 
of this complex from the cytoskeleton via a Tyr kinase-dependent mechanism 
[36]. This effect is accompanied by the disorganization of actin and the 
redistribution of occludin and ZO-1 from the TJ to the cytosol [37]. In this 
sense, the increased production of ROS has also been reported to play an 
important role in a number of intestinal disorders including inflammatory 
bowel disease [38]. Moreover, a significant body of evidence suggests that 
oxidative stress disrupts epithelial barrier function [39]. Indeed, the protective 
role of many substrates with antioxidant properties (such as taurine, quercetin 
and epithelial growth factors) has been proven as useful in TJ sealing [40-42]. 
 
3. Evaluation of epithelial barrier function 
 
 Experimentally, TJ barrier integrity and permeability in intestinal tissues 
and cells are evaluated by measurement of transepithelial electrical resistance 
(TER) and the paracellular passage of water soluble molecules of different 
molecular weight, such as mannitol, dextran, and inulin. The use of cultures 
of intestinal epithelial cells (Caco-2, IEC-6, HT-29, T-84, etc.) is frequently 
used as a reductionist experimental model to evaluate epithelial barrier 
function. The cells are allowed to grown on to semipermeable filters to create 
an apical and a basolateral compartment to measure transepithelial fluxes of 
paracellular markers and TER [43-45]. The tightness of the monolayer is 
indicated by high TER values and low permeability to paracellular markers. 
TER is considered an indicator of ionic fluxes across the epithelium or cell 
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monolayer (mainly Na
+
 and Cl
-
). In addition to charge selectivity, TJ differ in 
size selectivity. In this sense, it is described a pore pathway that is permeable 
to molecules with radii of 4 Å or less and a second pathway, which is refered 
to as the leak pathway, for flux of larger noncharged solutes [27]. The small 
ions do not discriminate between pore and leak pathways, and therefore TER 
cannot be used to investigate the selectivity of TJ size or charge. Increased 
permeability of both pathways reduces TER values. The permeability of the 
leak pathway is then evaluated from transepithelial fluxes of paracellular 
markers. In cells in culture the more commonly used tracers include D-
mannitol, sucrose, inulin, PEG or dextrans of different molecular weights 
[27].  
 The Caco-2 cell system is an efficient model to study the changes in  
epithelial barrier function induced by several infectious microorganisms that 
are also involved in gastrointestinal disorders, such as rotavirus, Escherichia 
coli, Vibrio parahaemolyticus and Salmonella [46-49]. Moreover, the role of 
the toll-like receptor 2 pathway, which plays a key role in microbial 
recognition and immune modulation in the regulation of TJ permeability, has 
also been described in this experimental model [50]. Similarly, the protective 
effect of probiotics, such as Lactobacillus rhamnosus and Lactobacillus 
casei, against the effect of pro-inflammatory cytokines has also been 
demonstrated in Caco-2 cells [51,52]. In this sense, intestinal cells in culture, 
mainly Caco-2 cells, can also be co-cultured with different immune cells to 
also consider the mechanisms of cellular interaction in the regulation of TJ 
permeability [53].  
 
4. Intestinal epithelial barrier function disruption by 
Salmonella: nutritional strategies to prevent this effect 
 
 The invasion of Salmonella Enteritidis into the intestinal epithelium 
triggers diverse transduction signals at the subepithelial compartment which 
induce the activation of immune cells and therefore the onset of the 
inflammatory process [14]. The secretion of proinflammatory cytokines 
disrupts epithelial barrier function which in turn contributes to water loss and 
bacterial translocation, perpetuating the inflammatory process and initiating 
systemic invasion [35]. In this sense, the infection of cultures of human 
intestinal Caco-2 cells with different strains of Salmonella confirms the 
ability of these bacteria to increase PP [48]. This is exemplified through a 
decrease in TER, increase in tracer permeability and TJ protein alterations 
when assessed in a variety of cell lines including MDCK, Caco-2 and T84 
cells [54-56]. In this regard, it has been concluded that Salmonella causes a 
decrease in both ZO-1 expression and in the amount of phosphorylated 
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occludin in the TJ by 2 h of T84 cell infections [56]. Studies aimed at 
elucidating the specific bacterial proteins involved in the documented 
Salmonella-induced TJ alterations have primarily used mutated strains of 
Salmonella to identify those that do not alter TER, ZO-1 and occludin 
localization. Through these experiments, the SPI1 effectors; SopB, SopE, 
SopE2 and SipA have all been implicated in TJ alterations [57]. Moreover, 
since Salmonella infection induces an increase in TNF-α production [58,59], 
the effect of infection on PP can be, almost in part, attributed to this cytokine. 
This suggests that synergistic and potentially redundant mechanisms are in 
place to ensure TJ are modified as part of the disease imparted by Salmonella. 
Since 2006, the use of antibiotics as chicken growth promoters has been 
baned (January, 1, 2006; Regulation 1831/2003 of the European Parliament 
and of the Council). This prohibition arises from the increase of antibiotic 
resistant bacteria in animal farms and represents a health hazard after 
resistance transfer to human pathogenic bacteria [3]. For this reason, 
extensive research has been conducted on the development of naturally 
occurring antimicrobials as alternatives to antibiotics. In this sense, probiotic 
and prebiotic feed additives are promising alternatives because they control 
intestinal microbiota, reducing pathogenic bacteria colonization and 
enhancing mucosal immune system [60]. 
 Probiotics are generally referred to as any live microbial feed 
supplements that benefit the host animals by largely improving intestinal 
microbial balance [61]. Intestinal microorganisms that are recognized as 
possessing probiotic properties include mainly Lactobacilli and 
Bifidobacteria spp. They exhibit identifiable beneficial effects for the 
respective host via promotion of gut maturation and integrity, antagonism 
against pathogens such as Salmonella and immune modulation [62]. The 
effects of probiotics in poultry also include maintaining normal intestinal 
microflora by competitive exclusion, increasing metabolism, decreasing 
enzymatic activity and ammonia production, as well as an increase in feed 
intake and the neutralization of digestive enterotoxins [63]. Therefore, the 
overall goal of probiotics intervention is to promote the general growth of 
healthy microorganisms that are competitive with or antagonistic to 
enteropathogens [61]. 
 Prebiotics can be defined as non-digestible carbohydrate fractions fed 
in diets that are beneficial to the host by stimulating the growth of one or 
more bacteria in the gastrointestinal tract [64]. Prebiotics are predominantly 
a constituent of plant cell walls and also consist of non-starch 
polysaccharides along with non-carbohydrate compounds including lignin, 
protein, fatty acid, and wax [65]. Dietary β-galactomannans are non 
digestible complexes used as prebiotics due to their ability to confer 
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favourable conditions to intestinal beneficial Lactobacillus. Taking into 
account that Salmonella express mannose-specific lectins involved in the 
adherence of these bacteria to the intestinal epithelium [66], β-
galactomannans show competition thus preventing Samonella colonization. 
The main source of β-galactomannans is the cell walls of Saccharomyces 
cerevisiae which contain 45% of mannose residues [67]. However, new 
sources are being investigated. In this sense, IRTA, the Research and 
Technology Food and Agriculture Institute from the Generalitat de 
Catalunya, has developed a food additive extract from the carob bean of the 
Ceratonia silliqua tree (Salmosan®) which approximately contains 88% of 
β-galactomannans [68]. We have reported, in cultures of intestinal pig cells 
(IPI-2I), the capacity of Salmosan® to inhibit Salmonella Typhimurium 
epithelial attachment and to reduce up to 70% Salmonella-induced mRNA 
expression of proinflammatory cytokines such as TNF-α, GM-CSF 
(Granulocyte/Macrophage Colony-Stimulating Factor) and chemokine 
CCL20 [59]. These results are very similar to the obtained for 
Sacharomyces cerevisiae used as a positive control. Moreover, scanning 
electron microscopy images obtained in our laboratory confirm that the 
capacity of Salmosan® to reduce Salmonella adhesion in these 
experimental conditions is due to bacterial attachment to this prebiotic [59] 
(Fig. 4).  
 
A B C
 
 
Figure 4. Interaction of Salmonella Typhimurium with Salmosan® on the surface of 
IPI-2I cells assessed by scanning electron microscopy. Images show Salmonella 
attachment on epithelial cells (A), Salmosan® over the control cells (B), and 
Salmonella interaction with Salmosan® (C).  
 
5. Conclusion 
 
 Foodborne pathogens such as Salmonella possess the capability to 
survive in external environments during transmission from one host to the 
next. The determination of microbial genetics and physiology associated with 
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these mechanisms could have great potential for better control of pathogen 
colonization. In this sense, although advances have led to an overall greater 
understanding, the detailed mechanisms that these microorganisms employ to 
modify TJ remain elusive. For this reason, a better understanding of these 
indicators could assist in designing more novel approaches to minimize the 
spread of Salmonella in the food animal industry and decrease the 
consequences to human health. 
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Abstract. Eradicating measles represents a major public health 
achievement, yet outbreaks still occur in territories where endemic 
measles virus (MV) had been eliminated. In Catalonia from the 
year 2000 cases have occurred as isolated cases or small outbreaks,  
both linked to imported cases up to the end of  2006 when a large 
outbreak started out affecting mainly children ≤15m. In 
consequence, immunization schedule was amended lowering first 
dose to 12m. Again new MV importations from neighboring 
countries triggered another outbreak on November 2010 with a 
different age distribution sparing small children from infection. 
Differences in incidence (IR), rate ratio (RR) and 95% CI and 
hospitalization rate (HR) by age group were determined. Statistic z 
was used for comparing proportions.  Total number of confirmed 
cases was 305 vs 381 in 2006; mean age 20 yrs (SD 14.8yrs; 3m -
51yrs) vs 15m (SD13.1yrs; 1m-50yrs).  Highest proportion of cases                    
was set in ≥25yrs (47%) vs 24.2% in 2006 (p<0.001). Difference in  
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IR for ≤ 15m was statistically significant (49/100,000 vs 278.2/100,000; RR:3.9; 
95%CI 2.9-5.4) and in HR 30.2% vs 15.7% (p<0.001). The change of the month of 
administration of the first dose proved successful. Given the current epidemiological 
situation, continued awareness and efforts to reach young adult population are needed 
to stop the spread of the virus.  
                                                                                                                                                  
Introduction 
 
 Eradicating measles represents a major public health achievement, yet  
outbreaks still occur in territories where endemic measles virus (MV) had  
been eliminated. In theory, if the right tools were available, all infectious 
diseases would be eradicable. In reality, there are distinct biological features 
of the organisms and technical factors of dealing with them that make their 
potential eradicability more or less likely. Today's categorization of a disease 
as not eradicable can change completely tomorrow, either because research 
efforts are successful in developing new and effective intervention tools or 
because those presumed obstructions to eradicability that seemed important 
in theory prove capable of being overcome in practice. Three indicators were 
considered to be of primary importance: an effective intervention is available 
to interrupt transmission of the agent; practical diagnostic tools with 
sufficient sensitivity and specificity are available to detect levels of infection 
that can lead to transmission; and humans are essential for the life-cycle of 
the agent, which has no other vertebrate reservoir and does not amplify in the 
environment [1]. 
 The effectiveness of an intervention tool has both biological and 
operational dimensions. Elimination validates the effectiveness of an 
intervention tool, but it does not necessarily make the agent a candidate for 
eradication. Highly developed levels of sanitation and health systems 
development may make elimination possible in one geographical area but not 
in another. 
 Diagnostic tools also have both biological and operational dimensions. 
The tools must be sufficiently sensitive and specific to detect infection that 
can lead to transmission, and also sufficiently simple to be applied globally 
by laboratories with a wide range of capabilities and resources. Eradication is 
a much more feasible target of deliberate intervention when humans form an 
essential component of the agent's life-cycle. An independent reservoir is not 
an absolute barrier to eradication if it can be targeted with effective 
intervention tools. 
 The costs and benefits of global eradication programmes can be grouped 
into two categories: direct effects and consequent effects. The direct effects 
of eradication are that no morbidity or mortality due to that disease will ever 
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again occur. Explicit efforts should be taken to maximize the effectiveness of 
both eradication and comprehensive health programmes [2]. 
 Eradication has been defined in various ways: as extinction of the disease 
pathogen, as elimination of the occurrence of a given disease, even in the 
absence of all preventive measures, as control of an infection to the point at 
which transmission ceased within a specified area, and as reduction of the 
worldwide incidence of a disease to zero as a result of deliberate efforts, 
obviating the necessity for further control measures. The hierarchy of 
potential public health efforts in dealing with infectious diseases was 
discussed at the Dahlem Workshop. Differences in these efforts made a 
distinction between the disease caused by the infection and the infection 
itself, the level of reduction achieved for either of these, the requirement for 
continuation of control efforts, and, finally, the geographical area covered by 
the intervention efforts and their outcomes. Although definitions outlined 
below were developed for infectious diseases, those for control and 
elimination apply to noninfectious diseases as well [3]. 
 
 Control: The reduction of disease incidence, prevalence, morbidity or 
mortality to a locally acceptable level as a result of deliberate efforts; 
continued intervention measures are required to maintain the reduction. 
Example: diarrheal diseases.  
 Elimination of disease: Reduction to zero of the incidence of a specified 
disease in a defined geographical area as a result of deliberate efforts; 
continued intervention measures are required. Example: neonatal tetanus.  
 Elimination of infections: Reduction to zero of the incidence of infection 
caused by a specific agent in a defined geographical area as a result of 
deliberate efforts; continued measures to prevent re-establishment of 
transmission are required. Example: poliomyelitis.  
 Eradication: Permanent reduction to zero of the worldwide incidence of 
infection caused by a specific agent as a result of deliberate efforts; 
intervention measures are no longer needed. Example: smallpox.  
 Extinction: The specific infectious agent no longer exists in nature or in 
the laboratory. (There is no example yet) [2]. 
 
 Globally, about 25% of disease morbidity and mortality are attributable 
to communicable diseases. In developed countries communicable diseases 
have decreased in a remarkable way because of antibiotics and vaccines. 
One of these candidate diseases to be eliminated and ultimately eradicated is 
measles [4]. Measles  is a highly transmissible disease for which conditions 
for eradication are favorable: humans are the only reservoir for the measles 
virus (MV), the vaccine is safe, inexpensive and produces life-long 
immunity, diagnostic tests are both specific and sensitive, all infected people 
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develop symptoms, and there are no chronic carriers [4,5]. Eradicating 
measles would represent a major public health achievement, well worth the 
investment it requires. For the EU, the first step towards eradication of 
measles is effective control within its own borders.  Finally, eradication will 
be the result of elimination of transmission on all continents. Elimination of 
measles by 2015 is part of the WHO strategic plan for measles in the World 
Health Organization (WHO) European Region. 
 Measles is caused by a single-stranded RNA virus of the genus 
Morbillivirus in the family Paramyxoviridae characterized in 1954 by Enders 
and Peebles with 23 known genotypes. It is spread by droplets or direct 
contact with nasal or throat secretions of infected persons; less commonly by 
airborne spread or by articles freshly soiled with secretions of nose and 
throat. Measles is one of the most readily transmitted communicable diseases 
and probably the best known and most deadly of all childhood rash/fever 
illnesses. Measles is characterized by rash, fever, and cough, coryza or 
conjunctivitis and is transmitted by pharyngeal or nasal secretions, normally 
from four days before to four days after the onset of rash. The incubation 
period is normally 10-14 days and the possible complications include otitis 
media, laryngotracheobronchitis, pneumonia, diarrhea, encephalitis and 
secondary bacterial infections. Children aged < 5 years who are living in poor 
conditions or are malnourished, and adults or patients with immune 
deficiencies have a greater risk of severe complications [6]. Subacute 
sclerosing panencephalitis (SSPE), a degenerative neurological disease that 
occurs several years after infection is the most severe condition related to 
measles infection especially in the very young. The increased risk of 
developing SSPE after measles virus infection in young children underscores 
the importance of childhood immunization programs that decrease measles 
virus transmission and, therefore, reduce the risk of exposure to measles 
among infants and  prevent the devastating disease SSPE [7].  Measles can be 
effectively prevented by vaccination which provides lifelong immunity to 
most recipients against all 23 recognized genotypes.  
 High immunization coverage has dramatically reduced the incidence of 
measles in Catalonia since measles vaccine was included in vaccination 
schedule in 1981. Despite overall high vaccination coverage, measles 
continues to cause frequent outbreaks. However, given the current 
epidemiological situation [8-12], continued awareness and efforts are needed.  
Especial efforts should be set concerning mass-gathering events and high 
travelling frequency among their population as well as from other parts of the 
world which offer favorable conditions for the spread of the virus between 
countries.  
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 In Catalonia, a region in the Northeast of Spain with a population of 
more than 7.5 million inhabitants, autochthonous measles was declared 
eliminated in the year 2000 [13] as the result of high Measles Mumps Rubella 
vaccine (MMR) coverage for first and second dose (15 months and 4 years.) 
since mid 90’s, from then on then sporadic imported cases and small 
outbreaks appeared until  August  2006, when a large measles outbreak 
appeared  affecting 381 people,  50% of which were below 15 months of age 
[14]. From January 2008 first dose administration of MMR was in 
consequence lowered to 12 months of age. A new honeymoon period went by 
until at the end of 2010, again, several new importations of different 
genotypes of wild MV, from neighboring countries triggered another 
outbreak on November 2010 with a different age distribution sparing small 
children from infection and striking young adults, mainly  adults  >25 years.  
 The aim of this study is to compare differences in age distribution and 
incidence rates (IR) of cases resulting from first dose MMR vaccine 
administration changed from 15months to 12months of age and to underscore 
the importance of enhanced surveillance and implementation of actions to 
prevent disease and hospitalization for all ages and especially in hard to reach 
susceptible population. 
 
1. Material and methods 
  
 Urgent reported suspected cases of measles to the Public Health 
Surveillance units were registered and   data on age, vaccination status, 
clinical course and epidemiological information were obtained by case 
interviews and review of medical records.  
 Samples for virological confirmation and genotyping of cases were 
collected as established in the Measles Elimination plan guidelines and 
delivered to the Microbiology Department of the H Clinic of Barcelona. 
Serum samples were collected after 3rd day of onset and measles specific 
antibodies IgG and IgM were determined by an ELISA Assay (Vircell 
®
). 
Nasopharyngeal and urine samples were collected and tested by real-time 
RT-PCR. In accordance with WHO recommendation for molecular 
epidemiology of measles, phylogenetic analysis of the 450 nucleotides that 
code for the carboxy-terminal 150 amino acids of the measles nucleoprotein 
(N) gene was used for genotype determination. Sequences obtained during 
this study were submitted to Health Protection Agency (HPA) measles 
database. Statistical assessment of incidence rates (IR) and risk ratios (RR) 
and their 95%CI, hospitalization rate (HR) by age group were determined. 
Statistic Chi
2
, Fisher’s test and statistic z were used for comparing variables 
and proportions. Statistical analysis was performed by means of the SPSS® 
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18.0 statistical package for windows (SPSS; Chicago, USA). Statistical 
significance set at α=0.05. 
 
2. Results 
  
 During the study period 489 suspected measles cases were notified to the 
corresponding regional epidemiological surveillance units versus (vs) 549 in 
the 2006-2007 outbreak. Total number of confirmed cases was 305 vs 381 in 
2006; showing slight statistical difference in confirmation rates (62.4% vs 
69.1%) [OR:0.73;95%CI: 0.56-0.95; (p=0.02)]. Difference in global IR 
showed statistical significance (4.05/100,000 vs 6.6/100,000; (RR: 1.3 
95%CI 1.08-1.46). Mean age of cases was 20 yrs in 2010 (SD 14.8 yrs; range 
3m-51yrs) vs 15m (SD13.1yrs; range 1m-50yrs) in 2006.  Highest proportion 
of cases was set in ≥    25 yrs (47.4%) in 2010 vs 24.2% in 2006 (p<0.001). 
Statistically significant differences were also observed in IR for ≤ 15m 
(49/100,000 vs 278.2/100,000; (RR: 3,9; 95%CI 2.9-5.4) (Fig. 1)  and  in HR  
29.8% vs 15.7%  (OR:2.3;95%CI: 1.54-3.45). 
 The highest percentage of hospitalized patients occurred in those older 
than 25yrs was 37.4 % vs 25.0 % in 2006 [OR:1.79;95%CI: 1.01-3.18 
(p=0.05)] (Table 1). Eighty percent of hospitalized cases presented complications 
 
 
 
Figure 1. Differences in incidence rates of confirmed measles cases of two outbreaks  
according to age group. Catalonia 2006-2007 and 2010-2011 outbreaks [15]. 
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Table 1. Differences in hospitalization rates of confirmed measles cases of two 
outbreaks  according to age group. Catalonia, 2006-2007 and 2010-2011 outbreaks 
[15]. 
 
 
Age group 
Hospitalization rate 
2006-2007 outbreak 
n            % 
Hospitalization rate 
2010-2011 outbreak 
n            % 
OR  
(95%CI) 
p 
≤15m /12m* 25/190       13.2% 12/44         27.3% 
2.48 
(1.14-5.38) 
0.04 
1-4 yrs 5/66        7.6%   4/35         11.4% 
1.57 
(0.42-5.85) 
0.72** 
5-14 yrs 4/23        17.4% 5/27          18.5% 
1.07 
(0.27-4.29) 
1** 
15-24 yrs 3/10        30.0% 15/52         28.8% 
0.95 
(0.23-3.78) 
1** 
>25  yrs 23/92        25.0%  55/147       37.4% 
1.79 
(1.01-3.18) 
0.05 
Total 60/381       15.7% 91 /305         29.8% 
2.3 
(1.54-3.45) 
<0.001 
 
 
 *Below first dose vaccination age ;** Fisher’s exact  Test  
 
in contrast to 58.3% in the 2006 outbreak, being gastrointestinal 
symptoms such as diarrhea and vomiting (33%) the most frequent. A 
higher, although not significant, proportion of pneumonia was observed 
(23 cases: 26%) when compared to 2006 (8 cases: 13.3%) [OR: 1.90; 
95%CI: 0.74-4.96 (p=0.21)]. 
 Laboratory testing was performed in 452 out of 489 suspected cases 
(92.4%) and of these 262 (58%) were confirmed cases and 190 were 
classified as non measles cases. Of the 262 laboratory confirmed cases, 
238 (90.8%) were positive for MV by real-time RT-PCR, 81 (31%) were 
positive for IgM measles specific antibodies and 54 (20.6%) cases were 
both positive for real-time RT-PCR and IgM. Seventy percent of cases 
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were confirmed on basis of positive urine and/or pharyngeal swab 
positive RT-PCR  MV test whereas in the 2006 outbreak this percentage 
accounted for only 19.7% of laboratory confirmed cases. 
 Phylogenetic analysis of the minimum recommended 450 nucleotides 
of N gene of 227/238 (91%) out of all RT-PCR positive samples revealed 
that the strains belonged to six different genotypes: A (3; 1.6%), B3 (147; 
59.5%), D4 (66; 33.2%), D8 (7; 2.8%), D9 (6; 2.4%) and G3 (1; 0.4%) 
(Fig. 2). 
 Genotype A was related to vaccine-induced virus infection. Two 
hundred and seventy one cases /305 (89%) were unvaccinated people of 
these 36/271 (13.3%) cases were below vaccination age (12 m) and 32 
(11.8%) refused vaccination on philosophical beliefs. Twenty six cases 
(8%) had one dose and 8 (3%) had 2 doses. One of these cases vaccinated 
with 2 doses of MMR occurred in a physician working at a                              
hospital emergency department. Seventy eight cases were of foreign                                                           
origin (25.3%) vs 39 (10.2%) in the 2006 outbreak [OR: 2.90;                        
95%CI: 1.87-4.53 (p<0.001)]; and 11 cases (3.6%) occurred in healthcare 
settings vs 11(2.9%)in the 2006 outbreak [OR: 1.25; 95%CI: 0.50-3.17 
(p=0.75)].   
 
 
 
Figure 2. Distribution of genotypes according to week of onset of confirmed cases. 
Catalonia  2010-2011 outbreak [15]. 
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3. Discussion 
  
 The increase in measles cases in 2010 occurred despite a steady rise in 
regional and global MMR coverage. Measles surveillance data and outbreak 
investigations provide critical information to identify gaps in population 
immunity and lead to corrective actions and refinements of vaccination 
strategies. 
 Adapting vaccination strategies to the epidemiological scenario is 
important to control of the disease, thus with the evidence gathered from one 
large outbreak [14], infants have been spared from measles infection in this 
second  large outbreak four years later when other European countries have had 
high incidence in infants below vaccination scheduled age [8,16-19]. 
Surveillance data analyses and outbreak investigations should continue to be 
used to complement vaccination coverage monitoring to identify gaps in 
vaccination programs [20]. Yet measles transmission has been firmly                     
re-established in some European Union (EU) Member States to the extent of  
even exporting measles to the rest of the world, threatening to undermine years 
of efforts to eliminate endemic transmission of the measles virus [10,21]. 
 The difference in global hospitalization rate (29.8% vs 15.7%) and higher 
proportion of  complications (80% vs 53.7%) could be explained by the 
higher proportion of adult cases affected in this second outbreak in which the 
mean age of cases was 20 yrs (SD 14.8 yrs; range 3m-51yrs) vs 15m in the 
2006 outbreak [22]. Yet hospitalization rate in infants below vaccination age 
was still high (27.3% vs 13.2%) compared to the previous and other  
outbreaks [23]. This could reflect a higher sensitivity and therefore higher 
degree of hospitalization not solely on severity of disease. Although further 
studies should explore whether the fact that cases were infected by different 
genotypes that might also have different severity.   
 The implementation of molecular diagnostic and genotyping techniques 
allowed to gathering epidemiological information on measles virus 
circulating types. Genotypes B3 and D4 were the predominant genotypes in 
the second measles outbreaks in Catalonia while the first was entirely 
identified as genotype D4 [24].
 
 Genotypes B3 and D4 showed genetic differences between sequences 
with a maximum genetic distance of 2 nucleotides in the genomic region 
studied, revealing different genetic viral variants within the same genetic 
group. The remaining genotypes D8 and D9 appeared in sporadic cases or 
related to small limited outbreaks during the study period. Measles genotype 
G3 is generally associated with measles infections in south-east Asia, or in 
sporadic cases with links to south-east Asia [25]. There had been no reported 
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cases of measles G3 in Europe since 2006 until by the end of 2010 it 
reappeared in several different countries in Europe [26]. Unlike other 
outbreaks [14,16,27] six different genotypes have been isolated in Catalonia 
during the study period, showing several importations as a result of the  high 
incidence in other neighboring territories. 
 The high proportion of cases in immigrant population (24.9%) reflects 
the fact that, although immigrants are offered the same health care services as 
the indigenous population, the rate of MMR vaccination coverage is lower in 
this population [28]. In the 2006 outbreak, this proportion was significantly 
lower (10.2%) probably because immigrant parents do adhere to pediatric 
vaccination schedules in a greater proportion than adults. This fact stresses 
the need to offer complete adult vaccination schedule to this population when 
consulting primary care services.  
 Although nosocomial infection has been described as an important 
source for measles infection [19,29], in this, as in the previous  outbreak, only 
11 cases (3.6% and 2.9% respectively) were related to healthcare workers 
with few secondary cases arising from them, this fact underscores the 
importance of maintaining high MMR immunization coverage and of  the 
efforts addressed to improve this coverage in order  to reach zero cases in 
healthcare workers in future outbreaks.  
 First cases identified in this 2010-2011 outbreak occurred within a setting 
of  unvaccinated children due to philosophical reasons (11.8%) giving place 
to transmission in an area where anti-vaccine movement is active. This was 
not so in the previous outbreak where rejection of vaccination for 
philosophical reasons  (1.5%) would not have greatly influenced maintained  
transmission of chains [14]. Parents who refuse to vaccinate their children are 
an important issue because of the influence it can have on sustaining 
transmission after an importation of MV within a community. Several authors 
have studied this phenomenon to find out which are the keys to this belief 
[30,31]. The anti-vaccine movement represents ongoing groups who share 
concerns based on misconceptions, unfortunately, they not only put their own 
children at higher risk for disease but they also contribute to the failure of 
communities to achieve protective vaccination rates and to herd immunity 
failure even among highly vaccinated populations [32]. 
 The  fact that a physician correctly vaccinated with 2 doses of MMR 
became  ill has also been observed by other authors [33]. It might indicate 
that in an outbreak setting with persistent close contact with MV, waning of 
immunity over time is another issue to be followed up closely, especially in 
regions where circulation of wild MV is low and could pose the possibility of 
recommending a booster dose for healthcare workers  in an outbreak setting 
[34,35]. 
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 Since the interruption of endemic measles transmission in December of 
2000 and in spite of the high-immunization coverage, measles outbreaks and 
sporadic infections have occurred in Catalonia due to importations of 
measles, yet no sustained transmission had occurred and outbreaks, to the 
exception of those described in this study, were quickly set under control. 
Surveillance data and results of molecular epidemiology indicate that there is 
a continuous exposure to MV from other regions of Europe and of the world. 
The co-circulation of different genotypes and several viral variants for 
genotypes B3 and D4 revealed that 2010-2011 outbreak was caused by 
multiple imports from abroad or other Spanish regions (Andalusia, Madrid) 
and confirms the absence of endemic infection. The change of the month of 
administration of the first dose proved successful in preventing disease and 
hospitalization in unvaccinated infants, but young adult population are far 
harder to reach than children. In this pouch of susceptible, achieving high 
coverage is difficult and furthermore they are the most mobile population, 
greatly prone to travel and be a source for importation themselves.  
 
4. Conclusion 
 
 Elimination and eradication programs are laudable goals, but they carry 
with them an awesome responsibility. There is no room for failure. Careful 
and deliberate evaluation is a prerequisite before embarking on any program. 
Elimination and eradication are the ultimate goals of public health. The only 
question is whether these goals are to be achieved in the present or some 
future generation. 
 In conclusion, given the current epidemiological situation, continued 
awareness and efforts to reach young adult population (especially healthcare 
workers and travelers) are needed to stop the spread of the virus. Enhanced 
measles surveillance is critical to disease control by early identification of 
measles cases and thus allowing for early detection and control of outbreaks, 
assessing on-going transmission patterns in order to mount more effective 
vaccination measures. 
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Abstract. Organic food products are highly susceptible to fraud. 
Currently, administrative controls are conducted to detect fraud, 
but having an analytical tool able to verify the organic identity of 
food would be very supportive. The state-of-the-art in food 
authentication relies on fingerprinting approaches that find 
characteristic analytical patterns to unequivocally identify 
authentic products. While wide research on authentication has been 
conducted for other commodities, the authentication of organic 
chicken products is still in its infancy. Challenges include finding 
fingerprints to discriminate organic from conventional products, 
and recruiting sample sets that cover natural variability. Future 
research might be oriented towards developing new authentication 
models for organic feed, eggs and chicken meat, keeping models 
updated and implementing them into regulations. Meanwhile, these 
models might be very supportive to the administrative controls 
directing inspections towards suspicious fraudulent samples.  
   
Introduction 
 
 Food products with high added value are susceptible to fraud. National 
and international regulations underpin mandatory label information, but   
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unfortunately, they are not sufficient to prevent food fraud [1]. Food fraud 
can occur intentionally or not, for instance during product cross-over in 
factories, or mislabeling errors. Products most susceptible to intentional fraud 
are those of high added value, for which consumers are willing to pay a 
higher price, but that are rather similar to other lower cost (and lower quality) 
products. Some examples of food fraud include foods from a particular 
geographical origin (i.e. foods under Protected Designations of Origin), or 
products from special production practices (i.e. organic, sustainable, animal 
welfare friendly products). Fraud committed at the first steps of the food 
production chain (i.e. in crops or feed) implies fraud in the final product (i.e. 
meat, milk, eggs). Therefore, it is important to control and to avoid fraud at 
all steps of the food chain.  
 All stakeholders are interested in fraud prevention. Fraud implies always 
an economic prejudice for the end consumer, but also to the retailer and the 
intermediate consumer/producer when fraud is committed at the first steps of 
the food chain. Moreover, fraud occurrence diminishes the quality of the 
sector and the confidence of consumers in the high quality product, which 
might have as consequence a decrease in the sector competitiveness. 
Accurate labelling is important to support fair trade [1]. Furthermore, fraud 
might become a food safety concern when it is committed using non-
authorized, unknown or uncontrolled substances.  
 An authentic product is one which strictly complies with the declaration 
given by the producer in terms of ingredients, natural components, absence of 
extraneous substances, production technology, geographical and botanical 
origin, production year, and genetic identity [2]. Authenticity in most food 
products is verified by means of administrative controls, certifications and 
inspections. However, this administrative system is rather expensive and slow 
because it requires one entire inspection for each product (including all steps 
in the production chain). This makes that fraudulent products easily scape 
undetected. The state-of-the-art research on food authentication is to find 
analytical tools that are able to distinguish authentic from non-authentic 
products. Such analytical tools would permit to analyze a great number of 
products in a relatively short period of time (depending on the analytical 
method involved) increasing therefore the number of inspected products with 
respect to the administrative system. Despite the evident supportive role of 
food authentication analytical tools to the administrative system, they are not 
currently applied in most food products. In most cases, the reason is that 
research has not been able to find suitable analytical tools to distinguish 
authentic from non-authentic products due to their similarities and natural 
variability of their composition. Moreover, implementing these analytical 
tools into legislation is nowadays a challenge.  
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1. Organic products 
  
 The Food and Agricultural Organization of the United Nations [3] 
defines „organic agriculture‟ as a holistic production management system 
which promotes and enhances agro-ecosystem health, including biodiversity, 
biological cycles, and soil biological activity. It emphasizes the use of 
management practices in preference to the use of off-farm inputs, taking into 
account that regional conditions require locally adapted systems. This is 
accomplished by using, where possible, agronomic, biological, and 
mechanical methods, as opposed to using synthetic materials, to fulfil any 
specific function within the system.  
 Nowadays, there is no common worldwide standard for the production 
and labeling of organic products. This complicates international trade of 
organic products. In Europe, the Council Regulation No 834/2007 [4] set the 
conditions on organic production and labelling of organic products. It was 
implemented by the Commission Regulation 889/2008 [5]. 
 Organic farming and the organic food market are rapidly growing [6,7]. 
Consumers purchase organic foods for different reasons, including animal 
welfare and environmental concerns, believe on an improved human health, 
and perceptions that organic foods are tastier than their conventional 
alternatives [8]. However, a recent literature review on health, nutritional and 
safety characteristics of organic and conventional foods concluded that 
published literature lacks strong evidence that organic foods are significantly 
more nutritious than conventional foods [9]. On the other hand, even if 
consumers believe that organic products taste better than conventional 
products, they failed in discriminating between organic and conventional 
products in a number of studies [6,10]. Furthermore, it has been shown that 
labeling associated with a food can create expectation regarding its sensory 
properties, and ultimately its acceptability [6,10].  
 As mentioned, organic produce tends to retail at a higher price than their 
conventional counterparts. This together with the relatively similar 
composition between organic and conventional products and the increase of 
organic food market makes them susceptible to fraud. Therefore, it is 
important to establish effective control systems to avoid fraud in the organic 
food sector. Currently, these are based on administrative controls and 
inspections, and there is no analytical tool routinely applied. However, some 
authentication models based on analytical determinations have been 
developed for some specific organic products [11].  
 Authentication of organic products is complex, and depends very much 
on the product examined. It is unlikely to find a unique marker that allows a 
general discrimination between organic and conventional farming [12]. 
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Instead, each type of organic product will require the development of a 
specific analytical tool, depending on its composition, characteristics and 
similarities with the corresponding conventional product. For instance, in 
chicken sector, fatty acid profile has been useful to discriminate organic from 
conventional hen feed [13], but it does not necessary imply that fatty acid 
profiling would be useful to authenticate other organic products. 
  
2. Considerations for developing authentication models 
 . 
2.1 Fingerprinting techniques 
 
 The global aim of an authentication model is that it can be used in the 
future for verifying the identity of unknown or suspicious samples. Apart 
from finding a suitable analytical marker to authenticate organic products, the 
statistical approach applied is of importance. Traditional analytical strategies 
for detecting adulterations have relied on the determination of the amount of 
a marker compound or compounds in a material and a subsequent comparison 
of the value(s) obtained with those from authentic products used as references 
(targeted approach). But this approach fails when the natural variability of 
the compounds in the authentic product is so large that reference values 
would need to be set so wide that some adulterations would still go 
unnoticed, which is the case of organic products [12]. Actually, the fewer the 
number of compounds used to authenticate a product, the easier to hide fraud 
by keeping the values of these target compounds in the fraudulent product 
within the limits established for the authentic product.  
 The state-of-the-art strategy in food authentication consists in finding, in 
high dimensional analytical data, (untargeted) patterns for the category to be 
authenticated that are different from those in other lower-quality categories. 
The pattern of unknown or doubtful samples might then be compared with 
that of the authentic one (which is considered the fingerprint of the authentic 
product) to verify its category. Indeed, these patterns might be built using raw 
analytical signals directly obtained from measuring equipment (i.e. 
chromatograms, Near Infrared –NIR- data). This fingerprinting approach has 
as advantage that it does not require to identify and quantify the compounds 
responsible for the discrimination (untargeted approach) to build the 
authentication model, although it is recommended to do so to be able to 
biologically understand why models are successful. The untargeted approach 
saves time invested in identifying and quantifying compounds, permits a 
faster application of the model, and allows dealing with any raw analytical 
data, even when the “shape” of this raw data complicates the identification 
and quantification of compounds (as it happens for instance with NIR data). 
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Also, the use of the raw analytical signals might imply an improved 
exploitation of the information included in the data. For instance, in 
chromatographic data, once peak integration and identification has been 
conducted a great part of the raw data is not further considered (all not 
integrated signal); however, these non-considered data might include very 
small peaks or differences in peak shapes that might contain very useful 
information on the identity of the samples. Due to the highly dimensional 
data collected in the fingerprinting approach, the application of chemometrics 
to build and validate authentication models is necessary. An intermediate 
approach between fingerprinting and the targeted approach is the application 
of selective fingerprinting in which authentication models are based on a 
great number of markers, half way between using only one or two single 
markers and the raw analytical data. This approach still requires the 
identification and quantification of the marker compounds, but it provides a 
more reliable and robust authentication tool than the targeted approach. 
  
2.2. Sample set 
 
 Classification models need to correctly identify the samples used to 
develop the model, but also samples in the future during its routine 
application. Therefore, several aspects need to be considered during model 
development to test and assure model‟s usefulness in the future. Here we will 
address those that might be particularly relevant in developing models for 
authenticating organic chicken products; more information in this respect 
might be encountered in previous literature [14,15]. 
 As for the authentication of other commodities, a proper sample set is 
essential to develop the model because its future applicability will depend on 
the number and type of samples used in model development. At least two 
sample sets are needed: one to build and optimize the model (training set) and 
a second one to externally validate the model by using it to predict the 
identity of samples in this new set (validation set) [14]. The authenticity of 
samples in both sets needs to be assured. Sample origin and identity (organic 
or conventional) need to be known. In this respect, it is important to remind 
that samples bought in supermarkets and stores cannot be considered 
authentic. Also, samples from experimental studies are neither valid as 
authentication samples because their production is so experimentally 
controlled that it might not reflect the real farming practices. Therefore, even 
though experimental studies and market surveys might provide some insights 
on possible authentication markers, they should not be considered valid as 
authentication studies. Unfortunately, most of the published studies on 
organic chicken products are market surveys [16–19] and experimental 
studies [20–22] rather than authentication studies. 
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Table 1. Possible sources of variability to take into consideration for developing 
authentication models for organic chicken products  
 
Source Examples of variability 
Regulations Changes in regulations within a country or region 
Product categories Categories included in the model (organic, free range, barn, cage,  
specialty eggs…) 
Animal Breed, age 
Feed ingredients Feed formulation (Authorized feed ingredients, price, availability) 
 Natural variability of feed ingredients  
Season  Differences in climate conditions between seasons 
 Grass availability and composition 
Geographical origin Differences in regulations between countries or regions 
 Differences in climate, environment, soil…. between regions 
 Farming practices in each location 
 
 The number of samples in the training and validation sets will mostly 
depend on the sources of variability included in the model. Consequently, this 
will condition the future applicability of the model because it can only be 
applied to authenticate samples belonging to the same sources of variability 
considered in the training and validation set. Therefore it is interesting that 
both sets cover as much natural variability as possible. Regarding organic 
chicken products, several sources of variability might be taken into 
consideration (Table 1). One of the first sources of variability is the changes 
in regulations regarding the production of (organic and conventional) chicken 
products, because they might imply a change the composition of the end 
products. Therefore, models developed on (feed, meat or egg) samples 
produced according to past regulations need to be (at least) validated with 
samples produced according to the present regulation.  
 Samples need to cover natural variation within the considered categories 
(Table 1). In organic chicken products, several subcategories exist for 
conventional products (cage, barn and free range). Therefore, all of them 
need to be represented in the set. If all categories are not included, models 
should only be used to verify the identity of samples belonging to the 
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included categories. For instance, van Ruth et al. [12] and Tres and van Ruth 
[23] did not include eggs produced by caged hens in their set. Therefore, in 
these studies, it would be necessary to validate and/or rebuild the models with 
cage eggs before using them to identify this category.  
 Another aspect to take into account is sample origin (Table 1). Models 
developed on sample sets collected in a confined geographical origin should 
only be used to authenticate samples from this particular origin [13]. Before 
being broadly used to identify samples from other origins, model 
performance needs to be validated using it to predict the identity of authentic 
samples from other origins. Sample origin might have an influence on certain 
composition parameters that depend for instance on the soil, latitude, altitude, 
environmental and climatic conditions. Differences in the regulations and 
farming practices within the organic chicken sector between geographical 
origins might also have an influence on some parameters. An example of 
geographical validation is the egg authentication study leaded by Van Ruth 
[12,24]. First, an authentication model to verify the organic identity of Dutch 
eggs was developed based on egg carotenoid profiling, and it was validated 
by authenticating eggs produced in New Zealand [12]. Later on, the model 
performance in authenticating eggs produced by other countries was 
evaluated (Austria, Belgium, Germany, Greece, Italy and Portugal), including 
countries outside Europe (Canada, Israel) [24]. The percentage of correctly 
classified organic eggs was above 90% for all countries, except for Israel.  
 Feed ingredient composition might also become a source of variability. 
As for any other natural product, natural variability makes that the 
composition of feed ingredients might change within and between years, 
between geographical origins, farming practices and feed ingredient 
producers. Moreover, feed formulations are designed depending on the 
regulations, and availability and price of ingredients; significant changes in 
any of these aspects might imply a change in the formulation that might 
affect meat and egg composition. Therefore, it is highly advisable that feed, 
meat and egg sample sets include samples produced in different seasons and 
years, as well as samples from animals fed with feeds from various 
producers.  For instance in Tres et al., [13,25] samples from two consecutive 
years and various feed producers were included. It would also be important to 
periodically validate the models by testing their performance in identifying 
samples from different production years. Published studies on the 
authentication of organic chicken products are so recent that no yearly effects 
have been detected so far; however, it is possible that in the future this aspect 
might become relevant, and thus, models will need to be updated.  
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 Seasonal influence on egg composition has been described in various 
experimental studies [21,22,26], especially for eggs laid by outdoor reared 
hens. The content of certain grass components, such as tocopherols and 
carotenoids, varies depending on the season [21,22,26]. This, together with 
grass availability led to differences in egg composition between seasons. 
Therefore, it is highly recommended that models based on these parameters 
are developed on sets that include samples from all seasons.  
 One of the advantages of fingerprinting models is that even if they are 
already developed, it is possible to easily test their performance in identifying 
samples from new origins, years, seasons… If this leads to a substantial 
reduction of model‟s performance, then it would be advisable to incorporate 
the new samples in model‟s data base, rebuild the model and validate it, so 
that the new source of variability is considered in model development. If this 
still does not provide a successful model, it might be necessary to build one 
specific model for each independent source of variability (i.e. one model per 
origin, per season…). Both approaches are correct, but model‟s robustness is 
improved if one single model could be used to authenticate samples from any 
source of variability.  
  
3. State-of-the-art in the analytical authentication of organic 
chicken products 
 
 As for other organic products, the production of organic eggs and meat 
has increased in the lasts years. Since they are products with added-value, 
they are highly susceptible to fraud [11]. However, research on developing 
analytical techniques to authenticate organic chicken products has only 
recently started, and only a few analytical techniques have been developed in 
this respect. In most cases, these techniques have been selected because 
comparative experimental (or market survey studies) revealed potential 
differences in the content of some compounds between organic and 
conventional chicken products. However, it is important to have in mind, that 
comparative experimental studies are not useful as authenticating studies but 
they might be a starting hypothesis to build models to discriminate various 
chicken product categories. In this section, we will cover the published 
authentication studies on chicken products. Moreover, we will summarize 
some of the market surveys and experimental studies on the effects of the 
rearing system on meat and egg composition. 
 In Europe, the production of organic chicken products requires that 
animals are fed with organic feed (that is to say that at least 95% of its dry 
matter should come from ingredients of organic farming) [5]. Moreover, for 
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the production of organic eggs hens should have access to an outdoor area      
(at least 4 m
2
/hen), and they cannot be kept in cages when they are indoors              
(6 hens/m
2
). Fraud at the feed level would imply a fraud in the end product, 
even though all the other conditions required for the production of organic 
products (such as animal housing) are respected. Therefore, the control of the 
organic production of chicken products should cover all stages of the 
production chain, from feed to the end product [13].  
 Within conventional chicken products, several categories exist in the 
European market, varying in price, quality and consumer demand. The 
European Council Directive 1999/74/CE [27] set minimum standards for the 
protection of laying hens. Conventional eggs include eggs from caged hens, 
barn and free range eggs [28]. For the production of free range eggs, hens 
should also have daytime access outdoors (min 4 m
2
/hen), and when being 
indoors, they cannot be kept in cages (9 hens /m
2
). Thus, as organic hens, free 
range hens can forage in soils, picking up grubs, beetles, worms, grass and 
seeds; they have more exposure to sunlight, and higher chances of physical 
activity. Hens laying barn and cage eggs do not have access outdoors, but in 
the case of barn hens, they cannot be kept in cages [28].  
 
3.1. Organic feed authentication 
 
 Studies on organic feed authentication are scarce. In several experimental 
studies in which the composition of organic and conventional eggs or chicken 
meat were compared feeds were also analyzed [20,21,29]. However, in most 
of these studies, feeds were experimental, specifically designed for a 
particular study, and not real market samples. In fact, in most cases the same 
ingredient composition was used, only differing in the organic or 
conventional source of each ingredient. However in the real market, strict 
regulations exist for the composition of organic feed, while a broader range 
of feed ingredients are authorized for conventional feed. This, together with 
the price and availability of ingredients, causes that ingredient composition of 
organic feed is usually different than that of conventional feed [13]. 
Therefore, these differences in feed formulas need to be covered by the 
authentication model so that it reflects real farming practices.   
 As far as we are concerned, only a study on the development of two 
analytical tools to authenticate organic chicken feed exists on published 
scientific literature [13,25]. The study was leaded by RIKILT – Wageningen 
University and Research Centre (The Netherlands), within the Cluster of 
Authenticity and Nutrients, a research group worldwide known as expert on 
authentication. Two models were developed to authenticate organic feeds 
used for laying hens in the Netherlands. One of the models was based on feed 
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fatty acid composition assessed by gas chromatography [13], and the other 
one was based on feed NIR spectra [25]. A total of 96 organic and 
conventional feed samples were collected in the Netherlands during two 
consecutive years. First, the fatty acid model was developed following a 
selective fingerprinting approach on 30 identified chromatographic peaks, 
combined with a PLS-DA algorithm (after data log10 transformation and 
scaling to unit variance). The classification model (Figure 1) was successful. 
It correctly identified all organic feed samples, and almost all conventional 
feed samples (Table 2). 
 
 
 
Figure 1. First two dimensions of PLS–DA on the fatty acid profiling data of organic 
and conventional feeds: (A) scores and (B) loadings plot (data preprocessing: log10 
transformation and scaling to unit variance; OSC = 1). (Reprinted with permission 
from [13]. Copyright © 2011 American Chemical Society). 
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 When examining PLS-DA scores and loadings plots (Figure 1) it was 
revealed that several fatty acids were responsible for the discrimination of 
organic and conventional feed. Fatty acids such as C24:0, C22:0 and C18:2 
n-6 and C18:3 n-3 were associated with the organic feed class. Fatty acids 
such as C12:0, C14:0, C16:1 n-9 and C16:1 n-7 were associated with the 
conventional feed class (Figure 1). These differences in fatty acid 
composition were attributed to differences in the ingredient composition 
between organic and conventional feed [13].  
 The determination of the fatty acid composition requires sample 
grinding, extraction of the feed lipid fraction by using solvents, and the 
determination (and quantification) of fatty acid methyl esters by gas 
chromatography. Therefore, the drawbacks of this method are the use of 
solvents and the costs related to the reagent expenses, gas chromatography 
and trained personnel. Also, the procedure, although quite fast, does not 
allow an immediate answer on the identity of the feed. These drawbacks led 
to search for alternative more rapid techniques that would provide a faster 
answer on the authenticity of a feed sample [25].  
 Near Infrared Spectroscopy (NIRS) is a nondestructive, easily applicable, 
and fast technique that requires minimal or no sample preparation and that 
permits the response of certain molecular bonds (such as O-H, N-H or C-H) 
to NIR radiation. NIRS generates a spectrum that may be characteristic of a 
sample and may be considered its “fingerprint” [30]. Its use in the feed sector 
is already quite commonly implemented, even in form of on line or in situ 
applications [31,32]. Due to these characteristics, Tres et al., [25] decided to 
evaluate it as a rapid authentication tool to verify the organic identity of feed. 
Classification models were developed on the same samples used in the fatty 
acid model [13]. PLS-DA classification models were successful in correctly 
identifying organic and conventional feed samples (Table 2). Apart from the 
NIR regions related to fat content, fatty acids and their unsaturation, regions 
related to the N-H stretch were also revealed as important in the NIR model 
 
Table 2. External validation of authentication models to verify the organic identity of 
laying hen feed 
 
Model     Approach 
      Organic 
   (% correctly 
  identified samples) 
 Conventional 
  (% correctly 
identified samples) 
 Reference 
Fatty acid composition  Selective fingerprinting           100%          90%      [13] 
NIR     Fingerprinting             91%          100%      [25] 
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[25]. This implied, that apart from fatty acid composition [13], the protein 
content and / or composition might differ between organic and conventional 
feeds [25].  
 Taking into consideration the results on model validation and the 
characteristics of both techniques, the model based on NIRS data was 
suggested as a screening model, and the model based on the fatty acid 
composition data as a confirmation model [25] (Figure 2). This combined 
approach permits to apply a fast technique that will correctly identify 
conventional feed. If some supposedly organic feed samples are identified 
as conventional by the model, their fatty acid composition will be analyzed 
and submitted to the fatty acid model. Its answer will determine if it is a 
real organic feed (that was revealed as false negative by the NIR model), or 
if it is a fraudulent feed (when the fatty acid model confirms it as 
conventional), reducing time, costs and environmental impact of solvent 
use [25].  
 
 
 
Figure 2. Decision tree combining NIRS and fatty acid models as screening and 
confirmation tools to verify the organic identity of a laying hen feed sample 
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3.2. Organic egg authentication 
 
 While there have been numerous investigations on supplementation of 
layer‟s diets to enrich eggs in n-3 fatty acids, vitamins A and E and other 
lipid-soluble nutrients; there has been little work investigating the effects of 
different production systems on these nutrients [33] and even less work has 
been conducted with authentication purposes. As mentioned in section 2, 
markers revealed as different between organic and conventional products by 
comparative experimental studies and market surveys might be the starting 
hypothesis to build authentication models. For instance, Rogers [34] claimed 
that δ15N values are a promising indicator to differentiate free range and 
organic eggs from cage and barn eggs; however, a higher number of samples 
would be recommended to confirm these results (only 18 samples were 
collected, only 4 of them being organic eggs and 2 out of these were 
considered outliers). On the other hand, δ13C values did not lead to any 
significant separation among egg farming regimens [34].  
 Higher Se and lower P and Zn contents in organic eggs than in cage eggs 
have been reported [35,36] even though feeds had similar Se and Zn contents. 
Differences between farm locations, access to soil and grass and higher 
physical activity of organic hens would be related with these differences. 
However, these were comparative studies, for which especial feed 
formulations were designed. Thus, more studies comparing trace element 
content between eggs produced by hens fed commercial (conventional and 
organic) feed, and from various farm locations would be needed to estimate 
the potential use of trace elements as authentication tools. 
 Another parameter that showed variations between egg production 
systems in experimental studies is the content [21,22,26] and composition of 
tocopherols [20]. Variations between free-range and indoor kept hens were 
found, especially when available pasture was large. As far as we are 
concerned, no egg authentication studies have relied on these compounds, but 
it seems that their utility as authentication tools would mostly depend on the 
season and on the amount of available grass [21,22,26].     
 Variations in the fatty acid composition between different egg production 
systems have been revealed by experimental studies and market surveys 
[16,18,20,22]. But the number and type of fatty acids varying among rearing 
systems, and the magnitude of the differences depended on several study 
design parameters such as feed composition and the number and origin of egg 
samples. Moreover, laying hens diets on free-range conditions include grass, 
which has a relative high level of n-3 polyunsaturated fatty acids, tocopherols 
and some other non-saponifiable lipid components [21,22]. This has been 
attributed as one of the reasons leading to higher n-3 polyunsaturated fatty 
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acids in eggs laid by free-range and organic hens [22], especially when the 
available grass area was larger than the minimum required by current 
regulations [21,26]. However, it needs to be taken into account that grass 
composition varies between seasons, and therefore its influence on the fatty 
acid and tocopherol composition also depends on the season [21,26].  
 Even if the differences on the fatty acid composition between egg 
categories were relatively small, an authentication model to discriminate 
organic vs conventional eggs was developed on the egg fatty acid profile 
[23]. For this study, 48 authentic egg samples including organic, free-range 
and barn eggs were collected directly from farms in the Netherlands. The 
authentication model was based on a selective fingerprinting on the fatty acid 
composition data and a PLS-DA algorithm. Although results were only 
internally validated (by leave 10%-out cross-validation), they were quite 
satisfactory with the 92% of the organic and 87% of the conventional eggs 
correctly classified. Even if results were not directly comparable with those 
from the feed authentication study [13] because egg and feed samples from 
both studies were not related, the fatty acid approach as authentication tool 
was better for feed than for egg authentication. Reasons behind this fact 
might include, among others, the influence of hen metabolism on egg fatty 
acid composition [23]. Still the main fatty acids discriminating organic from 
conventional eggs were similar: polyunsaturated fatty acids were important 
for the discrimination of organic eggs, and C16:0 for conventional eggs. 
Results are partially contradictory with those of some market surveys [16–18] 
that reported higher contents of palmitic acid in organic eggs. This fact might 
be explained by differences in the study designs, number of recruited 
samples, and differences between the origin of samples and thus the farming 
practices and feed formulations. Regarding conventional egg categories, no 
differences were encountered between barn and free range eggs for the fatty 
acid composition [23], although higher contents of n-3 polyunsaturated fatty 
acids had been revealed by comparative experimental studies comparing eggs 
laid by indoors and outdoors reared hens [22,26]. Real farming practices, 
seasonal effects (especially variations on the amount of available grass and its 
composition) and other natural variability might have masked these variations 
in the authentication model.  
 In organic egg production, hen feed cannot be supplemented with 
carotenoids [4], while it is permitted in conventional eggs. Therefore, in 
organic egg production, carotenoids need to be originated from the organic 
feed components such as maize, and from other sources such as grass, 
vegetation, insects, worms, and additional organic matter from the soil. 
Differences in the egg carotenoid profile between different rearing systems 
were revealed in various experimental studies [16,21,37]. In particular, lutein 
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and zeaxanthin were the predominant xantophylls in organic egg yolks, 
whereas synthetic carotenoids such as β-apo-8‟-carotenoic acid ethyl esther 
or citranaxanthin occurred in higher amounts in non-organic eggs [37]. 
Moreover, carotenoid content was higher in eggs laid by hens pasturing in 
large grass areas, especially in spring and autumn, revealing a seasonal effect 
depending on the carotenoid content of grass [21,26].  
 Later, van Ruth et al., [12] developed an authentication model to verify 
the organic identity of eggs through a multivariate approach on the carotenoid 
profile determined by HPLC-Diode array detector. Their classification model 
was based on a K-Nearest Neighbors (KNN) algorithm, and was developed 
with a first set of eggs, including authentic organic, free-range and barn              
eggs (but not eggs from caged hens), and validated with a second set of 
(market) eggs. Using the carotenoid profile, they discriminated organic from 
conventional eggs, lutein/zeaxanthin being the dominating carotenoids in the 
organic egg pattern. Interestingly, they encountered some misclassified eggs 
which belonged to conventional farms in transition to organic practices, but 
which were not still authorized for producing organic eggs. However, they 
could not discriminate free-range from barn eggs, although in some 
experimental studies, carotenoids were higher (in spring and autumn) in eggs 
laid by pasturing hens (10 m
2
/hen) [21,26]. Later on, the model was validated 
and expanded to the authentication of eggs produced in other countries 
(Austria, Belgium, Germany, Greece, Italy and Portugal), including countries 
outside Europe (Canada, Israel) [24]. The percentage of correctly classified 
organic eggs was above 90% for all countries, except for Israel. 
 
3.3. Chicken meat authentication 
  
 As far as we are concerned, while a few studies on organic feed and egg 
authentication have already been published, no studies on organic chicken 
meat authentication have been published in scientific journals. Instead, 
several market surveys [19,38] and experimental studies [39] have been 
conducted. A study comparing meat composition of chickens reared indoors 
or outdoors (receiving the same feed) showed that the contents of Fe (total 
and haem iron) and saturated and n-3 polyunsaturated fatty acids were higher 
in meat from outdoor reared animals [39]. Unfortunately, in this study, free-
range and organic rearing systems were not compared. Chen et al. [40] found 
that long periods of outdoor access lead to thigh muscles richer in 
polyunsaturated fatty acids, and lower in several monounsaturated fatty acids. 
These findings are consistent with those of market surveys [38]. On the 
contrary, a market study conducted by Jahan et al., [41] led to different 
results on organic chicken meat fatty acid composition; but it needs to be 
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taken into account that the number of samples included in this study was very 
low and samples came from completely different origins.  
 Another strategy to find suitable markers to develop authentication 
models for organic chicken meat could be to look into promising markers for 
the authentication of organic meats from other species. Stable ratio mass 
spectrometry of carbon, nitrogen, and sulphur isotopes has been successful in 
differentiating organic and conventional Irish beef [1,11]. These differences 
are partly due to differences in the feed intake (grass or concentrate). 
However, the higher content of δ15N in conventional beef meat compared 
with organic meat might be a result of the mineral fertilizers applied to the 
soil where conventionally grown animals are fed [1,11].  
   
4. Challenges and future perspectives 
 
 One of the most important challenges in food authentication is to keep 
models updated and ready to be applied when needed. This requires that their 
performance is tested periodically with new sets of authentic samples. They 
might include similar samples to those in the training set, but also samples 
from other years, seasons or geographical origins, not only to keep models 
updated but also to expand their possible applicability. Efforts in this respect 
have already been done for the egg authentication models by the research 
group headed by Dr van Ruth [24] when they expanded their model to other 
countries. Updating and validating the models are essential so that models 
can be routinely used to detect fraudulent samples.  
 The ultimate aim of authentication models would be to incorporate them 
into regulations; however, more research is necessary before this can be 
achieved. For accomplishing this, great efforts would need to be done with 
regards to model inter-laboratory validation, among others. Moreover, it 
would be necessary to build and share a common data base compiling the 
analytical data obtained from authentic samples. Sharing this data base would 
permit that models can be built on the same data by various laboratories and 
would contribute to incorporate more natural variability into the models. 
Moreover, since it is recommendable to build models on the largest number 
of samples as possible [14], the availability of such a database would be an 
efficient tool and improved use of resources. Actually, this has already been 
suggested for other commodities such as olive oil [42], but it does not exist 
yet, although much more research has been conducted in the authentication of 
olive oil than in organic products.  
 Meanwhile authentication models might be very supportive to the current 
administrative controls and inspections. If analysis cost is not extremely high, 
Authentication of organic chicken    115 
a great number of samples could be collected and analyzed. Only those 
showing suspicious values would then be submitted to an inspection 
procedure, focusing the inspection efforts and resources only to suspicious 
samples. In this respect, fast, easy and cost-effective analytical methods are 
desirable. In this line, a combination of a rapid screening model based on 
NIRS, and a confirmation model based on fatty acid profiling has been 
suggested as an authentication strategy for organic laying hen feed [25].  
 Apart from this, and according to what has been described in previous 
sections, it is evident that there is a lack of authentication models to verify 
the organic identity of feeds and eggs, and especially for chicken meat. 
Furthermore, the published authentication models have been mainly 
focused in discriminating organic from conventional products. However, 
the various conventional categories for chicken products also vary in price, 
quality and consumer demand (especially because of consumer‟s concerns 
on animal welfare). Therefore, it would be interesting to find suitable 
markers and models able to discriminate these categories. In some studies, 
differences between the composition of eggs laid by caged hens and other 
egg categories have been described [16,18]. Others, have found differences 
in composition between products from free range and indoor rearing 
[22,26,34]. These studies might become the starting point of future 
authentication models. 
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[…] segueix-me a una illa que et diré, a una illa on sempre hi fa calma, on 
els homes mai porten pressa, on les dones no es fan mai velles, on no es 
malgasten ni paraules, on el sol hi fa més estada i on fins la senyora Lluna 
camina més a poc a poc, encomanada de la mandra. [1] 
 
Abstract. This study reveals that a successful ethnobotanical 
survey can take place still nowadays, even close to one of the 
hotspots of tourism in the Mediterranean coast. This is the first 
approach in this field entirely based on interviews with local 
people in Mallorca. An amount of 235 informants has been 
inquired from all the 53 municipalities of the island. The data 
collected have been analyzed from the botanical and 
ethnographical points of view, and managed using the online 
platform of our research team (details at www.etnobiofic.cat). The 
Mallorcan ethnopharmacopoeia includes 255 plant taxa referring 
more than 150 medicinal use categories. Ethnomedical queries as 
the one here presented contribute to the knowledge of the 
traditional use of plants of the island and appreciate the benefits of 
this knowledge, applied to the present and future of its society.  
   
Correspondence/Reprint request: Dr. E. Carrió, Laboratori de Botànica, Facultat de Farmàcia, Universitat de 
Barcelona. E-mail: esperanca@mallorcaweb.net 
Esperança Carrió & Joan Vallès  120 
Introduction 
 
 In 1922, Santiago Rusiñol, a Catalan painter and writer, published a book 
called L’illa de la calma (the island of calm) [1], describing Mallorca as a 
paradise for peace and seclusion. Those days, Mallorca was turning from being 
one of the Spain’s poorest regions to one of the classiest vacation spots on the 
Mediterranean. It exploded in the 1970s as a package-tourism destination, and 
nowadays is one of the most expensive parts of Spain, a favourite hangout for 
film stars and celebrities. With the island’s identity shifting so dramatically, 
would it not be hard to get to know the “real” Mallorca? One of the answers 
can be found looking into the ethnobotanical keyhole. 
 Since its first definition [2], ethnobotanical research was targeted to 
tropical and subtropical cultures, sometimes as a consequence of colonial 
interests, but surely due to their floristic richness and their tightened 
relationship between ethnic groups and natural environment [3-6]. There is a 
fact, though, that overcame to the expansion of ethnobotanical surveys 
horizons: traditional societies from developed and touristic countries are 
keeping and preserving valuable plant use knowledge (orally transmitted 
across generations). Recent investigations of our research group (details 
available at www. etnobiofic.cat) pay attention to environments closer at 
hand for Europeans, which are also rich and varied in biodiversity as well as 
in cultural traditions [7].  
 Although over the last few years a significant number of contributions 
have been made in the Mediterranean basin (for instance, [8-12]), the current 
Mediterranean ethnobotany (and specifically the ethnopharmacological 
knowledge) is still an outstanding study item, despite the growing 
acculturation on this topic among citizens. Likewise, there is a need for urgent 
action to rescue traditional plant medicines before they are forever forgotten 
[13]. For that reason, the establishment of ethnofloristic catalogues or plant 
ethnopharmacopoeias could well help citizens and scientific communities to 
acquire further knowledge (as well as security and efficacy) about their 
traditional therapies, which are sometimes combined with conventional drugs. 
The shared ethnobotanical knowledge (regarding the species used repetitively 
over time and/or geographical space) provides a part of the scientific evidence 
of information and opens further possibilities to the study of transcultural 
ethnobotany as well as to that of ethnobotanical heritage within communities 
themselves [14]. A solid ethnographic basis brings meaningful results and 
makes easier the intellectual challenge of returning to the society the research 
findings in an understandable way [15, 16]. 
 This paper summarizes the (re)discovery of Mallorca from the 
ethnobotanical point of view, summing up the outstanding ideas of a PhD 
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project carried out from 2008 to 2013 [17]. This work belongs to a series of 
ethnobotanical studies on Catalan-speaking territories linked to the 
Etnobiofic research group [7, 10, 18, 19]. These studies share the common 
objective of contributing to the existing knowledge on plant biodiversity 
(taking into account that the biological diversity also concerns the human 
awareness about uses, applications and natural resources conservation) and 
making it available for further social and scientific interventions.  
 
1. The study area and the ethnobotanical context 
 
 The present ethnobotanical study takes place in Mallorca, the largest 
island in the Mediterranean Balearic archipelago and the seventh largest in 
the Mediterranean, located towards the east of the Iberian Peninsula (Fig. 1). 
The climate in Mallorca is typically Mediterranean [20]. Rullan [21] divides 
the island in three main natural (geobotanical) regions: (T) Tramuntana 
mountain range, to the NW, with a rugged relief, humid-subhumid climate, 
and north-facing oak (Quercus ilex L.) forests, (C) centre and N/NE, with a 
varied relief and less abrupt than the previous one, with dry weather, covered 
by oaks and maquis; (S) south plains, with a semiarid climate, covered by 
maquis, thicket and Aleppo pine (Pinus halepensis Mill.) forest (Fig. 1). 
 Around 870,000 inhabitants live in Mallorca [22]. Since the 1960’s 
Mallorca has depended on tourism as the main economy, having quickly 
left aside the primary sectors of agriculture and livestock, these now a 
mere witness of what had once been the main activities throughout its 
history. The primary sector has gone through several stages, but nowadays 
the percentage of people actively engaged in this sector (data from                     
[22, 23]) is 1.24%. A relevant part of Mallorcan peasants are retired people 
who continue to cultivate some extension of land not far from the place 
where they live; these people constitute the most important source of 
informants for this study. 
 
 
 
Figure 1. Location of the studied island in the Mediterranean Sea and the Catalan 
linguistic area, and the three main natural regions in Mallorca proposed by [21]. 
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 Ethnobotanical studies in Mallorca were practically lacking before this 
work. Distinguished botanists around the world have visited Mallorca at 
least since 1711 [24, 25] and its flora and vegetation have been described in 
many publications [26]; recent catalogues refer the complete list of plant 
species known so far from the island [27, 28]. Although ethnobotanical notes 
in the aforementioned floristic works are scarce, two of the classical 
Mallorcan floras include bibliographic information (and, in a few cases, data 
from popular knowledge) on useful Mallorcan plants [29, 30]. There is also 
an outstanding selection of 152 taxa of Balearic medicinal plants from a 
Catalan pharmacist established in Mallorca [31] and an informative dossier 
of 150 useful plants from a local botanical garden [32]. Also, some 
contributions, mostly from the linguistic and anthropological side, have been 
published [32-35], and they broadly address the use of plants in the field of 
health (medicine and/or food). Thus, the present work is intended to 
represent a starting point for the first systematic ethnobotanical study in the 
island, addressing the traditional use of medicinal plants in Mallorca.  
 
2. Data collection procedures, management and analysis 
 
 Information has been gathered using semi-structured, focalized 
interviews with people who work and live close to plants. Data have been 
compiled from 235 non-specialist informants queried in all the 53 
municipalities of the island, some of them in small groups, but normally 
through one-to-one meetings. Of those interviewed, 43% are women and 
57% are men. The interviewee’s mean age was 76, born mainly between 
1931 and 1940. Almost all the informants were autochthonous of the island 
(97%), 89% of them retired. Methodological details, including herbarium 
vouchers - deposited in the herbarium BCN, Centre de Documentació de 
Biodiversitat Vegetal, Universitat de Barcelona -, are provided in [16, 17]. 
 The medical issues dealt with informants during interviews were: (1) 
plants or preparations still used nowadays, (2) plants or preparations used in 
the past, (3) plants or preparations linked to festivities, (4) toxic plants or 
preparations, and finally (5) specific disorders and their treatment with 
plants. Other items, apart from human medicinal uses, were also treated: 
veterinary ailments, food and aromatic plants, and other applications of 
plants (such as in popular literature, handcraft, domestic uses, etc.). 
 To ensure an organized pool of the gathered information from 
interviews, our research group’s online internal database has been used, 
permitting the systematization of data entry and further analysis. This 
database has been designed as an open source interface, a constantly 
growing platform for ethnobotanical data collected in Catalan-speaking 
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territories. Information for the descriptive quantitative analysis was handled 
using the R software (r-project.com). 
 Some classical quantitative ethnobotanical indices have been calculated 
(see all indices and definitions in [7] and [10]). The cultural importance 
index (CI) has also been determined [36]. Each taxon referred by an 
informant within a medical use-category has been counted as a use-report 
(UR). The use of popular indices of relative or cultural importance in 
Ethnobotany [4] has been designed to quantify local botanical knowledge, 
and it has been valuable giving an ethnographical shift to deepen into plant 
traditional knowledge understanding. 
 Finally, to determine the degree of originality and novelty of the 
medicinal uses claimed by the informants, a review of the literature referring 
to Ethnopharmacology in the Mediterranean region has been carried out. 
International online databases (pfaf.org/index.php and ars-grin.gov/duke/) 
have also been consulted (last access to online databases 14.10.2011). 
 
3. The Mallorcan ethnopharmacopoeia 
 
General catalogue: Botanical and galenic aspects 
 
 The whole ethnobotanical catalogue of Mallorca includes 517 plant taxa. 
Referring to human medicine, a total of 1811 remedies involving 255 plant 
taxa were collected as traditionally used in human healing (cited for at least 
three independent informants; [37, 38]). Wild species predominate (137), but 
the presence of plants cultivated or bought through commerce is significant. 
The 517 plant taxa of the whole catalogue belong to 114 botanical families, 
and the three most relevant families much contributing to the medicinal flora 
of Mallorca are the Lamiaceae (10%), Rutaceae (9.8%, especially owing to 
cultivated species) and Asteraceae (9%), which at the same time represent the 
most common botanical families, apart from Poaceae, of the Mediterranean 
flora [28]. This statement connects with the idea that the closer to civilization a 
plant grows, the more it is used by local people [10, 38, 39, 40]. The complete 
ethnofloristic catalogue and most remarkable human and veterinary medicinal 
uses are provided in [7, 16, 17]. Here we will discuss general aspects of this 
dataset and we will provide, as a complement, the uses of Mallorcan endemic 
plants (Table 1 and subheading 5).  
 For the whole island, the ethnobotanicity index (EI) is 28%, 1674 taxa 
being an approximate count of the vascular flora [27]. Compared with other 
Catalan-speaking territories, this EI value is higher than in Cerdanya, 
Conflent, High River Ter Valley and Guilleries [41-44], but lower than in 
Alt Empordà, Montseny, Pallars and Castelló [45-48]. 
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Table 1. Names and ethnobotanical knowledge or uses of Mallorcan endemic plants. 
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The top five medicinal species cited with the greatest number of use-
reports (in brackets) are Olea europaea L. subsp. europaea (78), Santolina 
chamaecyparissus L. (76), Eucalyptus globulus Labill. (65), Ruta 
chalepensis L. (61) and Allium sativum L. (54). This order also corresponds 
to the CI index global values for these top five species: 1.09, 0.99, 0.45, 0.68 
and 0.78 respectively. Although not all the papers include CI values, a quick 
review of other works [35, 49], shows that top species have CI 0.6 – 0.7, so 
Olea europaea subsp. europaea and Santolina chamaecyparissus are for the 
local people culturally more important than top species in other territories. It 
is outstanding that an endemism appears as one of the top species of the 
ethnomedical catalogue of the island. Table 1 includes detailed results for all 
the useful endemic plants collected for this study. 
 When compared with previous ethnobotanical research in Catalan 
territories [39, 40, 50-53], several medicinal species appear at the top of the 
most cited medicinal plants in every territory studied (generally Thymus 
vulgaris L., Matricaria chamomilla L. and Sambucus nigra L.) [10]. This 
assertion leads us to conclude that general ethnobotanical results cannot be 
extended to all the Catalan-speaking areas. Other studies in the 
Mediterranean region have earlier concluded that it is hard to demonstrate a 
common ethnobotanical heritage throughout the whole Mediterranean 
without considering floristic or bioclimatic characteristics [17, 18, 54, 55].  
 Plant organs most commonly used for remedy preparation are leaves 
(20%), aerial parts (15%) and fruits (9%). Generally these are the plant parts 
that allow an easier identification to informants, so that they feel more 
confident to start with preparation.  
 The commonest methods of preparation in Mallorca are infusion and 
decoction, generally known as bullidures (by boiling in water), and the 
widest pharmaceutical form is tisane (42%), followed by the direct 
application of the plant part (14.5%) and then poultices and cataplasms 
(14%). The preferred administration way for traditional remedies is intern 
(69.13%). This pattern of preparations is generally the same as many 
previous Catalan ethnobotanical works [10]. 
 
Plant uses and informants’ knowledge about popular 
medicine 
 
 A total of 158 use categories have been recorded for the 255 medicinal 
plants, according to the thesauri of the Etnobiofic database created by our 
research group, which was constructed following Cook’s classification [56], 
emended and adapted to our field areas of study. The most frequent type of 
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medicinal use recorded, having calculated the index of medicinal importance 
(MI, the ratio between the number of use-reports referring to a category and 
the total of taxa that are used for a specific indication; [7]), is the 
antihelmintic (for intestinal worms) (8.64), followed by the tranquillizer 
(6.65), the gastric anti-inflammatory (6.40), the anticatarrhal (5.13), the 
antihypertensive (4.98) and the renal litothripter (3.54). 
 These are slightly different results from other studied areas of the 
Iberian Peninsula and the Mediterranean territory, which explain that the 
majority of remedies described by the interviewees refers to the treatment of 
mild ailments related to the skin, the respiratory and digestive systems [49], 
and also from very recent works in Turkey, where respiratory and throat 
diseases, gastrointestinal diseases, and kidney stones and urinary diseases 
represent more than 50% of use citations [57]. For the top categories in 
Mallorca, dermatological references are lacking. 
 Apart from the aforementioned quantitative information, there are also 
many data not included in the ethnopharmacological catalogue that also 
explain the Mallorcan ethnomedical cosmovision. This knowledge has been 
reported by the informants during interviews, and managed apart from the 
plant use-reports pool. It mainly refers the popular process of medical aid in 
the rural Mallorca. It does not only include plant knowledge, but also the use 
of animal and mineral derivatives (such as lard, all kind of waxes, seashells, 
etc.). The whole process against illness has been exposed by several 
informants of the study and also by Galmés [34] as a stepped and casuistic 
timeline: first the most well-known remedies were applied, the ones that 
were at hand and everyone knew. If the first option was unclear, they asked a 
neighbour or a relative that could know it. The next step of query was the 
local healer, sometimes the doctor, and if it still did not work, they went for 
a healer from another village or from the capital town, specialized with the 
particular ailment. Depending on the disease, it was told to a wizard or 
sorcerer. If nothing was successful, the last hope was to entrust to the saint 
specific for the ailment; it was a pray or a promise. Religion, after all, and 
the catholic beliefs in Mallorca, had an outstanding significance during the 
curative process of an illness.  
 
4. In addition to traditional medicine: Edible plants and 
other uses  
 
 A total of 199 plant taxa were cited as human food plants and 72 for 
other uses such as crafts, popular literature and religious beliefs. Out of all 
taxa mentioned as food in humans (199), 67% are grown or purchased and 
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the remaining are wild. An amount of 714 use-reports was unique. The most 
cited species is Foeniculum vulgare Mill., due to its properties for cooking, 
followed by fruits of Arbutus unedo L., usually consumed fresh without 
preparation, Capsicum annuum L. and Laurus nobilis L. as condiments and 
Rubus ulmifolius Schott and Cichorium intybus L., eaten fresh or in pies and 
salads. 
 There is a remarkable amount of plants (146 taxa) claimed to be useful 
both for food and medicine, and 19% of medicinal plants are also used as 
condiment. The coincidence with the data on food plants in previous works 
is almost complete, there is very little new in Mallorca, with the exception of 
species that are endemic to the island or that grow more abundantly than in 
other studied areas; it is worth mentioning Ampelodesmos mauritanica 
(Poiret) T. Durand et Schinz, some mallows (Lavatera arborea L. and L. 
cretica L.), Allium triquetrum L. and Salvia microphylla Humb., Bonpl. & 
Kunth. Numerous citations (103) were also collected for 62 taxa for plant 
use in animal feed. The above-mentioned plants refer to the fattening of pigs 
- which in turn is one of the main food products in Mallorca - and are 
Ceratonia siliqua L., Opuntia maxima A.Berger and Ficus carica L.. The 
gathering of information on wild edible plants served as the starting point for 
a wider study (Iberian Peninsula and Balearic Islands) in preparation, the 
hypothesis of which is that the socio-cultural factors (rather than ecological) 
are responsible of changes in consumption patterns, harvesting and 
marketing of wildlife plants. 
 Informants cited 72 taxa for which one must be careful when using 
them, both as medicine and food, with a total of 323 reports. Most of the 
information is related to the taking of the plant internally with a low degree 
of toxicity. After the ethnobotanical literature review of previous works, 
we conclude that the local knowledge of harmful or toxic plants is quite 
uniform and does not vary much with respect to the current bibliographic 
knowledge. 
 For uses that are neither food nor medicine (including toxicity), 
informants cited 351 taxa and 1142 unique use-reports. The most repeated 
use subcategory is horticultural and agricultural handling, and the most 
notable species is Asphodelus aestivus Brot., especially linked to the 
production of reeds for drying fruits of Ficus carica. Twenty seven taxa 
are shared when comparing the results of other uses in Mallorca with some 
of the studies carried out in Catalonia [43, 45, 46]. The inclusion of such 
different uses for food and medicinal ethnobotanical studies gives an idea 
of the social importance of plants in the past, at least partly surviving 
nowadays. 
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5. The relevance of insularity and the basis for a meta-
analysis of ethnobotanical data in the Catalan linguistic 
area 
 
 There are two aspects to be considered when assessing the relevance of 
insularity. First, the traditional use of endemic taxa among the 
autochthonous population and, second, the singularity of the plant 
knowledge (new or scarcely cited plant uses compared with other studies 
previously documented in closer territories, especially Mediterranean in this 
case). 
 The degree of knowledge or use of endemic local taxa in Mallorca has 
been calculated using the index of phytoethnoendemicity (PEEI), proposed 
by Mesa [58]; it determines the ratio between the endemic plants and the 
total ethnoflora. PEEI calculation allows the evaluation of the singularity of 
the plant use along the study area and also the isolation of population (the 
more endemic taxa are used, the most knowledgeable the inhabitants are 
about their closest environment). The PEEI of this study is 3.29%, a low 
value compared to [59] - 11.37% -, taking into account that in Mallorca more 
than 100 endemic plant taxa are known and the insularity factor benefits 
self-management. Apart from values of the mentioned index, it is worthy of 
mention that the absolute value of known and used endemic species (Table 1), 
17, is rather high. The percentage of this kind of plants that the informants 
know or use as compared with the total amount of endemic insular taxa (ca. 
15%) is not negligible - even less taking into account that some endemic taxa 
have an extremely restricted distribution are, so that they are a priori not 
suitable as objects of popular use - and indicates remarkable level of 
knowledge on the proper specific island’s flora among their inhabitants. 
 The set of novelty of Mallorcan ethnobotany, based on the consult of 
more than 200 works with ethnobotanical information mostly in the 
Mediterranean area (see [17], for details), is composed by 38 rarely reported 
taxa and 306 use-reports not appearing in the literature considered or 
recorded in less than three works. 
 
6. Conclusions and future prospects 
 
 This work summarizes the first comprehensive ethnobotanical study in 
Mallorca based on the PhD thesis titled “Contribution to the ethnobotany of 
Mallorca. Plant biodiversity and its management in a Mediterranean island” 
[17]. It is an important contribution to increase the ethnobotanical data 
available of the Catalan-speaking territories, and it will be part of further 
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analysis covering all the information of our research group. Ethnobotanical 
studies like this are, on the one hand, a useful tool for public health 
authorities to facilitate and enhance the detection and prevention of 
interactions and other problems resulting from combined medicinal plants 
and synthetic drugs, as well as to ensure accurate pharmaceutical advice and 
prescription by health professionals. On the other hand, they constitute the 
first step of a bioprospecting process, which may be the basis for new drug 
research and development. 
 Informants continue to use natural therapies learned from past times, 
especially for minor ailments (digestive, respiratory, etc.), and are receptive 
to learn new ones. The natural therapies are taken, in most cases, as a 
complement to conventional drugs. However, many of the collected use 
reports have stopped their usage in the present social setting due to 
sociocultural changes. Therefore, their collection prior their loss is very 
important, not only as cultural heritage, but also as a possible source of new 
medicines both for animals and for people.  
 The collected information, which may open new perspectives of plant 
use, is a good starting point for future studies, in both applied scientific 
research (especially related to ethnopharmacological activities of plants) and 
social research. In Mallorca, ethnobotanical intergenerational dialogue 
among citizens is necessary because the pressure of acculturation on the 
subject of plants, their names and their traditional uses is very remarkable. 
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Abstract. A multicompartment compliance aid (MCA) is a blister-
type repackaging system that aims to facilitate drug administration 
and thereby increase patient adherence. One of the characteristics 
of the MCA that should be taken into account is the moisture 
permeability, since this atmospheric condition is one of the most 
important factors that can modify the stability of medicines. In the 
current paper we report the moisture permeability tests performed 
on a MCA according to the US Pharmacopeia. This information on 
the suitability of the device will help pharmacists implement a 
high-quality professional service.  
 
Introduction 
 
      The scale of the problem posed by low levels of adherence to drug 
therapy represents a major concern for all health systems. A report published 
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by the WHO indicates that in developed countries, 50% of patients who 
suffer from chronic conditions fail to comply; and in developing countries 
this figure is even higher [1]. 
 Despite the fact that problems of adherence occur independently of the 
condition, type of patient and socioeconomic level, geriatric patients are more 
vulnerable to incorrect use of medicines; this is mainly due to a reduction in 
their functional capacity and the large number of drugs that they take long 
term [2]. According to Kendrick and Bayne [3], expected adherence to a 
treatment regimen for a person of advanced age who takes just one medicine 
is 65%; this is reduced to 54% when the patient takes four medicines; and it 
drops to below 7% as the number of medicines increases. In addition, the lack 
of adherence to the dosage schedule on the part of the geriatric patient is 
directly related to periods of hospitalisation [4]. Moreover, the current 
demographic situation, with a constantly increasing life expectancy, means 
that the incidence and prevalence of complex chronic conditions also 
increase, and it is these patients who consume large numbers of medicines 
[5]. Therefore, it is becoming ever more important to use tools and develop 
plans of action aimed at improving adherence and contributing to the 
increased safety, effectiveness and efficiency of drugs and of healthcare 
resources in general [6]. 
 
1. Multicompartment compliance aid 
  
 A multicompartment compliance aid (MCA), also called a monitored 
dosage system, is a blister-pack system into which drugs are re-packaged and 
which is used to organise all the solid medicines that a given patient takes 
over a week, following the prescribed dosage schedule. In accordance with 
the manufacturer’s certificate, the MCA is safe, hygienic and made of 
innocuous materials that do not interact at all with the medicines. The MCA 
is a tool designed to facilitate the administration of medication and therefore 
to increase patient compliance, as well as to reduce drug administration 
errors. The Pharmaceutical Services Negotiating Committee, which 
represents community pharmacies in England and Wales, already 
recommends the use and monitoring of this type of pack for all patients with 
problems when it comes to taking their medication [7]. Similarly, in 2005, the 
Australian Government’s Department of Health and Ageing, under the 4th 
Community Pharmacy Agreement, founded a specific MCA programme with 
the idea of reducing hospitalisations related to medication and improve 
treatment adherence in the population where it is required [8]. 
 In Spain, Royal Decree Law 9/2011 of 19th August consisting of 
measures to improve the quality and cohesion of the national health system 
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[9] modified Section 1 of Article 84 of Law 29/2006 of 26th July regarding 
the guarantees and rational use of medicines and healthcare products [10]. 
The regulations pertaining to MCA use currently declaim: ―In pharmacies, 
the pharmacists, being those responsible for the dispensing of medicines to 
citizens, will encourage compliance with the schedule established by the 
physician responsible for prescribing medicines to the patient, and will aid in 
treatment adherence through pharmaceutical care procedures that contribute 
to ensuring efficacy and safety. The pharmacist will also take part in a series 
of activities designed to enhance the rational use of medicines, in particular 
through informed dispensing to the patient. Once the medicine has been 
supplied, the pharmacist may provide monitored dosage systems to patients 
who ask for them, in order to improve treatment compliance, for those 
treatments and with the attendant conditions and requirements that the 
competent health authorities establish.‖ In September 2012, the first guide to 
drug therapy adherence with MCA use was published under the coordination 
of the regional Council of Pharmaceutical Colleges in Catalonia [11]. More 
recently, in May 2013, at the national level the General Pharmaceutical   
Council approved distribution of the Standard MCA Working Procedure [12]. 
The elements necessary for the pharmacist in a community pharmacy to 
provide professional MCA service are defined in both documents.  
 
2. Selection of the Multicomparment Compliance Aid 
 
 The MCA is required to conform to a series of characteristics, including: 
―… preserving the stability of the medication they contain; … The 
manufacturer must guarantee (through supplying the corresponding 
certificate) that it is made of innocuous materials that do not interact with the 
contents; … The degree of hermeticity specified in the US Pharmacopeia 
(USP)‖. However, despite the fact that different devices are available on the 
market, is the pharmacist, or in general the healthcare professional, who 
decides which to choose to work with, as well as assigning a use date after re-
packaging the medication into the MCA [13]. 
 One of the characteristics of the MCA that should be taken into account 
is the degree of protection from moisture, since this atmospheric condition is 
one of the most important factors that can modify the stability of medicines. 
In accordance with the USP [14], the so-called moisture permeability test 
establishes whether a MCA meets the hermeticity or moisture impermeability 
requirements specified for this type of device (Class B). In the current paper 
we report the results of moisture permeability tests performed on a MCA. 
This information on the suitability of the device will help healthcare 
professionals implement a high-quality professional service. 
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3. Moisture permeability test 
 
 The material used to perform the moisture permeability test included: the 
MCA and a support for the repackaging supplied directly by the distributor 
(Fig. 1). 
 It consists of a lamina of polyethylene terephthalate plastic with 28 
compartments or blisters (divided into four vertical columns —to indicate the 
doses—and seven horizontal rows —to indicate the days of the week) and a 
piece of cardboard. One side of the piece of cardboard has a sheet of a 
greaseproof aluminium compound stuck to it covered in a water-based self-
adhesive material to strongly hold in place or glue porous supports to plastic 
surfaces, which is protected by what appears to be silicon-coated paper. It is 
cold sealed using a suitable support which the plastic lamina is placed on. 
The piece of cardboard is placed on top of the plastic lamina (once the 
silicon-covered paper has been removed), in such a way that the side with the 
aluminium is in contact with the plastic lamina, sealing the two parts of the 
system by applying pressure to the cardboard. In this way the containers or 
blisters of the device are individually sealed.  
 We also used: desiccant pellets (TK-1002L), 8 mm in diameter × 10 mm, 
in accordance with the specifications of the USP, supplied by Medical 
Packaging Inc.; two stability chambers, Memmert mod.100 and Kötterman 
mod. 2736, one to perform the test and one to activate the pellets; a precision 
balance (Precisa mod.125 A) to weigh both the test MCA and the controls; a 
desiccator, to keep the pellets isolated from atmospheric humidity once 
activated; a maximum and minimum mercury thermometer (Celsius®) to 
monitor temperature in the chamber, and a digital maximum and minimum 
 
     
 
Figure 1. Multicompartment Compliance Aid (MCA) assayed (a) and support used 
for repackaging (b). 
(b)  
(a)  
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thermo-hygrometer (TFA®) to monitor the humidity. Solutions of 35 g of 
NaCl (Panreac, Castellar del Vallés, Barcelona) per 100 ml of water were 
prepared to maintain the relative humidity (RH) constant within the chamber 
(75% ± 3%).  
 The test was performed in accordance with the USP, section 671 [14] of 
which details the method to be followed to determine the moisture permeability 
of devices (packs) that incorporate a number of single-dose individually-sealed 
blisters (Method II). The packs are classified, according to the results, from the 
least to the most permeable as Class A, Class B, Class C and Class D. A 
package is designated Class A if no packs tested exceeds 0.5 mg/day in average 
blister moisture permeation rate; it is designated Class B if no pack tested 
exceeds 5 mg/day in average blister moisture permeation rate; it is designated 
Class C if no pack tested exceeds 20 mg/day in average blister moisture 
permeation rate; and it is designated Class D if the packs tested meet none of 
the above average blister moisture permeation rate requirements. The test was 
performed on 12 MCA for each Class (A, B, C or D), depending on the 
moisture permeability. The procedure was the same for all of them:  
 
- 6 of them were filled at random with the desiccant pellets (test MCA) 
and the other 6 were tested as controls (control MCA) (Fig. 2). 
- All the packs were stored at 23ºC ± 2ºC and 75% ± 3% RH for 24 h, at 
which time they were removed from the chamber and left to equilibrate 
for 45 min.  
- The initial weighing was then carried out (the test MCA were weighed 
individually and the control MCA together to find their average weight) 
and then they were again placed into the chamber, for the appropriate 
time for each Class (24 h for Class D, 48 h for Class C, 7 days for class B 
and at least 28 days for Class A). If, during the procedure, any pellet 
turned pink or there was a 10% increase in the average weight of the 
pellets in any test pack, the assay was considered over, with the prior 
determination being taken as valid.  
- The average rate of moisture permeation, in mg/day, for each container 
or blister in each MCA was calculated by applying the following 
formula:  
 
(1/NX) [(Wf–Wi) – (Cf–Ci)] 
 
where:  
 
 N is the number of days expired (beginning after the initial 24-hour 
equilibration period);  
Pilar Modamio et al. 138 
 X is the number of separately sealed units per pack (in the MCA assayed 
is 28);  
 (Wf –Wi) is the difference, in mg, between the final and initial weights of 
each test pack; and  
 (Cf –Ci) is the difference, in mg, between the average final and average 
initial weights of the control packs. 
 
          
 
Figure 2. Test Multicompartment Compliance Aid (MCA) (a) and control MCA (b). 
 
4. Results of the permeability test  
 
 In accordance with the method described and based on the design of the 
study, the results are shown in Tables 1-4. 
 
Table 1. Moisture permeability test for Class D packs. 
 
Test MCA Control MCA 
Average rate of  
moisture permeation 
(mg/day) 
Initial weight 
 (mg) 
Final weight 
 (mg) 
 Initial average weight  
 (mg) 
Final average  
weight (mg) 
32210 32363 
26892 
 
26905 
 
5.000 
32344 32479 4.357 
32080 32217 4.429 
32810 32933 3.929 
32510 32650 4.536 
32707 32862 5.071 
 
 
(b)  (a)  
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Table 2. Moisture permeability test for Class C packs. 
 
Test MCA Control MCA Average rate of  
moisture 
permeation 
(mg/day) 
Initial weight 
 (mg) 
Final weight 
 (mg) 
Initial average  
weight (mg) 
Final average  
weight (mg) 
32712 32983 
26690 
 
26751 
 
3.750 
32380 32611 3.036 
32854 33115 3.571 
32448 32660 2.696 
31822 32043 2.857 
32018 32221 2.536 
 
Table 3. Moisture permeability test for Class B packs. 
 
Test MCA Control MCA Average rate of  
moisture 
permeation 
(mg/day) 
Initial weight 
 (mg) 
Final weight 
 (mg) 
Initial average  
weight (mg) 
Final average  
weight (mg) 
32894 33573 
26705 
 
26798 
 
2.990 
32791 33430 2.786 
32574 33190 2.668 
32786 33405 2.684 
32593 33201 2.628 
32844 33476 2.750 
 
Table 4. Moisture permeability test for Class A packs. 
 
Test MCA Control MCA Average rate of  
moisture 
permeation 
(mg/day) 
Initial weight 
 (mg) 
Final weight 
 (mg) 
Initial average  
weight (mg) 
Final average  
weight (mg) 
32094 32899 
26692 
 
26839 
 
0.839 
32915 33792 0.931 
32561 33374 0.849 
32688 33306 0.601 
32769 33428 0.653 
32714 33547 0.875 
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5. Implications for the quality of professional pharmaceutical 
services 
 
 Royal Decree Law 9/2011 [9] authorizes Spanish community 
pharmacists to prepare MCA for those patients who need them, and therefore 
it foresees that the use of this type of device will spread over the coming 
years, and moreover that this should happen in a standard way throughout the 
whole country. Taking into account that one of the basic functions of a MCA 
is to ensure that the medicines remain in similar conditions to those of their 
primary packaging, it is of utmost importance to know the different degrees 
of protection against environmental conditions that the MCA available on the 
market guarantee. The permeability test for packs that incorporate a number 
of individually sealed single-dose blisters is the first test that should be 
performed on this type of devices to establish whether they meet the 
requirements of hermeticity given in the pharmacopeia. The type of material 
the MCA is made of together with the loading process and the type of seal 
will determine the degree of protection against moisture the pack offers [15]. 
The results of the present study are based on the method described above 
with the objective of guaranteeing the highest standard for a professional 
service that uses these MCA. The results show that the MCA tested can be 
considered as Class D packs, since none of the average blister moisture 
permeation speeds was more than 20 mg/day after 24 h. They also meet the 
requirements for Class C and Class B packs, since all the average blister 
moisture permeation speeds were less than 20 mg/day after 48 h, and less 
than 5 mg/day after 7 days, respectively. However, they did not meet the 
Class A pack requirements, as over the 28 days of study all the average 
moisture permeation speeds were more than 0.5 mg/day. Despite the fact that 
the MCA studied here did not offer maximum barrier protection against 
atmospheric moisture (Class A), it does meet the conditions of hermeticity 
that the pharmacopeia demands for this type of packs (Class B). 
 The technical stage of re-packaging medicines into a MCA involves 
removing the medicine from its primary packaging of presentation, which 
annuls the manufacturer’s stability guarantee, and it is the responsibility of 
the pharmacist who prepares and dispenses it to establish a use date for the 
MCA once it has been loaded. That date indicates the moment after which the 
MCA should not be used (and therefore the medicines re-packaged) and in 
order to establish that date it is important to take into account, among others, 
the following information [13,15]: the nature of the medicine re-packaged 
into the MCA, available information about drug stability, the primary 
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packaging in which it was presented by the manufacturer and its expiry date, 
the characteristics of the MCA into which it has been loaded, the expected 
storage conditions the medicines will be exposed to, and the useful life the 
MCA is expected to have (Fig. 3). 
 
What type of MCA to use?
Pharmacist’s decision
Characteristics of the MCA: 
Properties of protection 
(humidity, temperature,…)
Useful life 
of the 
MCA 
The nature of 
the medicine 
repackaged
Primary packaging and 
expiry date of the 
medicine
Expected storage 
conditions of the 
MCA
 
 
Figure 3. Some relevant aspects to consider by pharmacists in the decision of what 
type of multicompartment compliance aid (MCA) to use. 
 
6. Conclusions 
 
 We performed a study to determine the degree of hermeticity of a cold-
sealed MCA. In accordance with the USP and the method detailed above, we can 
conclude that the MCA tested meets the hermeticity requirements specified by 
the pharmacopeia for this type of device.  
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Abstract. The Lycopodium alkaloids are a structurally diverse 
group of natural products isolated from Lycopodium with 
important biological effects for the potential treatment of cancer 
and severe neurodegenerative diseases. To date, full biological 
studies have been hampered by lack of material from natural 
sources. Total synthesis represents a possible solution to meet 
this demand as well as the most effective way to design new 
compounds to determine structural activity relationships and 
obtain more potent compounds. The aim of this chapter is to 
summarise the work carried out in this field so far by presenting 
an overview of the synthetic strategies used to access each of the 
four key Lycopodium alkaloid types. Particular emphasis has 
been placed on methods that rapidly construct each nucleus 
utilizing tandem reactions.  
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1. Introduction 
 
 The Lycopodium alkaloids, isolated from the Lycopodium genus of 
clubmosses belonging to the family of Lycopodiaceae, represent a diverse 
group of structures with important, wide-ranging biological effects. These 
compounds show great potential for the treatment of severe 
neurodegenerative diseases and cancers but to date biological studies have 
been hindered due to limited availability of material from natural sources. 
Attempts to access material via cultivation or fermentation have so far been 
unsuccessful [1] leaving total synthesis as the most promising way to access 
quantities of material for further biological testing. In addition, synthesis has 
the advantage that it easily enables structural modifications to be carried out 
to determine activity relationships and as a consequence design more potent 
analogues with improved biological profiles. The aim of this minireview is to 
give an overview of the synthetic strategies used to access each type of key 
Lycopodium alkaloids with particular emphasis on those synthetic 
approaches that feature tandem reactions enabling a rapid synthesis of each 
nucleus. Whilst a brief overview of the structures, biological properties and 
biosynthesis will be presented for contextual purposes, the authors direct the 
reader to the excellent review by Ma [1] for a more detailed coverage of these 
aspects. 
 
1.1 Classification of the Lycopodium alkaloids 
  
 At the moment of writing this report almost 300 Lycopodium alkaloids 
have been discovered [2] which can be divided into four structural classes 
[3,4] based on the parent compound: phlegmarine (1), lycopodine (2), 
lycodine (3) and fawcettimine (4) (Fig. 1).   
 
 
 
 
Figure 1. Representative examples of the four Lycopodium alkaloid classes. 
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1.2 Bioactivities  
 
 An extensive biological investigation of the Lycopodium alkaloids has as 
yet not been carried out. However, from the limited studies undertaken so far 
it has been discovered that many of these compounds possess important 
biological activities that warrant further investigation and development. One 
key area of potential of these compounds is for the treatment of severe 
neurodegenerative diseases such as Alzheimer’s. Examples include huperzine 
A [5] and lycoposerramine C [6], which act as inhibitors of the enzyme 
acetylcholinesterase (AChE), while lycodine-type complanadine B stimulates 
nerve growth factor (NGF) production in human glial cells [7]. 
Lycoposerramine Z from the phlegmarine structural class may potentially 
have neuroprotective properties due to the presence of the nitrone moiety, 
which can act as a free radical trap [8]
 
helping prevent destructive cascades 
leading to brain deterioration (Fig. 2). 
 The Lycopodium alkaloids have also been shown to possess anticancer 
activities. For example, complanadine A was found to be cytotoxic against 
leukaemia cells in mice [9]. Lyconadine B, from the phlegmarine group 
exhibits biological activity against brain tumors [10] and lycopodine has the 
ability to bring about inhibition in the growth of HeLa55 cells [11]. 
 
 
 
Figure 2. Some biologically active Lycopodium alkaloids. 
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1.3 Biosynthesis of the Lycopodium alkaloids  
 
 The biosynthetic pathway leading to all Lycopodium alkaloids is still 
not clear, although a basic overview is outlined in Scheme 1 based on the 
present knowledge [1]. The vast structural diversity encountered among the 
Lycopodium alkaloids is thought to derive from just two simple 
components, lysine and malonyl Co-A. The entry point into the pathway is 
through the decarboxylation of lysine to form cadaverine
 
which is 
transformed to Δ1-piperideine. At the same time, two molecules of malonyl-
CoA are condensed to form acetonedicarboxylic acid, whose union with  
Δ1-piperideine leads to 4-(2-piperidyl) acetoacetate (4PAA). This is then 
decarboxylated to form pelletierine, which is coupled to another molecule 
of 4PAA to form the phlegmarine-type Lycopodium alkaloids. These 
compounds are formed with multiple stereochemistries that can be 
separated into two main classes depending on whether the hydrogens at the 
ring fusion are arranged cis or trans (see section 2). It is assumed that on 
dimerisation slightly different pathways exist with different methods of 
control thus leading to the diverse range of stereochemistries observed. 
Phlegmarine (1) which is characterized by a trans fusion at the ring 
junction is considered to be the key intermediate from which the other three 
classes (2-4) of Lycopodium alkaloids are derived. Bond formation between 
C-4 and C-13 gives the lycodane skeleton, which after oxidation of the 
piperidine ring leads to lycodine (3). Detachment of C-1 from Nα of the 
lycodane skeleton and reattachment to Nβ then gives lycopodine (2). 
Rearrangement of (2) via migration of the C-4 to C-13 bond to C-12 forms 
the 5-membered ring of fawcettimine (4). Further complexity within each 
of these groups is arrived at by a series of modifications of these basic ring 
structures such as oxidations, ring fragmentations, dimerisations and 
additional skeletal rearrangements. 
 The cis-fused phlegmarine alkaloids comprise the entry point to the 
miscellaneous class of the lycopodium alkaloids, including compounds 
such as lyconadine A or dihydroluciduline which maintain the same cis 
stereochemistry relationship as the parent compound. Cernuine and related 
quinazoline Lycopodium alkaloids are speculated to arise from an opening 
of the B ring of the phlegmarine skeleton, additional oxidation, followed by 
a 4+2 cycloaddition reaction.  Due to the loss of the fusion stereochemistry, 
these compounds may arise via the trans or cis phlegmarine group 
intermediates.  
Synthetic approaches towards the Lycopodium alkaloids  147 
 
 
Scheme 1. Overview of the biosynthesis of the Lycopodium alkaloids. 
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2. Phlegmarine class 
 
 Phlegmarine is the parent member of the miscellaneous group of the 
Lycopodium alkaloids and as mentioned above, is considered to play a key 
role in the biosynthesis of all the lycopodium alkaloids. While phlegmarine 
(1) is characterized by a trans substitution pattern at the ring fusion carbons, 
other compounds belonging to this group feature a cis relationship between 
the ring fusion hydrogens (e.g lycoposerramine Z and cermizine B). In 
addition to the wide variety of stereochemistries observed, other key 
variations are the oxidation of the nitrogen containing rings leading to 
pyridines (lycoposerramine V and W), nitrones (huperzine M and 
lycoposerramine Z) or N-oxides (huperzine N) (Fig. 3).  
 
 
 
Figure 3. Representative compounds of the miscellaneous class based on the 
phlegmarine skeleton. 
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2.1. Previous synthesis of Phlegmarine type alkaloids   
 
 Despite the importance of this class of compounds from a biosynthetic 
point of view and their potential for use as biomimetic precursors of the other 
classes of Lycopodium alkaloids, the phlegmarine type has been one of the 
least studied (Table 1). Although the relative configuration of phlegmarine 
was established in 1981 [12] the absolute configuration of a phlegmarine 
derivative was not determined until 1999 [13] when Comins et al carried out 
the first asymmetric total synthesis of Nα-acetyl-Nβ-methylphlegmarine using 
a pyridine auxiliary for the construction of both the C and A nitrogen-
containing rings. Takayama's enantioselective syntheses of lycoposerramines 
V, W [14], X and Z [15] were accomplished using (5R)-methyl-2-
cyclohexenone as the source of chirality. Comins then completed the 
synthesis of phlegmarine in 2010 [16] based on his original methodology and 
finally, the Bonjoch group utilized organocatalysis to form the 
decahydroquinoline ring system as the key step.[17] 
 
Table 1. Previous synthesis of some Phlegmarine-type Lycopodium alkaloids 
(*denotes enantioselective synthesis). 
 
Year Natural Product 
 
Author         Ring Construction                                                     
Strategy 
1981 [12] Nα-methyl-Nβ-acetylphlegmarine Maclean B→C→A 
1999 [13] Nα-acetyl-Nβ-methylphlegmarine Comins C→B→A* 
2007 [14] Lycoposerramine-V 
+(Lycoposerramine W) 
Takayama B→C→A* 
2009 [15] Lycoposerramine-X 
+(Lycoposerramine Z) 
Takayama B→C→A* 
 
2010 [16]  ( )-Phlegmarine and derivatives Comins C→B→A* 
2013 [17] Lycoposerramine-Z Bonjoch acyclic→BC→A* 
 
2.2 Bonjoch's synthesis of Lycoposerramine Z [17] 
 
 Bonjoch’s group developed an asymmetric synthesis of 
lycoposerramine Z, where the decahydroquinoline core was assembled via 
an organocatalyzed diastereo and enantioselective one-pot tandem 
procedure (Scheme 2). Removal of the tert butyl ester group with TFA and 
coupling with pyridine phosphonate 5 assembled the complete carbon 
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skeleton in a rapid manner. Hydrogenation of alkene 6 took place 
exclusively from the top face leading to 7, which has all the stereocentres 
required for lycoposerramine Z in place. The sensitive nature of the nitrone 
unit necessitated exchange of the tosyl group for the more readily labile 
Teoc group (trimethylsilylethylcarbonate), which was previously used in 
Takayama's synthesis of the same compound. Finally reduction of the 
pyridine ring followed by oxidation with Na2WO4 in the presence of urea 
peroxide installed the nitrone unit. Treatment with TFA smoothly removed 
the Teoc group to complete the synthesis.  
 It was also later shown that this method can be adapted to access all the 
different core decahydroquinoline stereochemistries present in the 
phlegmarine group via a series of controlled equilibration reactions [18]. 
 
 
 
Scheme 2. Bonjoch’s total synthesis of lycoposerramine Z. 
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3. Lycodine class  
 
 The lycodine (3) group comprises around 30 of the 300 known 
Lycopodium alkaloids. Some examples are shown in Fig. 4. Complanadine A 
is a dimer of two lycodine units. Hydroxypropyllycodine is the first 
Lycopodium alkaloid found to possess a 19-carbon skeleton [19]. In some 
compounds such as huperzines A and B the D ring is unsaturated whilst in 
the former the C ring has been cleaved. Casuaririne I features an 
unprecedented 5-membered tetrahydropyrrole ring and is believed to derive 
from huperzine A [20]. 
 
 
 
Figure 4. Representative compounds of the Lycodine group. 
 
3.1 Previous synthesis of Lycodine and related compounds 
 
 Along with the phlegmarine group, the synthesis of the lycodine class has 
been the least studied. The D→C→B→A ring strategy is the most commonly 
used to construct the lycodine nucleus. The first synthesis of (±)-lycodine was 
performed by Heathcock [21],
 
who closed the DCB skeleton in a one-pot 
diastereoselective Mannich condensation. Another racemic synthesis of 
lycodine was developed by Hirama [22] and involved a Diels-Alder 
cycloaddition followed by an intramolecular Mizoroki-Heck reaction to 
furnish the complete skeleton. In Sarpong’s complanadine A synthesis [23] 
Boc-protected lycodine was prepared as a key intermediate en route to the  
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Table 2. Previous syntheses of Lycodine and its dimer's Complanadine A and B.                 
(* denotes enantioselective synthesis). 
 
Year Natural Product Author                    Ring Construction 
Strategy 
1982 [21] Lycodine Heathcock D→C→B→A 
2010 [22] Lycodine Hirama acyclic→CD→BA 
2010 [23] Complanadine A Sarpong D→DCBA* 
2010 [25] Complanadine A Siegel D→C→B→A* 
2013 [24] Complanadine B Sarpong D→DCBA 
2013 [26] Complanadines A/B Hirama acyclic→CD→BA 
 
final product in enantiopure form (see Scheme 3). This same key 
intermediate was later used in his synthesis of complanadine B [24].
 
Seigel 
[25] made use of two Co-mediated [2+2+2] cycloaddition reactions to furnish 
complanadine B starting from a thioether derivative of (5R)-methyl-2-
cyclohexenone. While as yet no enantioselective synthesis of lycodine has 
been described, recently Hirama [26] and co-workers reported the synthesis 
of Complanadines A and B starting from enantiopure ( )-lycodine, which 
was obtained by chiral HPLC separation.   
 
3.2 Sarpong’s synthesis of Complanadine A [23] 
 
 Sarpongs´s synthesis of complanadine A takes advantage of the 
symmetry of the product to construct the dimer from two lycodine units via a 
palladium-based coupling reaction as the key step.  Preparation of the (5R)-
methyl-2-cyclohexenone starting material 8 was accomplished in 3 steps 
from R-(+)-pulegone using a reported procedure [27]. Iodination and radical 
addition to acrylonitrile gave 9 which after acetalization and reduction of the 
nitrile gave 10 the key material for the subsequent tandem cyclisation 
reaction. Treatment of this compound with perchloric acid led to an 
intermediate that was trapped with an enamide 11 via a Michael-Mannich 
tandem procedure to furnish the DCB core [28] followed by condensation of 
the amide to the carbonyl formed the A ring giving a rapid synthesis of the 
complete lycodine skeleton (Scheme 3). Protection of the resulting compound 
followed by oxidation with lead tetraacetate and triflation of the pyridone 
ring provided 12. Removal of the triflate group gave Boc-protected lycodine 
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13 to which was introduced a boronic ester with an iridium-catalyzed 
functionalization at the 3 position to give 14.  Finally, Suzuki cross-coupling 
of 12 and 14 followed by cleavage of the Boc protecting groups completed 
the synthesis. 
 
 
 
Scheme 3. Sarpong's total synthesis of complanadine A. 
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4. Lycopodine class  
  
 Lycopodine (Fig. 5), the first isolated Lycopodium alkaloid [29], is the 
most widespread and can be found in several different Lycopodium species. 
Out of the 300 known Lycopodium alkaloids discovered so far, 100 belong to 
the lycopodine class.  
 
 
 
Figure 5. Some representative alkaloids belonging to the lycopodine class 
 
4.2 Previous synthesis of Lycopodine and related compounds 
 
 Along with the Fawcettimine nucleus, the synthesis of lycopodine has 
been one of the most intensively studied, with most of the approaches 
reported to date relying on a common D→C→B→A ring construction 
strategy. The key ring-forming step usually involves the manner of formation 
of the B ring, which can be divided into two main approaches. The first, 
described by Stork, involves an intramolecular Pictet-Spengler cyclization 
onto an iminium group located between the D and C rings. The aromatic ring 
is then fragmented and used to form the required carbon atoms of the A ring. 
Padwa and Mori later arrived at the same key intermediate precursor in their 
synthetic approaches albeit by very different methods.  The other key strategy 
to form the B ring involves an intramolecular diastereoselective Mannich 
cyclization approach which was first reported by Heathcock (see Scheme 4). 
This strategy, and variations thereof, has been the most commonly employed 
in subsequent synthetic approaches. The first enantioselective synthesis of a 
lycopodine related compound, clavolonine A was described by Evans and 
used a similar Mannich strategy. However, instead of following Heathcock 
and starting from a racemic D ring building block, a chiral auxiliary strategy 
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was used to form an acyclic chain which was then cyclised to form the D ring 
in enantiopure form. A few years later, Carter achieved the first 
enantioselective synthesis of lycopodine using an analogous approach to 
Evans employing a chiral auxiliary and a Mannich cyclisation as the key 
steps. Whilst a number of strategies do not fall into the categories described 
above, the methods employed have usually required a significant amount of 
additional functional group manipulation steps and consequently these 
strategies have not been exploited in further synthetic approaches. 
 
Table 3. Summary of the most relevant previous syntheses of Lycopodine and its 
derivatives. (* denotes enantioselective synthesis). 
 
Year Natural Product Author             Ring Construction 
Strategy 
1967 [30] 12-epi-Lycopodine Weisner D→C→B→A 
1968 [31] 12-epi-Lycopodine Weisner D→C→A→B 
1968 [32] Lycopodine Stork D→C→B→A 
1968 [33] Lycopodine Ayer BC→A→D 
1978 [34] Lycopodine Heathcock D→C→B→A 
1978 [35] Lycopodine Kim D→B→C→A 
1982 [28] Lycopodine Schumann D→C→B→A 
1982 [21] Lycopodine Heathcock D→C→B→A 
1984 [36] Lycopodine Wenkert C→A→B→D 
1985 [37] Lycopodine Kraus D→B→C→A 
1998 [38] Lycopodine Mori D→B→C→A 
1998 [39] Lycopodine Grieco B→D→CA 
1997 [40] Lycopodine Padwa acyclic→CD→B→A 
2005 [41] Clavolonine Evans acyclic→D→C→B→A* 
2008 [42] Lycopodine Carter acyclic→D→C→B→A* 
2010 [43] Acetylfawcettiine Breit D→C→B→A* 
2011 [44] Clavolonine Fujioka D→C→B→A* 
2012 [45] 7-hydroxylycopodine Snider D→C→B→A 
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4.3 Heathcock’s synthesis of Lycopodine [21] 
 
 Key to Heathcock’s synthesis is an equilibrating Mannich cyclisation 
reaction which assembles the DCB tricyclic in a single step. The requisite 
material required for the cyclisation was prepared from                                        
5-methylcyclohexane-1,3-dione, which underwent Michael addition to 
acrylonitrile followed by formation of the cyclohexenone. Conjugate addition 
of a tosyl hydrazine to 9 followed by hydrolysis of the hydrazone gave 15. 
Protection of the ketone moieties as acetals then allowed the nitrile to be 
reduced to the primary amine. Treatment of 16 with strong acid over an 
extended period resulted in a diastereoselective Mannich cyclization to 
forming the DCB tricyclic system via equilibration to the most stable 
structure. Removal of the methoxyether group with HBr resulted in 
subsequent formation of the primary alkyl bromide, which was then cyclised 
onto the nitrogen under basic conditions giving lycopodine. 
 
 
 
Scheme 4. Heathcock’s total synthesis of lycopodine. 
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5. Fawcettimine class  
  
 About a third of all the known lycopodium alkaloids are of the 
fawcettimine type. Key structural variations to the parent structure include 
skeletal oxidations as well as the formation of dimeric products. The 
fawcettimine nucleus can be simplified to the three-ring DBA system since 
the C ring forms spontaneously via the free amine condensing with the 
carbonyl to form the hemiaminal unit. 
 
 
 
Figure 6. Representative compounds of the fawcettimine class. 
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5.2 Previous synthesis of Fawcettimine and related compounds 
 
 Fawcettimine-type products have been the area of most intensive 
synthetic research in the field of Lycopodium alkaloids, with the vast majority 
of syntheses being reported from 2007 onwards [46].
 
 
Table 4. Previous synthesis of fawcettimine and related compounds. (* denotes 
enantioselective synthesis). 
 
Year Natural Product Author            Ring Construction 
    Strategy 
1979 [47] Fawcettimine Inubushi D→B→A→C 
1986 [48] Fawcettimine Heathcock D→B→A→C 
1989 [49] Fawcettimine Heathcock D→B→A→C 
2002 [50] Magellanine Liao BC→ A→D 
2007 [51] Fawcettimine Toste D→B→A→C* 
2008 [52] Fawcettidine Dake D→C→B→A* 
2010 [53] Fawcettimine 
(Fawcettidine) 
Takayama acyclic→DB→A→C* 
2010 [54] Fawcettimine Jung D→B→A→C* 
2010 [55] Fawcettimine 
(Lycoposerramine-B) 
Mukai acyclic→DB→A→C* 
2010 [56] Fawcettimine 
+(Lycoflexine) 
Yang D→B→A→C* 
2010 [57] Lycoflexine 
(Fawcettimine) 
Mulzer D→BA→C* 
2011 [58] Huperzine-Q Takayama acyclic→DB→A→C* 
2010 [59] Alopecuridine Meng D→A→B→C 
2012 [60] Fawcettimine Willliam D→A→B→C* 
2012 [61] Fawcettimine (Fawcettidine  
and Deoxyserratinine) 
Lei D→A→B→C* 
2013 [62] Lycojaponicumin C 
8-Deoxyserratinine 
Fawcettimine 
Fawcettidine 
Zhao D→B→A→C* 
2013 [63] Lycopladine D, Fawcettidine 
Lycoposerramine Q 
Tu DB→A→C* 
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 As a consequence most of the syntheses carried out are enantioselective 
with 3-methyl cyclohexenone 8 (derived from pulgeone) as the most popular 
source of chirality. As in all the previous syntheses of the Lycopodium 
alkaloids one strategy dominates for the construction of the fawcettimine 
skeleton. Most methods employ the D→B→A→C order (see Table 4) with 
the key differences in strategy centring on the assembly of the 5-membered B 
ring. This usually involves a conjugate addition onto a suitably substituted 
cyclohexenone followed by a subsequent trapping of the nucleophile via the 
formed carbonyl enolate. In a number of cases the order is reversed, with the 
6-membered D ring being appended onto a 5-membered B ring starting 
material precursor, for example, using a Diels-Alder [60] or a Robinson 
annulation reaction [62] Alternatively, the 6,5-bicycle (D-B) core has been 
constructed in a single step from an acyclic precursor using a Pauson-Khand 
reaction [53,55].    
 Subsequent closure of the 9-membered A ring usually involves a 
Mitsunobu-type reaction. Finally, deprotection of the nitrogen yields the free 
amine, which then spontaneously cyclises via the hemiaminal to close the C 
ring.  
 
5.3 The Mulzer synthesis of Lycoflexine and Fawcettimine  
 
 Mulzer and co-workers [57] have reported an efficient route to construct 
the 6,5,9-tricylic framework of fawcettimine which features an enyne ring-
closing-metathesis to construct the B and A rings in a single step. Like many 
Lycopodium syntheses it utilises 3-methylcyclohexenone 8 as the starting 
material and source of chirality. A Sakurai-aldol sequence gave substituted 
cyclohexanone 17 which after oxidation with IBX was alkylated with a 
nitrogen-containing side chain. Conversion of the methyl ketone to an alkyne 
prepared the starting material 18 for the tandem cyclization reaction. 
Treatment with Grubbs II catalyst initiated the enyne ring-closing-metathesis 
first forming the five-membered B ring followed by the 9-membered A ring. 
The resulting diene was hydrogenated in-situ to selectively remove the less 
substituted alkene. The remaining alkene then underwent a hydroboration-
oxidation sequence using IBX as the oxidant to directly introduce the desired 
ketone in the cyclopentane ring system. Deprotection of the Boc group 
liberated the secondary amine which underwent spontaneous cyclisation to 
fawcettimine. The addition of formaldehyde precipitated a Mannich reaction 
to give lycoflexine. 
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Scheme 5. Mulzer’s total synthesis of (+)-lycoflexine. 
 
6. Conclusions 
 
 An overview of the synthetic approaches used to construct the four core 
structural types of the Lycopodium alkaloids has been presented. As can be seen, 
for each  nucleus type one ring construction strategy tends to dominate for each 
nucleus type and there exists significant similarity between the starting materials 
and intermediates employed across the range of different approaches. There are 
now efficient procedures for the rapid construction of each nucleus type, using 
tandem reactions that construct many of the rings in a single step. It is hoped that 
continuing work within this field will lead to new and more efficient approaches 
to the Lycopodium alkaloids and their analogs that will enable a full investigation 
of their important biological activities for the treatment of serious diseases such 
as Alzheimer’s or cancer. 
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Abstract. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
is considered a housekeeping protein that is present in virtually all 
organisms, where it performs metabolic functions essential for 
survival. GAPDH plays an essential role in the process of energy 
production, and is also involved in numerous biological processes. 
GAPDH belongs to a subset of proteins called moonlighting 
proteins, in which different functions are associated with a single 
polypeptide chain. The multifunctionality of GAPDH has been 
described in pathogenic and probiotic microorganisms, in 
mammals and in plants. In this review, we summarize the 
moonlighting role of GAPDH in bacteria.  
 
 
1. Moonlighting proteins 
 
 There are different mechanisms by which a gene may encode multiple 
functions, but there are also mechanisms that determine the ability of a given 
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protein to perform more than one function. One subset of multifunctional 
proteins are called moonlighting proteins, in which the different functions are 
associated with a single polypeptide chain. A general feature of moonlighting 
proteins is that their different functions are unrelated and independent. 
Consequently, the inactivation of one of the functions does not usually affect 
the other functions and vice-versa [1]. It has been hypothesized that many of 
these proteins initially had just one role, but acquired additional functions 
during evolution. Proteins in which the different functions result from gene 
fusion, homologous protein families, splice variants or enzymes with 
promiscuous activity are not considered moonlighting proteins, nor are 
proteins that exhibit the same function in different cell types or subcellular 
localizations [2,3,4].   
 The first examples of moonlighting proteins were described in the early 
1980s, when it was discovered that certain structural proteins in the lens of 
vertebrates were well-known metabolic enzymes such as argininosuccinate 
lyase [5], lactate dehydrogenase [6] or the glycolytic enzyme enolase [7]. At 
present, the concept of moonlighting protein is not restricted to enzymes, but 
also applies to other proteins such as receptors, membrane channels, 
chaperones and ribosomal proteins. 
 Different mechanisms have been proposed to explain how a 
moonlighting protein can exert different functions. Thus, the function of the 
protein may vary according to its subcellular localization, cell type, 
oligomeric state, interaction with other proteins or macromolecules, cell 
concentration of a ligand, substrate, cofactor or product. In these proteins, the 
binding of a metabolite, interaction with another protein or association into a 
multiprotein complex may induce a change in function. In most cases, these 
strategies are not mutually exclusive and a combination of them may be 
involved. In general, moonlighting proteins use different exposition surfaces 
for each function. In this context, the resolution of the three dimensional 
structure of multifunctional proteins is of great importance since, in many 
cases, it provides key information about the molecular mechanism associated 
with each of the functions [4].  
 An example of a moonlighting protein with a known switching 
mechanism between functions is PutA of Escherichia coli or Salmonella 
typhimurium. In the absence of proline, this protein remains in the cytoplasm 
where it acts as a transcriptional repressor through its interaction with a 
specific DNA sequence in the promoter of the put operon. However, binding 
of proline induces a conformational change that leads PutA protein to 
associate with the cell membrane where, by means of its proline 
dehydrogenase and pyrroline–5-carboxylate dehydrogenase activities, it 
catalyses the degradation of proline [8].   
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 Until now, many of the functions of proteins could be inferred from 
known functions of homologous proteins. However, the existence of 
moonlighting proteins complicates this interpretation. Similarly, 
multifunctionality can hinder the analysis of results obtained from proteomic 
studies, since the same protein can have different expression patterns or 
multiple non-related interaction partners. Nevertheless, large-scale proteomic 
approaches can be very useful in identifying moonlighting proteins [4]. Thus, 
identification of a protein in a non-expected cell type or as a part of a new 
multiprotein complex may suggest a new function for it. For example, using a 
proteomic microarray-based approach, new DNA-binding activity was 
identified for the yeast mitochondrial enzyme Arg5,6(N-acetyl-gamma-
glutamyl phosphate reductase/ acetylglutamate kinase) involved in the 
synthesis of ornithine [9]. In the immediate future, proteomic studies of this 
type, which use massive screening methods, are seen as tools of great 
potential for identifying new moonlighting proteins.  
 The existence of multifunctional proteins benefits the organism. It 
reduces the number of proteins to synthesize, and therefore the amount of 
DNA to replicate. In many cases, the combination of functions provides a 
mechanism to coordinate diverse cellular processes, such as metabolic and 
signalling pathways, which allows the cell to respond to changes in the 
environment.  
 
2. Bacterial secreted moonlighting proteins and virulence 
 
  An increasing number of reports show that certain pathogenic 
microorganisms (bacteria, fungi, and parasites) display typically considered 
cytoplasmic proteins on the cell surface, where they exert functions related 
with virulence. These are highly conserved housekeeping proteins with basic 
metabolic functions essential for survival that fit into the category of 
moonlighting proteins. Considering bacterial moonlighting proteins in the 
context of bacteria-host interactions, besides their basic metabolic function, 
when secreted these proteins play a role in host adhesion and/or virulence. 
Once in the extracellular medium, these proteins have been shown to interact 
with host components, or interact directly with the host cells to elicit signal 
transduction events, and in this way enable pathogens to colonize and 
modulate the host immune response. Examples of these moonlighting 
proteins are glycolytic enzymes such as glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), enolase, fructose-bisphosphate aldolase or 
pyruvate kinase, other metabolic enzymes such as malic enzyme or succinyl-
CoA synthase subunits, chaperones like DnaK or GroEL, and the elongation 
factor EF-Tu [10,11]. 
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 These cytoplasmic moonlighting proteins lack any typical secretion 
signal and the mechanism responsible for their secretion remains in many 
cases unknown. Although several studies point to cell lysis as the mechanism 
involved in the release of these non-classically secreted proteins into the 
extracellular medium [12], specific secretion processes have been reported 
[13]. For instance, in Mycobacterium tuberculosis and Listeria 
monocytogenes the SecA2-dependent system has been shown to be involved 
in the secretion of some of these cytoplasmic proteins [14,15]. In 
staphylococcus aureus, the export of such proteins depends on the major 
autolysin Atl [16]. 
 
3. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as 
a moonlighting protein 
 
 GAPDH (EC 1.2.1.12) is a constitutively expressed enzyme that plays 
an important role in the glycolytic pathway, due to its catalytic activity in the 
synthesis of 1,3-bisphosphoglycerate. This enzyme is considered a 
housekeeping protein that is present in practically all organisms, where it 
performs metabolic functions essential for survival. The enzyme is even 
expressed in organisms that lack the tricarboxylic acid cycle, which provides 
essential metabolic activity for anaerobic or microaerophilic growth. 
Although GAPDH plays an essential role in the process of energy production, 
it cannot be considered only as a classic glycolytic protein. Several studies 
described GAPDH as a multifunctional protein involved in numerous 
biological processes in pathogens [10], probiotics [17,18], mammals [19,20] 
and plants [21]. Indeed, GAPDH can be considered a model of a 
moonlighting protein that displays a wide variety of cellular functions, due to 
their ability to form complex interactions. The multifunctionality of GAPDH 
has been extensively documented in human cells, where it was shown to be 
involved in numerous cellular processes, such as transcriptional and post-
transcriptional gene regulation, chromatin structure, intracellular trafficking, 
DNA replication and DNA repair [19,20,22]. Each novel function requires 
GAPDH association into specific protein complexes and may involve 
different regions of the protein structure. The different moonlighting 
functions of GAPDH may also depend on specific post-translational 
modifications, which can define its oligomeric state, subcellular localization 
and/or different binding partners [19,20,23]. In fact, GAPDH was shown to 
be the target of several covalent modifications such as S-glutathionylation, S-
nitrosylation, phosphorylation, acetylation and ADP-ribosylation among 
others. These changes give rise to various forms of the protein, which differ 
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in their isoelectric point, and therefore can be separated by two-dimensional 
gel electrophoresis. Most of these modifications are associated with oxidative 
stress responses and may have important physiological consequences [24]. 
 
4. Extracellular GAPDH in Gram-positive pathogens  
 
 As stated above, GAPDH is one of the proteins secreted and exposed on 
the bacterial surface, which enables pathogens to colonize and manipulate 
host cells [10]. 
 The first description of the location of GAPDH on the surface of a 
pathogen was in Streptococcus pyogenes, a Gram-positive bacterium that 
causes pharyngitis and skin infections [25-27]. The protein located on the 
bacterial surface is enzymatically active and able to bind several human 
proteins such as fibronectin, lysozyme, laminin, cytoskeletal proteins (myosin 
and actin) [26] and proteins from the human fibrinolytic system (fibrinogen) 
[26,28,29]. In addition, in pharyngeal cells the membrane protein 
uPAR/CD87 (urokinase plasminogen activator receptor) was identified as a 
receptor for S. pyogenes extracellular GAPDH [30]. It has been shown that 
interaction of group A Streptococci with human plasminogen through surface 
exposed GAPDH improves adhesion of these pathogens to the pharyngeal 
cells [29]. Plasminogen is the zymogen form of plasmin, an enzyme with 
serine-protease activity that is abundant in human plasma and extracellular 
fluids, and plays a fundamental role in the dissolution of fibrin clots, the 
extracellular matrix and other key proteins involved in immunity and tissue 
repair [31]. In this context, extracellular GAPDH either in the surface of the 
pathogen or secreted near the host cell promotes activation of plasminogen to 
plasmin, which can degrade extracellular matrix proteins and facilitate 
bacterial migration. GAPDH has also been found on the surface of other 
Streptococci, such as the swine pathogen Streptococcus suis serotype 2 and 
Streptococcus pneumoniae [32-35]. In these pathogens, GAPDH also acts as 
a plasminogen receptor. The involvement of GAPDH in the infection 
mechanism by means of its ability to interact with plasminogen is not specific 
for Streptococci isolates, but has also been reported for other Gram-positive 
pathogens such as Bacillus anthracis. In this pathogen, GAPDH has been 
detected both in the secretome and at the spore surface [36]. In Mycoplasma 
pneumoniae, cell surface exposed GAPDH mediates interactions with the 
extracellular matrix proteins of the human host and contributes to the 
colonization of the respiratory tract [37]. 
 Other studies report the ability of extracellular Streptococci GAPDH to 
interact with the C5a component of the complement system, which promotes 
its degradation, in coordination with the bacterial surface protease (SCPA). 
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This strategy allows the pathogen to escape from detection by the host 
immune system [38]. In Group B Streptococci, comprised of human 
commensal bacteria with the capacity to cause life-threatening meningitis and 
septicaemia in newborns, GAPDH is exported outside the cell [39]. In this 
extracellular location, GAPDH can induce activation of polyclonal B cells 
and secretion of interleukin IL-10. The ability of microbial components to 
induce the activation of polyclonal B cells of the infected host is an immune 
evasion mechanism employed by pathogens to suppress specific immune 
responses. IL-10 has anti-inflammatory effects, and therefore its stimulation 
by GAPDH may decrease the immune response and facilitate colonization by 
the pathogen [40].  
 Soluble GAPDH was identified as the main protein secreted into the 
extracellular medium by Streptococcus gordonii FSS2, which produces 
endocarditis. In this pathogen, secretion of GAPDH is regulated by pH. This 
protein remains associated with the cell surface at pH 6.5, whereas a shift to 
pH 7.5 causes its secretion to the medium [41]. New functions of 
extracellular GAPDH have been reported in other Gram-positive pathogens. 
In Listeria monocytogenes, cell wall-associated GAPDH was shown to 
catalyse the ADP-ribosylation of Rab5a [42], a protein that localizes to early 
endosomes. ADP-ribosylation of Rab5a blocked the Rab5a-exchange factor 
(Vps9) and impaired maturation to late endosomes [43]. In Streptococcus 
oralis, extracellular GAPDH can bind the major fimbriae of the Gram-
negative pathogen Porphyromonas gingivalis. This interaction is important 
for colonization of the oral cavity by this pathogen [44]. 
 Moreover, the ability of antibodies against bacterial GAPDH to mediate 
opsonophagocytosis and to provide protection against bacterial infection by 
Gram-positive pathogens such as Streptococcus pyogenes [30,45], 
Streptococcus agalactiae [40] or Bacillus anthracis [36] points to GAPDH as a 
potential vaccine target. The proposed functions in host interaction of 
extracellular GAPDH of Gram-positive pathogens are summarized in Table 1. 
 
5. Extracellular GAPDH in Gram-negative pathogens   
 
 As stated above, the first description of GAPDH on the surface of 
Gram-positive pathogens was published in 1992 [25,26]. However, reports 
describing the extracellular localization of GAPDH in Gram-negative 
pathogens and the involvement of this protein in the interaction with the host 
appeared more than 10 years later. Our group has contributed to this field. 
We showed that GAPDH is localized on the surface of enteropathogenic 
(EPEC) or enterohemorrhagic (EHEC) Escherichia coli strains and that this 
protein is also secreted into the medium in a soluble and active form [46]. 
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Although secretion of GAPDH is regulated by environmental pH in other 
bacteria [41,47], this factor does not affect GAPDH secretion in EHEC and 
EPEC strains. In these pathogens, secretion depends on the external medium 
and temperature. The protein is secreted at 37ºC by cells grown in LB or in 
eukaryotic culture media such as DMEM or Ham’s F12, but not in glucose 
minimal medium [46]. Western blot and ELISA assays have revealed the 
capacity of this protein to interact with the human proteins fibrinogen and 
plasminogen, as well as its association with Caco-2 cells upon infection [46]. 
Pathogens need to attach to host components as the first step in the 
establishment of infection. As mentioned above, these interactions with 
human proteins confer GAPDH a function in the degradation of extracellular 
matrix proteins that, in the case of enteropathogens, would facilitate their 
migration through the intestinal mucosa. Another aspect of GAPDH function 
in the interaction with the intestinal mucosa is linked to post-translational 
modifications, such as ADP-ribosylation. This is a reversible, covalent 
modification in which the ADP-ribose moiety of NAD
+
 is enzymatically 
transferred to a specific amino acid of the target protein. We have shown that 
E. coli GADPH catalyses its own modification and that this modification 
affects Cys149 at the active site. ADP-ribosylation assays have shown that 
the E. coli enzyme is modified by NAD
+
 both in the cytosol and in the 
extracellular medium, and that nitric oxide stimulates the NAD
+
-dependent 
post-translational modification of GAPDH [48]. ADP-ribosylation of 
extracellular GAPDH may play an important role in bacteria-host interaction, 
as proposed for other pathogens. The secreted protein may protect bacteria 
against the oxidative host response during infection and/or it may be involved 
in signal transduction events in the host [26,48]. 
 Studies performed in our group have provided genetic and biochemical 
evidence that at least two different secretion pathways mediate GAPDH 
secretion in EPEC, depending on the growth conditions. In cells grown in 
DMEM, GAPDH secretion depends on T3SS, whereas in cells grown in LB, 
conditions that do not induce the expression of T3SS proteins, GAPDH is 
secreted by a T3SS-independent system that has not yet been identified [49]. 
EPEC and EHEC are members of a related family that intimately attach to the 
intestinal epithelial cells and induce characteristic attaching and effacing 
(A/E) lesions on the host cells, causing diarrhoea. In EPEC, the ability to 
induce A/E effects is encoded in a 41-gene pathogenicity island, called the 
locus of enterocyte effacement (LEE). The T3SS components are encoded in 
this locus together with transcriptional regulators, chaperones and effector 
proteins. EPEC can secrete and translocate multiple effector proteins to the 
infected cells through the T3SS. The secretion process is dependent 
frequently on a bacterial chaperone that is not secreted. One chaperone that 
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displayed broad substrate specificity and plays a central role in recruiting 
multiple type III effectors to the T3SS is CesT. This soluble, small protein 
interacts with type III ATPase EscN and promotes the recruitment of cognate 
effectors to the T3SS apparatus for efficient secretion [50]. Our studies 
showed that secretion of GAPDH in DMEM is abolished in a mutant 
defective in the type III ATPase EscN, but restored upon complementation 
with the escN gene. It is well-known that escN mutations abolish secretion of 
both translocator and effector proteins through the T3SS apparatus. In cells 
that are defective in SepD protein, secretion of GAPDH is increased, which is 
in accordance with previous results for other T3SS effectors. Direct binding 
of CesT with GAPDH was shown by means of different methodologies such 
as pull-down experiments, overlay immunoblotting and bilayer 
interferometry. We evidenced that this interaction is strong and slow 
dissociating. Modelling of the N-terminal sequence of E. coli GAPDH 
revealed that this protein displays in this region the structural determinants of 
the CesT targets. We proposed that during the synthesis of GAPDH in 
ribosomes, interaction of its nascent N-terminal sequence with CesT may 
stabilize a population of GAPDH molecules in a secretion competent-state 
and target them to the T3SS secretion apparatus.  
 In addition to E. coli, there are descriptions of GAPDH on the surface of 
other gram-negative pathogens, as in Neisseria meningitidis [51], Brucella 
abortus [52] and Edwardsiella tarda [53]. Neisseria meningitidis has two 
genes (gapA1 and gapA2) encoding GAPDH. From them, gapA1 has been 
reported to be up-regulated upon bacterial contact with human epithelial 
cells. Constitutive expression of gapA1 has been seen among diverse isolates 
of Neisseria species, whereas the GapA1 protein can only be detected on the 
surface of capsule-deficient strains. GapA1 is not necessary for Neisseria 
growth in vitro, but deficiency in GapA1 significantly reduces adhesion of 
the pathogen to human epithelial and endothelial cells through a capsule-
independent mechanism. From these results, the authors suggested a role of 
GapA1 in the pathogenesis of meningococcal infection [51]. In Brucella 
abortus, recombinant GAPDH protein was shown to have immunoreactive 
properties and induce a protective T-cell mediated immune response in mice 
and natural hosts as well as in acute brucellosis patients [54]. The Brucella 
recombinant GAPDH protein was recognized by IgG antibodies from 
naturally infected sheep and cattle, which supports its potential use as a 
vaccine. In fact, partial protection against Brucella infection was achieved in 
mice upon immunization with gap and IL-12 genes [52]. The use of 
recombinant GAPDH as a protective antigen in vaccination processes has 
also been explored in Edwardsiella tarda, a Gram-negative pathogen which 
causes systemic infection in turbot. The increasing frequency of 
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edwardsiellosis in fish farming has stressed the need to develop prevention 
and control strategies. A vaccine based on E. tarda recombinant GAPDH has 
been proven to significantly protect zebrafish not only against E. tarda, but 
also against Aeromonas hydrophila, Vibrio anguillarum, Vibrio alginolyticus 
and Vibrio harvei, thus showing its potential as a vaccine candidate against 
polymicrobial infections in the aquaculture industry [55]. The proposed 
functions in host interaction of extracellular GAPDH of Gram-negative 
pathogens are also summarized in Table 1. 
 
6. Extracellular GAPDH in probiotics 
 
 Certain extracellular activities are advantageous in the colonization of 
the intestinal mucosa and may in fact be a mechanism of competition 
between commensal or probiotic bacteria versus pathogens. In this context, 
certain housekeeping proteins secreted by pathogens, initially related to their 
pathogenesis mechanisms, have been identified in recent years in the 
secretome of probiotic strains. Probiotics are a group of non-pathogenic 
intestinal microorganisms that, when administered to humans, produce 
positive effects on the microbiota balance and increase gastrointestinal 
homeostasis. They are utilized as dietary supplements or as pharmaceutical 
products in the treatment of intestinal alterations and diseases. Some 
probiotic strains reduce colonization by pathogens through direct competition 
for adhesion sites, the production of antimicrobial agents, or modulation of 
the host’s acquired immune response. Furthermore, they have a beneficial 
influence upon the epithelial cells, thereby regulating their development and 
function. By virtue of their extracellular localization, proteins secreted by 
probiotic strains may be responsible for some of these probiotic traits [56,57]. 
In order to identify proteins related with probiotic effects or the adaptation of 
bacteria to changing environmental conditions, several studies have been 
carried out to characterize the secretome of Gram-positive probiotics [58-60]. 
Among the housekeeping proteins secreted by Gram-positive probiotics are 
EF-Tu, enolase, GroEL chaperone, or GAPDH. 
 Regarding GAPDH, several reports describe GAPDH secretion by some 
Gram-positive probiotic Lactobacillus species [56,60,61], and by the Gram-
negative probiotic Escherichia coli Nissle 1917 [49]. In Lactobacillus 
plantarum, export of GAPDH to the bacterial cell surface was shown to be 
closely related to plasma membrane permeability [62]. In E. coli Nissle 1917, 
GAPDH was found in the proteome of outer-membrane vesicles isolated 
from LB cultures [63]. L. plantarum extracellular GAPDH can bind mucin 
[17]. The adhesion mechanism can be partly attributed to GAPDH binding          
to human ABO-type blood group antigens expressed on human colonic mucin  
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Table 1. Bacterial extracellular GAPDH and the proposed function in bacteria-host 
interaction. 
 
Bacteria Host target  Functions References 
Gram-positive  
Streptococcus 
pyogenes 
Fibronectin, 
lysozyme, laminin, 
myosin, actin, 
fibrinogen, 
uPAR/CD87 
Adhesion and 
degradation of 
extracellular matrix 
proteins. Bacterial 
migration 
[26,28,29,30] 
C5a component of 
the complement 
system 
C5a degradation. 
Evasion of the host 
immune system 
[38] 
Streptococcus suis  
serotype 2 
Plasminogen Degradation of 
extracellular matrix 
proteins 
[32,34] 
Streptococcus  
pneumoniae 
Plasminogen Degradation of 
extracellular matrix 
proteins 
[33,35] 
Streptococci  group B  Induction of polyclonal 
B cells and secretion of 
IL-10. 
Decrease of immune 
response. 
Contribution to the 
colonization process 
[39,40] 
Bacillus antracis  Plasminogen Degradation of 
extracellular matrix 
proteins 
[36] 
Mycoplasma 
pneumoniae 
Fibrinogen. Interaction with 
extracellular matrix. 
Colonization of the 
respiratory track 
[37] 
Lysteria 
monocytogenes  
Rybosylation of 
Rab5a 
Impaired maturation 
to late endosomes 
[43] 
Gram-negative  
Escherichia coli 
(EHEC and EPEC) 
Fibrinogen, 
plasminogen  
Adhesion  and 
degradation of 
extracellular matrix 
[46,48] 
Neisseria meningitidis  Adhesion to epithelial 
and endothelial cells 
[51] 
Brucella abortus   Induction of protective 
T-cell mediated 
immune response 
[52,54] 
Probiotics  
Lactobacillus 
plantarum 
Mucin Adhesion to the 
intestinal mucosa 
[17,18] 
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[18]. It has been suggested that GAPDH interaction with mucin helps the 
probiotic to colonize the human intestinal mucosa, and provides a mechanism 
for competition with pathogens that also secrete this protein (Table 1). 
Studies performed with 30 lactobacilli isolates from human intestinal samples 
revealed a good correlation between extracellular GAPDH activity and the 
adhesion capacity to human colonic mucin. This fact has led authors to 
propose a new screening method based on extracellular GAPDH enzymatic 
activity to predict highly adhesive lactobacilli without the need to perform 
adhesion tests, which are complex and time-consuming [64]. In a similar 
study, adhesion to mucin was investigated in 43 human lactobacilli (32 
vaginal and 11 intestinal isolates). GAPDH was found among the bacterial 
proteins recovered from mucin binding experiments [65].  
 
7. Moonlighting functions of intracellular GAPDH in bacteria 
 
 Besides the role of secreted GAPDH in virulence or host colonization 
processes, few studies have dealt with new GAPDH intracellular functions 
that are unrelated to glycolysis in bacteria. 
 As stated above, GAPDH export to the bacterial surface is an essential 
step in the pathogenesis of Streptococcus pyogenes. Studies performed with a 
strain expressing a modified GAPDH form that prevents its export to the cell 
surface showed down-regulation of emm1, a gene encoding the cell wall 
protein M, which is one of the main virulence factors of this pathogen [29]. A 
transcriptomic analysis of this mutant, which displays higher GAPDH 
intracellular levels than the wild type strain, revealed down-regulation of 
genes encoding virulence factors as well as genes involved in carbohydrate 
and amino acid metabolism, whereas genes involved in lipid metabolism 
were up-regulated. These results prompted the authors to suggest a new role 
for intracellular GAPDH in the transcriptional control of virulence genes [45] 
(Fig. 1). In E. coli, some studies also suggest that GAPDH could interact with 
DNA and act as a regulator of gene expression. In a study performed by 
Green et al. [66] using the methodology of Dynabeads, GAPDH was 
identified among the proteins that could interact with the promoter of ndh 
gene, which encodes NADH oxidase-2. However, no functional 
characterization of this interaction has been performed so far.  
 To explore new GAPDH functions in E. coli, we carried out protein 
interaction studies. In the area of systems biology, the identification of 
protein-protein interactions within cells is of prime importance to understand 
biological processes at the molecular level. Indeed, most human GAPDH 
functions were identified through the detection of GAPDH as a component of 
protein complexes involved in the cellular processes under study [20]. We 
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investigated new intracellular functions of E. coli GAPDH following a 
proteomic approach, to identify the proteins that interact with GAPDH using 
in vivo formaldehyde cross-linking followed by mass spectrometry-based 
protein identification. This methodology covalently fixes interaction partners 
in living cells, thus allowing identification of even transient interactions or 
weakly binding proteins [67]. Experiments were performed with E. coli cells 
that express GAPDH fused to the V5 epitope to facilitate immunoaffinity 
purification of the protein complexes with anti-V5 beads. Experiments in the 
absence of cross-linking were also performed. From these experiments, 
several proteins were identified to putatively interact with GAPDH. The 
identified proteins include the metabolic enzymes phosphoglycolate 
phosphatase, enolase, tryptophanase, the ATP synthase - and -subunits, 
aldehyde dehydrogenase, pyruvate kinase, transketolase, aconitase, 
anthranilate synthase component II, dihydrolipoyl dehydrogenase,                    
D-tagatose-1-6-bisphosphatase, the ATP binding proteins AraG and RbsA, the 
chaperones DnaK and trigger factor, the periplasm D-ribose binding protein 
(RbsB), the outer membrane protein OmpC, as well as factors involved in 
protein synthesis such as EF-Tu [68]. Four proteins (trigger factor, DnaK, 
phosphoglycolate phosphatase and aldehyde dehydrogenase) also appeared as 
candidates to interact with GAPDH in other large-scale studies performed in 
E. coli following different approaches [69,70] or in databases such as DIP 
(database of interacting proteins) or IntAct. Since proteomic studies aimed at 
identifying protein interactions are intended to assign new functions to a 
given protein, we further characterized GAPDH interaction                                  
with phosphoglycolate phosphatase (Gph). This enzyme is involved in the  
 
 
 
Figure 1. Intracellular functions of GAPDH in bacteria. The experimental evidences 
for function assignment are indicated in gray and the proposed functions in blue.  
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metabolism of 2-phosphoglycolate formed in the DNA repair of                            
3- phosphoglycolate ends generated by bleomycin damage [71]. We showed 
that interaction between Gph and GAPDH increases in cells treated with 
bleomycin, which suggests that GAPDH may be involved in cellular 
processes linked to DNA repair mechanisms. Moreover, since                              
2-phosphoglycolate is also generated in the degradation of the autoinducer-2 
precursor 4,5-dihydroxy-2,3-pentanedione (DPD) [72,73], interaction 
between GAPDH and Gph may suggest that GAPDH participates in quorum 
sensing signalling processes [68] (Fig. 1).  
 
8. Conclusion 
 
GAPDH, a key glycolysis enzyme, is a moonlighting protein 
performing additional functions unrelated with its original metabolic role. 
In bacteria, moonlighting GAPDH functions have been mainly associated 
with its extracellular location. This protein is secreted and exposed on the 
bacterial surface enabling pathogens and probiotics to colonize and/or 
modulate the host immune response. Multifunctionality of intracellular 
GAPDH has been widely studied in humans; however such kind of studies 
is scarce in bacteria. Recent reports on S. pyogenes and E. coli provide 
evidence that bacterial GAPDH may also be involved in intracellular cell 
processes like transcriptional regulation, DNA repair and quorum sensing 
signaling.   
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Abstract. Leishmaniasis comprises a group of diseases caused by 
protozoa of the genus Leishmania and has two basic clinical forms, 
visceral Leishmaniasis and cutaneous Leishmaniasis. The clinical 
features of Leishmaniasis depend on the species of Leishmania, the 
interaction between host and parasite and the immune response. 
      This work focuses on cutaneous leishmaniosis because 
although it is not a deadly disease it results in significant scars and 
facial disfigurements, thus being clinically important. Furthermore, 
the first-line treatment consists of intravenous or intramuscular 
administration of intralesional pentavalent antimonials, which are 
highly toxic, making hospitalization of patients compulsory during 
treatment, with the associated financial costs. Herein, we review 
studies on drugs and treatments with fewer side effects and easier 
routes of administration such as topical administration. Recent 
research shows that the topical route of administration holds 
promise for the future treatment of cutaneous leishmaniosis.  
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Introduction 
   
1.1. Overview of leishmaniasis     
 
 Leishmaniasis comprises a group of diseases caused by protozoan 
parasites of the genus Leishmania. There are two main clinical forms, 
visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL). It is 
transmitted by vectors of the genus Phlebotomus and Lutzomyia in Europe 
and America respectively, and a large number of vertebrates act as reservoirs. 
It is considered a zoonosis in most cases, and can affect around 100 species 
of animals including humans [1]. 
 The World Health Organization (WHO) has reported a wide distribution 
of leishmaniasis, extending from South America, Africa and Asia to Europe. 
The disease is endemic in 88 countries, 72 of which are developing countries 
(Fig. 1 and 2). According to the WHO, as many as 12 million people are 
believed to be currently infected, with about 1–2 million estimated new cases 
occurring every year of which 500,000 are VL (90% in India and Sudan) and 
1,000,000 are CL (90% Afghanistan, Saudi Arabia, Algeria, Brazil, Iraq, 
Iran, Syria and Sudan). Furthermore, a total of 350 million people live in risk 
areas. 
 
 
 
Figure 1. Areas of the world affected by leishmaniasis. The visceral form is shown in 
green and the cutaneous and mucocutaneous form in red (WHO). 
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Figure 2. Global distribution of cutaneous leishmaniasis (WHO). 
 
Aetiological agent 
 
 The genus Leishmania contains a number of species. Its taxonomic status 
is as follows (Lainson and Shaw, 1987): 
 
Phylum: Sarcomastigophora (Honigberg & Balamuth, 1963). 
Subphylum: Mastigophora (Diesing, 1866). 
Class: Zoomastigophorea (Calkins, 1909). 
Order: Kinetoplastida (Vickerman, 1976). 
Suborder: Trypanosomatina (Kent, 1880). 
Family: Trypanosomatidae (Gobben, 1905). 
Genus: Leishmania (Ross, 1903). 
 
 About 29 species of Leishmania have been described, of which 21 have 
been isolated from humans. These are responsible for producing the different 
clinical forms of the disease with a wide range of clinical symptoms. The 
species are grouped according to their geographical distribution in the Old 
and the New World, and their main clinical form: visceral, cutaneous or 
mucocutaneous. Cutaneous leishmaniasis is the most common form. Visceral 
leishmaniasis is the most severe form, in which vital organs of the body are 
affected. The same species can be found in both geographical areas, and can 
be responsible for more than one clinical form (Table 1). 
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Table 1. Classification of different species of Leishmania in human species, 
geographical distribution and clinical form (WHO, 2010). 
 
 Leishmania found in humans 
 
Subgenus L.(Leishmania) L.(Leishmania) L. (Viannia) L. (Viannia) 
Old World L. donovani L. major   
 L. infantum L. tropica   
  L. killicki
a   
  L. aethiopica   
  L. infantum   
New World L. infantum L. infantum L. braziliensis L. braziliensis 
  L. mexicana L. guyanensis L. panamensis 
  L. pifanol
a L. panamensis  
  L. gamhami
a L. shawi  
  L. amazonensis L. naiffi  
   L. lainsoni  
   L. lindenbergi  
   L. peruviana  
   L. colombiensis
b  
Principal 
tropism 
Viscerotropic Dermotropic Dermotropic Mucotropic 
 
aSpecies status is under discussion 
bTaxonomic position is under discussion 
 
1.2. Morphology and life cycle 
 
 The life cycle of Leishmania involves transfer between a vertebrate host 
and an invertebrate host, with two main morphological forms: 
 
- Amastigote form: it is reproduced within macrophages and cells of the 
mononuclear phagocyte system of vertebrate host. It is oval,                           
without a flagellum, and is therefore immobile. It measures about 2.5 to 7 
μm in diameter. The cytoplasm contains a nucleus and kinetonuclei                  
(Fig. 3). 
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Figure 3. Amastigote form (WHO).            Figure 4. Promastigote form (WHO). 
 
- Promastigote form: the parasite is a motile form with an anterior 
flagellum that develops in the sandfly, the insect vector. It is larger than the 
amastigote form. It has a central oval nucleus and prenuclear kinetonuclei 
(Fig. 4). 
 The cycle begins when the vector of female sand flies (invertebrate host) 
ingests blood of the vertebrate host and inoculates infective promastigotes, 
also called metacyclics. These promastigotes are phagocytized by 
macrophages in the skin, mucosal membranes and viscera. Within the 
cytoplasm of macrophages, the promastigotes transform into amastigotes. 
The amastigotes multiply until the cell explodes. Free parasites invade other 
macrophages or spread directly through the skin or the systemic circulation. 
Macrophages loaded with amastigotes can be re-ingested by the vector at a 
recent sting and then transform into promastigotes in the digestive tract. The 
promastigote form develops into a metacyclic infectious form over 
approximately 10 days. 
 
1.3. Clinical manifestations of leishmaniasis 
 
 The clinical manifestations of leishmaniasis are varied and depend on the 
species of Leishmania, the interaction between host and parasite and the host 
immune response [2-4]. This polymorphism is grouped into three different 
clinical forms: 
 
Cutaneous leishmaniasis  
 
 There is a wide variety of clinical presentations. A ‘classical’ lesion starts 
as a papule or nodule at the site of inoculation; it grows slowly, taking at least 
1 week to reach its final size. Generally it is a single lesion located on the 
face, arms or legs. A crust develops centrally, which may fall away, exposing 
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an ulcer up to 5 cm in diameter with a raised edge and variable surrounding 
induration, which heals gradually over months or years, leaving a depressed 
scar with altered pigmentation. Satellite nodules at the edge of the lesion are 
common. Occasionally, it may be complicated with bacterial superinfection 
or regional lymphadenopathy [5] (Fig. 5A). 
 
Mucocutaneous leishmaniasis 
 
 This clinical form occurs in just a few species of the New World. Studies 
in Brazil have shown that mucocutaneous leishmaniasis can present from 
several months to 20 or more years after a cutaneous lesion. Nasal lesions are 
always present, with nodules and infiltration of the anterior cartilaginous 
septum, leading to obstruction of the nostril and, later, perforation of the 
septum with collapse and broadening of the nose. In one third of patients, 
other sites are involved, in the following descending order of frequency: the 
pharynx, palate, larynx, trachea and upper lip. Mucocutaneous leishmaniasis 
almost never heals spontaneously. Secondary bacterial infections are 
frequent, intercurrent pneumonia being the commonest cause of death                 
(Fig. 5B). 
 
Visceral leishmaniasis or Kala azar 
 
 This is the most severe form of leishmaniasis. Clinically it is 
characterized by the appearance of fever, vomiting, shivering, diarrhoea, 
weight loss and anaemia. The common clinical signs are non-tender 
splenomegaly, with or without hepatomegaly, wasting and pallor of mucous 
membranes. In more advanced cases clotting disorders occur. Without 
treatment, it can lead to death (Fig. 5C). 
 
 
 
Figure 5. Cutaneous leishmaniasis (A), mucocutaneous leishmaniasis (B), visceral 
leishmaniasis [6] (C). 
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1.4. Cutaneous leishmaniasis: its problematic healthcare 
 
 Cutaneous leishmaniasis is not deadly, and some forms may heal 
spontaneously with time, but others may leave significant scarring, resulting 
in disfigurements to the face that are a barrier to finding work or marriage, 
especially for women. This in turn leads to social and economic 
consequences and increased poverty [7]. 
 Another important point to remember from health and epidemiological 
points of view is that patients with lesions act as reservoirs of infection, and 
thus without treatment the potential for transmission increases. Unfortunately 
the high cost of treatment means that in many cases it does not reach poor 
people [7]. 
 According to the WHO (2010), the main problem with cutaneous 
leishmaniasis relates to access to treatment, because the cost of 
hospitalization is added to the drug and may not be affordable in developing 
countries. For this reason and because leishmaniasis is one of a group of 
neglected diseases, the Drugs For Neglected Disease Initiative (DNDi) has 
highlighted the urgent need for affordable and effective drugs with short 
treatment schedules and uncomplicated  management (such as topical 
administration) that do not require complex health infrastructures. 
 The first-line treatment of cutaneous leishmaniasis is based on 
pentavalent antimonial drugs that can be administered in intravenous or 
intramuscular form or by intralesional injection, depending on the severity of 
the injury and the species responsible. These drugs are highly toxic, so it is 
necessary to hospitalize patients, which is very expensive in developing 
countries. Drugs with fewer toxic effects, such as liposomal amphotericin B 
(Ambisome®), can be administered in cases of complicated cutaneous and 
mucocutaneous leishmaniasis, but these are costly and are not widely 
available in countries with a high poverty index. 
 Herein we review existing conventional treatments currently available for 
cutaneous leishmaniasis and describe the different drugs and therapies 
currently used, as well as the different treatment regimens specific to the Old 
World and the New World. Also, we report on new treatments for cutaneous 
leishmaniasis that are currently being tested and studied: studies of new 
drugs, formulations, and drug combinations. 
 
2. Conventional treatments for cutaneous leishmaniasis 
 
 There are currently several therapies for the treatment of leishmaniasis. 
The most commonly used compounds are pentavalent antimonials, and these 
are considered the drugs of first choice in the treatment and control of 
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leishmaniasis. Alternatives include the liposomal amphotericin B, the 
pentamidine paramomycin, drugs derived from imidazole, and an orally 
administered drug, miltefosine [8]. 
 Treatment of cutaneous leishmaniasis involves a combination of topical, 
systemic and non-pharmacological approaches. The therapeutic decision 
depends on the infecting species and geographic region. 
 
2.1. Pentavalent antimonials 
 
 Two pentavalent antimonials are available: sodium stibogluconate (SSG, 
Pentostam
®
) (Fig. 6A) and meglumine antimoniate (AMG, Glucantime
®
) 
(Fig. 6B). These have been used since the 1940s and are the first-line 
therapeutic agents for cutaneous leishmaniasis. 
 They cannot be administered orally. The recommended dose is 20 
mg/kg/day sodium stibogluconate intramuscularly or intravenously for 20 
days or 60 mg/kg/day of meglumine antimoniate. The principal problems 
encountered are their cost, toxicity and emergence of resistance. Intralesional 
administration at a dose of 0.5 to 5 mL injected at the base of the lesion is 
also an option [9]. 
 
      
 
Figure 6. A. Sodium stibogluconate (Pentostam®). B. Meglumine  antimoniate             
(Glucantime®). 
 
2.2. Amphotericin B 
 
 This drug has low antifungal spectrum activity and is derived from 
Streptomyces nodosus. It shows high leishmanicidal activity by joining the 
parasite lipids. It is a second-line drug (Fig. 7). 
 A test dose of 1 mg, given by infusion, is recommended, followed by a 
full dose 4–6 h later. Infusion reactions are common. Nephrotoxicity is also 
common. Treatment should always be given in hospital to allow continuous 
monitoring of patients [9]. 
B A 
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Figure 7. Amphotericin  B. 
 
2.3. Pentamidine 
  
 This drug is an antiprotozoal compound that is considered a second-line 
drug with significant toxic effects (damage to the pancreas, kidney and bone 
marrow). The drug is given intramuscularly or, preferably, by intravenous 
infusion (Fig. 8). 
 
 
 
Figure 8. Pentamidine. 
 
2.4. Paromomycin 
 
 Paramomycin (aminosidine) is an aminoglycoside antibiotic, first 
isolated from Streptomyces krestomuceticus in the 1950s. It is usually 
administered intramuscularly. Its mechanism of action is inhibition of 
mitochondrial activity of Leishmania. It acts synergistically with antimonials 
and is often used in combination or as the therapy of second choice (Fig. 9). 
 
 
 
Figure 9. Paromomycin. 
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2.5. Medicines derived from imidazole 
 
– Ketoconazole: This is an antifungal drug that inhibits the synthesis of 
ergosterol in the membrane of the parasite. It has been proven effective in the 
treatment of cutaneous leishmaniasis (Berman, 1997) (Fig. 10). 
 
 
 
Figure 10. Ketoconazole. 
 
– Itraconazole: This is another antifungal drug with a similar effect to 
ketoconazole (Davidson, 1998), but improved pharmacokinetics (Fig. 11). 
 
 
 
Figure 11. Itraconazole. 
 
2.6. Miltefosine 
 
 This is an alkyl phospholipid (hexadecylphosphocholine) that was 
originally developed as an oral anticancer drug but was shown to have 
antileishmanial activity. It was the first oral agent effective against 
leishmaniasis and should only be administered once a day. Unlike other 
antileishmanial drugs, its mechanism of action involves disrupting cellular 
signaling pathways and the synthesis of cell membranes of the parasite 
through different mechanisms. Unfortunately the development of resistance is 
common [10, 11] (Fig. 12). 
 
 
 
Figure 12. Miltefosine. 
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3. Treatment of cutaneous leishmaniasis in the Old and the 
New World 
 
 The choice of treatment is based mainly on the risk-benefit ratio for each 
patient, with different therapeutic interventions in the Old and the New 
World [8]. 
 
3.1. Cutaneous leishmaniasis in the Old World 
 
 Old World cutaneous leishmaniasis is caused by five species of 
Leishmania: L. infantum, L. tropica, L. major, L. aethiopica and                         
L. donovani. These are mainly species of the Mediterranean coast, the Middle 
East and Africa. 
 Cutaneous lesions caused by L. infantum are seen especially in the 
Mediterranean basin. L. infantum is the most frequent cause of cutaneous 
leishmaniasis in southern Europe. The lesions are usually single nodules, 
with little inflammation but triggering an ulcer. The lesions heal 
spontaneously within about 1 year and seem to confer immunity [8]. 
 L. tropica, which causes anthroponotic or urban anthroponotic cutaneous 
leishmaniasis, is distributed mainly in Morocco, Saudi Arabia and West Asia. 
This leishmaniasis is characterized by the presence of multiple painless and 
dry ulcers of the skin. These generally heal spontaneously within a year, 
often leading to disfiguring scars [1].  
 Cutaneous leishmaniasis caused by L. major (previously known as 
zoonotic or rural zoonotic cutaneous leishmaniasis) is a rural zoonosis typical 
of North Africa, West Asia and Asia Minor. Like other forms of cutaneous 
leishmaniasis it is characterized by painless lesions and often severe 
inflammation and ulceration. These lesions heal after 2–8 months. Multiple 
lesions may occur, especially in nonimmune immigrants; these are slow to 
heal and can leave large disfiguring or disabling scars [1]. 
 Finally, cutaneous leishmaniasis, caused by L. aethiopica (Ethiopia, 
Kenya and Sudan), results mainly in localized cutaneous nodular lesions. A 
less frequent complication is mucocutaneous lesions of the oropharynx, 
causing a distortion of the nostrils of the nose and lips. Most lesions develop 
slowly and can spread locally. Ulceration is late or absent. Spontaneous 
healing usually occurs within 2–5 years. 
 
Established criteria for topical treatment 
  
 According to WHO guidelines, local treatment of the lesion is indicated 
in patients who meet the following requirements [8]: 
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- Confirmed or strongly suspected infection with L. major. 
- Fewer than four lesions requiring immediate treatment. 
- Lesions < 5 cm in diameter. 
- No potentially disfiguring or disabling lesions (face, joints, toes, fingers). 
- No immunosuppression. 
- Possibility of follow-up. 
 
The options for topical treatment are (Table 2) [8]: 
 
Intralesional therapy with pentavalent antimonials: injected at a dose of 
0.5 to 5 mL at the base and margins of the lesion between 3 and 7 days. 
Infiltration can be performed daily, on alternate days or weekly until healing 
of the lesion. These injections are effective but repetitive administration may 
lead to resistance. 
 
Table 2. Recommendations for treatment and dosage of Old World cutaneous 
leishmaniasis  (WHO 2010). 
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Paromomycin ointments: either a formulation of 15% paromomycin plus 
12% methyl benzethonium chloride (CLMB) or a formulation of 0.5% 
gentamicin and 15% paramomycin in paraffin, twice daily for up to                     
20 days. 
 
Thermotherapy: it consists of one or two applications of localized heat at 50 °C 
for 30 seconds. One of the drawbacks of this therapy is the high cost of the 
device and also the second-degree burns that occur. Local anaesthesia is 
therefore necessary. 
 
Cryotherapy: cryotherapy with liquid nitrogen (−195 °C) applied once or 
twice a week for up to 6 weeks. The application of liquid nitrogen requires 
specific devices and expensive specialist medical equipment. Although it is 
highly effective it is less effective than intralesional therapy with pentavalent 
antimony. 
 
 Local therapy is an attractive option with little toxicity, but 
thermotherapy and especially intralesional treatment cause significant 
discomfort. 
 
3.2. Cutaneous leishmaniasis in the New World 
 
 Cutaneous leishmaniasis of the New World refers to infection caused 
by species found in Mexico, Central America and South America. These 
species belong to both the Leishmania and the Vianna subgenera, as 
follows: L. (L.) mexicana, L. (L.) amazonensis L. (V.) brazilensis, L. (V.) 
panamensis, L. (V.) guyanensis and L. (V.) peruviana [1]. 
 The clinical manifestations are similar to cutaneous leishmaniasis in the 
Old World but are usually more aggressive and tend to become chronic. 
Lesions caused by L. mexicana generally have a benign evolution, whereas  
L. amazonensis causes a single or multiple lesions that are resistant to 
treatment and have a high tendency to evolve to diffuse lesions.  
 On the other hand, species of the subgenus Vianna tend to form 
mucocutaneous lesions. These are normally single or multiple lesions that 
heal routinely, in the case of L. brazilensis, or have a low cure                         
rate (L. panamensis, L. guyanensis). If the lesion is located near a 
lymphatic chain or if treatment is inadequate the mucocutaneous form can 
develop. 
 Finally, L. peruviana is the most benign species because healing is 
spontaneous and there is no tendency to cause the mucocutaneous form.  
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 Local therapy is considered inadequate for the treatment of cutaneous 
leishmaniasis in the New World when caused by L. brazilensis or                         
L. panamensis, due to the potential risk of spread to mucous membranes. 
Topical treatment is currently considered acceptable in specific cases of 
cutaneous leishmaniasis in the New World.  
 
 Experience with local therapy for cutaneous leishmaniasis in the New 
World is limited. The criteria for the use of local treatment are similar to 
those of the Old World. The proposed options are thermotherapy and 
paramomycin. One to three applications of localized heat (50 °C for 30 
seconds) proved to be 70% effective in studies in Colombia and Guatemala, 
3 months after treatment. On the other hand, 15% and 12% paramomycin 
ointment applied twice daily for 20 days was 70–90% effective against 
cutaneous leishmaniasis caused by L. mexicana, L. panamensis and                    
L. brazilensis in Ecuador and Guatemala.  
 
 The options for systemic treatment are (Table 3) [8]: 
 
Pentavalent antimonials: The cure rate is very high at around 77% and 
90% when pentavalent antimonials are administered at a dose of 20 
mg/kg/day for 20 days intravenously or intramuscularly respectively. They 
are most effective against cutaneous leishmaniasis caused by L. braziliensis 
and L. panamensis. 
 
Pentamidine: Administered at a dose of 3–4 mg/kg on alternate days for a 
total of three or four doses intramuscularly, and is as effective as 
pentavalent antimonials against cutaneous leishmaniasis caused by                    
L. panamensis or L. guayanensis. However, it is less effective than 
antimonials in the case of L. brazilensis. 
 
Miltefosine: Oral miltefosine at a dose of 2 mg/kg/day for 28 days is 
effective against cutaneous leishmaniasis caused by L. panamensis but not 
against L. brazilensis or L. mexicana, for which the cure rate is less than 
60%. The response of L. brazilensis cutaneous leishmaniasis  to miltefosine 
may vary depending on the area. 
 
Ketoconazole: At a dosage of 600 mg daily for 28 days this is highly 
effective (76–90%) against L. panamensis and L. mexicana in Guatemala 
and Panama. 
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Table 3. Recommendations for treatment and dosage of New World cutaneous 
leishmaniasis (WHO, 2010). 
 
 
 
4. New treatments for cutaneous leishmaniasis  
 
4.1. New drugs 
 
 Many of the drugs mentioned in the previous section have led to 
resistance in many species of Leishmania and consequently their 
effectiveness has diminished in areas in which the parasite was previously 
susceptible to such treatment. For this reason, many research groups have 
focused on investigating new therapeutic alternatives against 
leishmaniasis. The following table provides a summary of various natural 
products that have been reported to have leishmanicidal properties [12] 
(Table 4): 
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Table 4. Sources of essential oils with leishmanicidal properties [12]. 
 
Family Species Leishmania species 
Lauraceae Ocotea duckei L. infantum and L. 
amazonensis 
Rutaceae Dictyoloma peruviana L. amazonensis and L. 
brazilensis 
Verbenaceae Lyppia alba L. infantum 
Zingiberaceae Curcuma longa Leishmania spp. 
Myristicaceae Myristica malabàrica L. donovani 
Pinaceae Cedrus atlantica Leishmania spp. 
 
 Moreover, the importance of metal compounds in antiparasitic 
development is well known. For example, in vitro and in vivo studies of                 
L. major and L. tropica showed greater susceptibility to zinc than pentavalent 
antimony [13]. 
 Finally, a recent study examined the antileishmania effectiveness of a 
drug called buparvacuona, a hydroxynaphthoquinone used for the treatment 
of theileriosis in cattle. Specifically, the efficacy and toxicity of different 
topical formulations of buparvacuona against L. major were tested in vivo in 
BALB/c mice. The results of this study were encouraging, as parasite load 
and lesion size were reduced, and therefore the introduction of a topical 
formulation of this type would be a significant advance for the treatment of 
simple cutaneous lesions [14]. 
 The search for new drugs with antileishmanial activity is essential for 
new treatment options for cutaneous leishmaniasis. Avoiding the use of 
parenteral antimony would greatly increase patient compliance and reduce 
treatment costs. 
 
4.2. New formulations 
 
 As mentioned above, the standard topical treatment used at present is 
intralesional therapy with pentavalent antimony. However, this requires 
multiple injections, which are painful and not tolerated by most patients. 
Furthermore, they are not always effective, have many adverse effects and 
can lead to the development of resistance. Alternative topical therapies 
mainly contain paramomycin e.g. a formulation called WR 279,396, a 
hydrophilic formulation of paramomycin 15% and gentamicin 0.5% that is 
currently in a Phase III trial in Tunisia [15]. 
 Other researchers studied the permeability of the skin and the 
leishmanicidal activity of a hydrophilic gel containing 10% paramomycin in 
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vivo in experimental mice infected with L. major and compared its activity 
with parenteral pentavalent antimony. The gel showed higher efficiency than 
the pentavalent antimony administered intravenously. The same formulation 
was tested on hamsters infected with L. brazilensis and showed similar 
efficacy to that of parenteral antimony [16]. 
 Other authors studied a new topical formulation containing amphotericin 
B and evaluated its leishmanicidal effectiveness in CBA mice as a model for 
human cutaneous leishmaniasis. For the first time, they showed that 
amphotericin B administered topically as a complex with phospholipids or 
with cholesterol sulphate in the presence of ethanol can penetrate the skin and 
act in a localized manner even at very low concentrations, which therefore 
makes it less toxic [17]. 
 Liposomes have been widely used as drug delivery systems to treat 
infections caused by bacteria, fungi, viruses and parasites. These are 
nanometric spherical vesicles containing one or more phospholipid bilayers 
[18]. Their molecular architecture can capture a wide variety of active agents, 
thus providing a means of transport to bring drugs to their sites of action at 
appropriate concentrations, in turn ensuring a safe and effective 
pharmacological response. Furthermore, they are biodegradable, non-toxic 
and non-immunogenic. A further advantage is the ability of liposomes to 
isolate active substances during their passage through the organism, 
protecting them from enzymatic actions and also protecting the organism 
against toxic effects. 
 Liposomic formulations have demonstrated the ability to increase the 
penetration of drugs through the skin in comparison to conventional 
formulations. In addition, in open injuries, liposomes show the ability to 
accelerate healing [19]. 
 Various studies have shown promising results when investigating 
liposomal formulations containing sulphate of paramomycin (PM). In one 
study liposomal formulations of PM were assessed as topical delivery 
systems. Two types of liposomes were used: large multilamellar vesicles 
(MLVs) and large unilamellar vesicles (LUVs). Skin permeation experiments 
across stripped and normally hairless mouse skin were performed in modified 
Franz diffusion cells, revealing higher entrapment of paramomycin in LUV 
compared to MLV and better penetration into the skin with paromomycin 
liposomal encapsulation. The study concluded that liposomal formulations of 
paramomycin are an interesting alternative for the treatment of cutaneous 
leishmaniasis as they increase the skin penetration of paramomycin [20]. 
 In another study, liposomal formulations containing 10% and 15% 
paramomycin sulphate were developed to evaluate the antileishmanial 
activity of paramomycin against L. major-infected BALB/c mice. The study 
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also evaluated the penetration properties of PM into the skin, as this antibiotic 
shows a low level of penetration. Such low penetration reduces the 
effectiveness of paramomycin treatment of some injuries, particularly those 
that are not ulcerated, and is therefore a major drawback. The overall results 
of the study showed that liposomes are interesting paramomycin carriers and 
that liposomal PM could be a suitable candidate for the treatment of 
cutaneous leishmaniasis [21]. 
 
4.3. Combined treatment 
 
 Combination therapy provides several advantages: it reduces the duration 
of treatment, increases compliance, and reduces the dose of each drug, which 
helps to reduce the cost and side effects of therapy, as well as reducing the 
risk of emergence of resistance. Various authors have investigated different 
combination therapies with favorable results. One study verified the 
effectiveness of a combination of paramomycin gel and oral miltefosine in 
BALB/c mice infected with L. major for the treatment of cutaneous 
leishmaniasis. Miltefosine was administered orally at 2 mg/kg/day for 10 
days while the 10% paramomycin gel was applied twice daily for 10 days. 
This combination was highly effective, significantly reducing the size of the 
lesion and the load of parasites in the skin, and leading to complete healing of 
ulcers, in comparison with oral miltefosine alone [22]. 
 Other drugs such as azithromycin and allopurinol have been studied in 
the search for new therapies for cutaneous leishmaniasis. One study 
compared the efficacy and tolerance of azithromycin plus allopurinol with 
intramuscular Glucantime
®
, and found similar results. One of the benefits of 
allopurinol and azithromycin is that they are less expensive than Glucantime
®
 
and more readily available in developing countries. Furthermore, they are 
administered orally and therefore can be considered an alternative option to 
Glucantime
®
 treatment in patients who do not tolerate the latter [23]. 
 Another study evaluated the efficacy of combination with pentoxifylline 
and Glucantime
®
. Pentoxifylline is an inhibitor of TNF-α that has been 
shown to enhance the beneficial effects of antimonial compounds. The results 
of this study indicated that Glucantime
®
 with pentoxifylline is more effective 
than Glucantime
®
 alone. However, more tests are needed with different 
populations of patients with CL to demonstrate the real efficacy of the 
combination of pentoxifylline and Glucantime
®
 and develop specific 
treatment guidelines [24]. 
 The results of a study that evaluated the effectiveness of a combination of 
oral ketoconazole with intralesional estibogluconat sodium for the treatment 
of localized cutaneous leishmaniasis were promising. Furthermore, this 
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combination is easier to use, less aggressive and free of side effects compared 
to treatment with intralesional pentavalent antimonial compounds [25]. 
 A compound called Imiquimod, an inhibitor of tumor necrosis factor 
TNF-alpha, is useful in patients with moderate to severe psoriasis and other 
skin diseases and is currently used for the treatment of cervical warts caused 
by human papillomavirus infection. In vitro, this drug has proven to be an 
immunomodulator that activates macrophages to release nitric oxide, thus 
killing intracellular Leishmania amastigotes. A study evaluating combination 
therapy with Imiquimod and meglumine antimoniate in patients with 
cutaneous leishmaniasis  who previously had not responded to treatment with 
meglumine antimoniate alone showed promising results, as all patients 
responded well to combination therapy [26]. 
 
5. Conclusions 
 
 Intralesional and systemic therapy with pentavalent antimonials has been 
the treatment of choice for cutaneous leishmaniasis to date. 
 The application of paramomycin ointments to localized lesions and those 
less than 5 cm in diameter was the first attempt at local therapy and indicated 
the potential benefit of this type of administration. 
 The search for new drugs with anti-Leishmania activity is important for 
new treatments for CL. Avoiding the administration of derivatives of parenteral 
antimony greatly increases patient compliance and reduces treatment costs. 
 Studies of formulations based on liposomes and hydrophilic gels 
containing paromomycin indicate the effectiveness of these formulations in 
the topical treatment of cutaneous leishmaniasis. 
 Combination treatment has the potential advantages of: shortening the 
duration of treatment, thereby increasing compliance; reducing the overall 
dose of medicines, thereby reducing their toxic effects and cost; and reducing 
the probability of selection of drug-resistant parasites, thereby prolonging the 
effective life of the available medicines. 
 Due to the importance of this parasitic disease and the low efficiency of 
the limited therapies available, the search for new therapeutic alternatives 
against leishmaniasis is very important for the future treatment of cutaneous 
leishmaniasis. 
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